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Introduction: Early clearance (EC) is the eradication of M. tuberculosis infection by 
innate immunity, before an adaptive immune response develops. Case contact studies 
consistently report a group of highly exposed but uninfected contacts that could be 
early clearers, and genetic loci are associated with the trait. Understanding how early 
clearers are protected could lead to vaccines or other therapies to prevent M. 
tuberculosis infection.  
 
Methods: In Indonesia, contacts of smear and x-ray positive Tuberculosis (TB) cases 
were recruited within 2 weeks of the case starting treatment. A Quantiferon Gold In 
Tube (QFN-GIT) test was performed at baseline, and contacts with a positive test 
were classified as “baseline positive” (BP), and those with a negative test received a 
repeat QFN-GIT 14 weeks later. Contacts who continued to test QFN-GIT negative, 
were classed as “persistently negative” (PN) and those who tested positive were 
classified as “converters”. Cell populations, cytokine responses to stimuli, serum 25-
OH vitamin D and the expression of candidate innate immune genes were measured 
in samples collected at baseline. The primary comparison was of the PN group, 
putative early clearers, to converters. Measurements collected from the whole cohort 
(peripheral blood cell counts, 25-OH vitamin D) were modelled for their association 
with risk of conversion in multi-level models that adjusted for clustering and 
confounding variables. Sub-studies on cytokine responses, gene expression and M. 
tuberculosis lineage were performed in subsets of participants.  
 
Results: A total of 941 case contacts of 317 index cases were recruited. One hundred 
and sixty-two (51%) of index cases had lung cavities on x-ray. Of the contacts 544 
(57.9%) were BP, 223 (23.6%) were PN, 76 (8.0%) were converters, 18 had 
indeterminate QFN-GIT results and 22 (2.3%) had TB disease. A further 27 (2.9%) 
had unevaluated symptoms and 31 (3.1%) were lost to follow up. Risk of conversion 
was higher for contacts exposed to a 3+ smear grade case than those exposed to a 
grade 1+ or scanty case (RR=2.63; 95% CI 1.54 - 4.50; P<0.0001), and it was also 
higher for current smokers versus non smokers (RR=1.63; 95% CI 1.03 - 2.57; 
P=0.04). Risk of conversion was lower in those who been vaccinated with Bacillus 
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Calmette-Guérin (BCG) compared to those who had not (RR=0.52; 95% CI 0.35 - 
0.77; P=0.001). Risk of conversion increased with each additional mg/kg2 increase in 
body mass index (RR=1.06; 95% CI 1.01 - 1.10; P=0.01), and each 1000 cells per 
microliter decrease in immature granulocyte count (RR=0.72; 95% CI 0.60 - 0.90; 
P=0.004) and a neutrophil count in the lowest quartile, relative to the second quartile 
(RR 1.91 95%CI 1.05 - 3.50; P=0.04). There was no association with risk of 
conversion and vitamin D insufficiency (RR=1.10; 95% CI 0.65 - 1.85; P=0.7) or 
deficiency (RR=1.12; 95% CI 0.64 - 1.98; P=0.7).  
 
Cytokine responses to whole blood stimulation were analysed for 97 PN contacts and 
41 converters. Responses to M. tuberculosis stimulation were not significantly higher 
for the primary comparison, but the IL-6 response to Streptococcus (RR=1.41; 95% 
CI 1.09 - 1.84; P=0.01) and the IL-8 responses to E. coli (RR=1.38; 95% CI 1.04 - 
1.84; P=0.03) were higher in PN than converters. Restricting the analysis to 111 BCG 
vaccinated contacts (81 PN, 30 converters) revealed PN had higher IL-1 and IL-6 
responses to Mtb lysate (RR=1.43; 95% CI 1.00 - 2.03; P=0.047) and (RR=1.40 95% 
CI 1.04 - 1.88; P=0.027) respectively and higher IL-6 response to S. pneumoniae 
(RR=1.52; 95% CI 1.14 - 2.03; P=0.005) and E. coli (RR: 1.26; 95% CI 1.00 - 1.59; 
P=0.054). 
 
Out of 45 candidate genes, the expression of nine genes differed at the P<0.05 
threshold and of these only one (CTSD) was higher in PN than converters.  
 
Data on the M. tuberculosis lineage of the index case was available for 271 contacts. 
In this sub-study exposure to an index case with a lineage two isolate was cultured 
was associated with a positive QFN-GIT at baseline or follow up (RR=1.22; 95% CI 
1.02 – 1.46; P=0.03), relative to exposure to M. tuberculosis of another lineage.  
 
Conclusions: Higher concentrations of immature granulocytes, neutrophils and pro-
inflammatory innate cytokines in the PN group reveal early clearers have a pro-
inflammatory phenotype. ECwas associated with BCG vaccination, and a higher 
innate cytokine responses in vaccinated contacts. This findings suggest BCG 
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mediated protection occurs by trained innate immunity. Lineage two M. tuberculosis 
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Chapter 1: Introduction 
 
Tuberculosis 
Tuberculosis (TB) is caused by bacteria in the Mycobacterium tuberculosis complex, 
that comprises seven closely related species. Of these M. tuberculosis sensu 
stricto (hereafter M. tuberculosis) and M. africanum cause almost all human TB, and 
have humans as their only reservoir. The species in M. tuberculosis complex are 
clonally related, and are thought to have evolved from a common ancestor that first 
infected humans over a million years ago, and was carried across the globe as humans 
migrated out of Africa [1].  
 
M. tuberculosis is highly adapted to human immunity. It is capable of establishing a 
long term latent infection in which dormant bacteria reside within macrophages 
evading detection [2]. Active lung lesions can resolve either by resorption or fibrosis 
but these responses do not necessarily eliminate the bacteria. In the pre-antibiotic era 
TB could follow a chronic course with episodes of disease activity followed by 
quiescence and relapse, evidence that some hosts will not develop sterilising 
immunity despite years of exposure. This unique ability to evade immunity belies M. 
tuberculosis’ status as the leading infectious cause of death worldwide [3], and the 
challenges in creating an effective vaccine [4]. 
 
Public health significance of Tuberculosis  
TB was endemic in Enlightenment Europe where death rates as high as 800 to 1000 
per 100,000 per year were recorded [5]. TB cases in Europe have declined since, a 
secular trend that preceded vaccination and chemotherapy [6]. Further progress 
followed the advent of chemotherapy, but in the late 20th century TB re-emerged 
globally in the context of crumbling public health infrastructure in former Soviet 
republics, increasing population density in emerging economies and the AIDS 
epidemic. In 1993 the World Health Association took the unprecedented step of 
declaring TB a global public health emergency. Today, TB is the world’s leading 




TB disease [7]. The 2015 global burden of disease study estimated the impact of TB 
to be 40,302 Disability Adjusted Life Years globally and ranked TB as the 18th 
individual cause of disability worldwide [8]. As 95% of TB occurs in low and middle 
income countries [7] the cost of TB care is often catastrophic for affected families [9]. 
 
The continued emergence of antibiotic resistance multiplies the personal and public 
health impact of TB, as longer treatment courses are required, disability and mortality 
are increased and cases are infectious for longer [10, 11]. Currently, Multi-Drug 
Resistant Tuberculosis (MDR-TB) is estimated to account for 3.7% of new TB cases 
and 20% of previously treated cases, or 480,000 cases each year. Of these, 9% are 
Extensively Drug Resistant Tuberculosis (XDR-TB), a condition that carries a 50% 
mortality rate [12].  
 
Natural history of M. tuberculosis infection  
Transmission 
M. tuberculosis is usually transmitted from a TB case whose cough generates 
infectious particles that are inhaled by contacts. These small aerosol droplets can 
travel to terminal airways and establish an infection in the lower parts of the lungs 
[13]. 
  
Pathology of early infection  
TB disease is characterised by sites of granulomatous inflammation called tubercules 
[14]. Lurie’s seminal experiments in rabbits identified alveolar macrophages as the 
primary target cell in early (stage I) infection [15]. Infected cells migrate into the 
tissue and form an aggregate of predominantly epitheloid macrophages, called a 
granuloma (stage II) [16]. Recent studies using molecular barcoded M. tuberculosis to 
infect cynomolgus macaques reveal a single bacillus is sufficient to start a granuloma 
[17]. This second stage of infection is characterised by logarithmic expansion of 
bacilli and precedes the development of TB specific CD4+ T cells. Although once 
considered a protective structure, recent studies in a zebrafish M. marinum infection 




granuloma [16, 18]. The development of granulomata may facilitate bacterial 
replication.  
 
M. tuberculosis dissemination occurs early in infection before adaptive responses 
develop. Intracellular M. tuberculosis is trafficked to draining lymph nodes by 
dendritic cells and haematogenous dissemination to distant sites may also occur at this 
point [19]. Localised granulomatous inflammation is traditionally known as the Ghon 
focus, and associated lymphangitis and lymph node inflammation is the Ghon 
complex. The Ghon complex is the pathologic correlate of primary TB.  
 
Clinical studies of early infection period 
The clinical manifestations of primary TB are detected around the time of skin test 
conversion, which is approximately 6 weeks after a well-defined exposure. Detailed 
follow up of TB case contacts in the Faroe islands showed that primary infections are 
frequently accompanied by an “initial fever” [20]. In a subsequent study this initial 
fever was identified in 63% of converters, and coincided with an elevated erythrocyte 
sedimentation rate (a non-specific marker of inflammation) and pulmonary infiltrates 
in 23% [21]. In a small proportion primary TB will progress (primary progressive TB) 
but in the majority the Ghon complex will heal and calcify, sequestering dormant 
organisms [22]. Transient culture positivity may be detected in recently exposed 
contacts without symptoms or radiographic evidence to suggest this is disease [23, 
24].  
 
Development of T cell responses  
The development of T cell responses to M. tuberculosis marks Lurie’s third stage of 
infection, and is delayed in M. tuberculosis infection compared to other pathogens 
[20, 25, 26]. Dendritic cells must phagocytose M. tuberculosis and migrate to 
mediastinal lymph nodes where bacterial replication initiates the activation and 
proliferation of M. tuberculosis specific CD4+ T cells [26]. CD4+ T cells migrate to 
the lung where they produce Interferon-g (IFN-g) to drive macrophage activation and 
enhance intracellular killing of M. tuberculosis, but are not capable of eliminating it 




circumstantial, and relies heavily on the observation that they are depleted in HIV 
when TB susceptibility is also increased [28].  
 
Latent infection and progression to disease 
Latent TB infection (LTBI) of humans was demonstrated experimentally when 
material from healthy lymph nodes collected at necropsy was found to cause TB when 
inoculated in to guinea pigs [29]. For clinical purposes LTBI is described as 
asymptomatic and it is diagnosed by detecting immune sensitisation to M. 
tuberculosis antigens, by the Tuberculin Skin Test (TST) or Interferon Gamma 
Release Assay (IGRA).  
 
Modelling of administrative data collected in the 20th century estimated that the 
lifetime age standardised risk of LTBI progressing to active disease was 12% [30]. 
Molecular linkage of Dutch TB isolates confirmed that the majority (83%) of cases of 
reactivation occur within five years of infection [31]. There is substantial individual 
variation in risk of disease progression, and risk is higher in people with immune 
suppression such as those with HIV [32] or those using TNF- inhibitors [33].  
 
Usually M. tuberculosis infection progresses slowly to TB disease. A longitudinal 
study of TB case contacts revealled the gene expression changes that herald disease 
can be identified up to two years before clinical diagnosis [34]. A variety of 
pathological states may exist between strictly latent and active disease. This is 
suggested by M. tuberculosis infection of cynomolgus macaques, that induces 
pathologically heterogeneous granulomata within any animal, and substantial overlap 
in the types of lesions observed in latent and active disease [17].  
 
TB occurs most frequently within 2 years of exposure when it is described as 
“primary progressive TB” and can occur at distant sites seeded during early infection 
[25]. Primary progressive TB frequently occurs in children.  
 
“Reactivation TB” occurs years to decades after primary infection and classically 




dissemination in early infection. TB can affect any organ but is most common in the 
lungs. The classic clinical features are chronic cough, sputum production, appetite 
loss, weight loss, fever, night sweats [35]. Inflammatory cells recruited to a 
granuloma die and form a caseous centre in granulomas that may undergo liquefaction 
and necrotic inflammation and produce a cavity that promotes the aerosolisation of M. 
tuberculosis and spread to new hosts. 
 
Tuberculosis control  
Background 
M. tuberculosis could be controlled by the treatment or isolation of cases of disease to 
prevent transmission, or by preventing infection or the progression of infection to 
disease.  
 
The Directly Observed Therapy Short course (DOTS) programme, which began in 
1994, sought to improve TB care and achieve TB control globally by passive case 
finding and treatment of TB disease [36]. Direct observation of therapy to improve 
adherence was the cornerstone of the programme, as well as efforts to secure drug 
supply that later included second line agents to treat MDR TB. The programme relies 
on sputum microscopy, for diagnosis, meaning diagnosis usually occurs late in the 
disase after transmission to many contacts has occurred. Therefore the DOTS has had 
limited impact on TB incidence.  
 
Prophylactic treatment of LTBI to prevent progression is recommended for particular 
populations in low burden countries [37]. Although mass prophylactic approaches 
have been successful in high burden settings in the past [38], LTBI treatment has not 
been deployed in high burden countries in the modern era. This approach was recently 
revisited by a trial of mass prophylactic treatment of LTBI in South African miners. 
The study did not demonstrate any benefit to prophylaxis, perhaps reflecting 
challenges related to the high prevalence of HIV and the relatively low uptake of the 





Bacillus Calmette-Guérin (BCG) vaccine is the world’s most widely administered 
vaccine. It is included in the WHO’s expanded programme on immunisation in high 
TB burden countries. BCG is primarily given to neonates for the consistent protective 
effect it has shown against disseminated M. tuberculosis disease [40]. A meta-analysis 
of trial results estimates neonatal vaccination as 59% (RR 0.41, 95: CI: 0.29-0.59) 
effective against pulmonary tuberculosis, although individual trial results vary widely 
[41].  
 
Current situation in TB control 
The combined impact of these policies has been a modest reduction in global TB 
incidence. From 2000 to 2013 new TB incidence declined by an average of 1.65% per 
year; if this rate of decline continues it would take 200 years to eliminate TB [42]. 
Multiple factors underpin this poor performance, including programme reliance on 
patient self-referral, and sputum microscopy that has low sensitivity and does not 
detect drug resistance. Consequently one million TB cases are undiagnosed each year 
[42].  
 
Identifying junctures for novel interventions 
New approaches to TB prevention are needed to achieve the global community’s goal 
of TB eradiation by 2035 [43]. Developing a more effective vaccine than BCG has 
proved challenging. Whereas study of recovered individuals has successfully 
identified correlates of protective immunity and led to vaccines for other infectious 
diseases, this strategy is not applicable to M. tuberculosis, primarily because infection 
does not lead to sterilising immunity after the disease is treated [4]. For decades the 
immune correlates of LTBI, which only reactivates in a proportion of individuals, has 
been studied as a protective phenotype [44]. This lead the presence of CD4+ T cells 
and the interferon gamma (IFN-g) they produce to be adopted as a correlate of 
protection despite a lack of epidemiological data supporting the correlation [45]. The 
protective effects of BCG were also assumed to be through its induction of the same 
response to M. bovis antigens. 
 
However, numerous observations have cast doubt on the protective role of CD4+ T 




field trials despite inducing TB specific CD4+ T cells in recipients [46, 47]. Similarly 
BCG specific CD4+ T cells were not associated with BCG mediated protection in a 
large study of neonates [48].  
 
In this context, there is increasing interest in alternative approaches, including 
vaccines that prevent M. tuberculosis infection, rather than progression. Mathematical 
modelling suggests modest reductions in the probability of infection following each 
exposure can result in meaningful vaccine effectiveness [49]. Vaccination has the 
advantage of greater feasibility than mass chemoprophylaxis for LTBI and potentially 
greater effectiveness than the modest gains achieved through improved case detection 
and management under DOTS.  
 
Early clearance 
What is early clearance? 
Early clearance (EC) of M. tuberculosis infection can be defined as the eradication of 
infecting M. tuberculosis before an adaptive response develops. This phenotype has 
long been speculated to exist, however its immunological correlates are yet to be 
described [50]. Figure 1 contextualises EC in the natural history of M. tuberculosis 
infection. By definition EC occurs before the development of an adaptive response 
(Stage III) is measurable through a positive tuberculin skin test (TST) or IFN-g release 
assay (IGRA). A vaccine or other intervention that promotes EC could be considered 
a “transmission blocking” vaccine, as it prevents an established infection.  
 
EC must occur when M. tuberculosis infection is confined to alveolar macrophages 
(stage I) or in the early granuloma (stage II), as T cell immunity follows these stages. 
Ewer et al speculate that clearance could also occur at the time of or after TST/IGRA 
conversion: I term this delayed clearance [51]. However, at present, clearance in a 
person with a positive IGRA or TST could only be distinguished from LTBI by 






Figure 1. Natural history of M. tuberculosis infection.  
Early clearance (EC) occurs before the development of an adaptive immune response 
and is likely to be due to innate factors, during Stages I or II [52]. 
 
Epidemiological evidence for EC 
Case contact studies repeatedly find that exposure to M. tuberculosis does not always 
lead to a positive Interferon Gamma Release Assay (IGRA) or Tuberculin Skin Test 
(TST). In 1941, Israel et al remarked on heavily exposed nursing students: “the 
persistence of a negative reaction in these students, after the majority of other students 
had long been infected, is a striking phenomenon.” [53]. TB case contact studies show 
that approximately half of exposed persons are TST negative, even in high prevalence 
settings [54]. TST positivity would be expected to approach 100% in such settings 
unless there was innate immunity.  
 
M. tuberculosis exposure is a function of duration, proximity and grade of sputum 
positivity, so EC can be best appreciated when these dimensions of exposure are 
maximal [55]. Table 1 presents examples of highly exposed populations and the 
proportion uninfected. Outbreaks in closed environments illustrate this best; for 
example, in a US naval ship where 66 sailors shared a cabin with seven others with 
pulmonary TB, thirteen remained TST negative after six months [56]. In such settings 
pro-inflammatory cytokine production, chemokine secre-
tion and antimicrobial peptides.20 This may influence the
activation state of other target cells. The seminal rabbit
studies by Lurie et al. identified infection of alveolar mac-
rophages as th first stage of pulmonary TB, and point at
which pathological findings in rabbits bred to resist infec-
tion diverged from those found in susceptible rabbits.21
However, if M. tuberculosis escapes the alveolar macro-
phage, a period of logarithmic growth (second stage)
ensues with infection of newly recruited monocytes. More
recently, a zebra fish Mycobacterium marinum model has
indicated that granuloma formation occurs at this stage
and facilitates further infection of new macrophages.22
The arrival of the CD4+ T cells secreting interferon-c
(IFN-c) to activate recruited macrophages marks the third
stage and the start of an adaptive response. Early clear-
ance is more likely when intracellular mycobacterial kill-
ing in alveolar macrophages is successful in the first stage,
and least likely once mycobacterial outgrowth and infec-
tion of recruited macrophages favour pathogen survival.
The role of alveolar macrophages in early
clearance
As the dominant phagocyte in the healthy lung, alveolar
macrophages probably play a key role in EC, by phagocy-
tosis and immune recognition of M. tuberculosis, and the
subsequent inflammatory response and M. tuberculosis
killing. Mathematical models differ in their estimates of
EC, because of differing assumptions about the killing
capacity of alveolar macrophages.23,24 Some view alveolar
macrophages as alternatively activated or promoting
anergy.24,25 However, Flynn et al. argue that they may
not fit either category, particularly in the early stages of
infection, before cytokine activation.26 Notwithstanding
these controversies, a model of M. tuberculosis infection
of alveolar macrophages can be advanced drawing on
murine studies and ex vivo human studies. Figure 2
describes how the outcome of infection can be influenced
by different events including pathogen recognition, cyto-
kine production, intracellular killing and the mode of
macrophage death.
Phagocyosis, pattern recognition of
M. tuberculosis and induction of protective
cytokines
Uptake of M. tuberculosis by phagocytes occurs via spe-
cific receptors that can influence subsquent events within
the cell. The mannose receptor (MR) is heavily expressed
by alveolar macrophages and the primary avenue for
uptake of non-opsonized M. tuberculosis in the alveolar
space where complement is rare. Ligation of the MR by
mannose-capped lipoarabinomannan induces phagocyto-
sis.
When certain M. tuberculosis cell wall components bind
to pattern recognition receptors (PRRs) on the surface or
in the cytosol of host innate cells, this shapes the subse-
quent immune response. Toll-like receptors (TLRs),
nucleotide-binding oligomerization domain (NOD) -like
receptors and C-type lectins recognize M. tuberculosis and
drive cytokine signals that influence mycobacterial clear-
ance.27 TLR2 binds lipoarabinomannan, and as a dimer
with TLR6 binds a 19 000 molecular weight M. tuberculo-
sis lipoprotein. These signals are transduced through
MyD88 and transcription of nuclear transcription factor-
jB (NF-jB) and so promote inflammatory cytokine
secretion, particularly tumour necrosis factor-a (TNF-
a).28 TLR4 recognizes heat-labile cell-associated factor
and also activates MyD88 and NF-jB, yet induces inter-
leukin-1b (IL-1b) production.29 TLR8 and TLR9 are en-
dosomally located and so are able to detect the nucleic
acids of intraphagosomal M. tuberculosis. Stimulation
results in the expression of NF-jB-dependent cytokines as
well as type 1 interferons.30,31 TLR8 expression is
increased in patients with active TB and in ex vivo cell
stimulation experiments, and genetic variants have been
associated with susceptibility to active TB in two popula-
tions.32
Similarly, ligation of NOD2, another PRR expressed by
human alveolar macrophages, limits intracellular
M. tuberculosis growth through up-regulation of auto-




















Figure 1. Ph notypes in the progr ssi n to tuberculosis (TB) disease
after exposure. Mycobacterium tuberculosis (Mtb) exposure leads to
infection. Early clearance (EC) occurs before the development of an
adaptive immune r sponse and is likely to be due to innate factors,
during Stage I o II. If the pathogen vades EC mechanisms, an
ad ptive response d velops (Stag III), measurable through a positive
tuberculin skin test (TST) or interferon-c release assay (IGRA). Early
evasion of both innate and adaptive responses results in primary
progressive TB. However, in the majority of infected individuals
M. tuberculosis is contained as latent TB infection with only 5% later
reactivating disease. Others speculate that clearance could also occur
at the time of or after TST/IGRA conversion, we term this delayed
clearance.
ª 2013 John Wiley & Sons Ltd, Immunology, 141, 506–513508




it is highly likely M. tuberculosis was inhaled, contained and cleared before an 
adaptive response developed.  
 
Table 1. Selected highly exposed populations and proportion Tuberculin Skin Test 
negative. 





American sailors shared cabin with 
seven pulmonary TB cases.  
6 months 19.7% [56] 
Nurses, in 1930s New York 
hospital  
3 years 7%* [57] 
Household contacts in Jinan, China 
with average exposure 9 hours/day 
and proximity 30-40cm 
Not stated 31% [58] 
Household case contacts in The 
Gambia sharing same bed 
 
43% [59] 





Contact at least alternate days with 
a case of laryngeal TB  
6 months 31% [61] 
* Boosting may occur in health care workers undergoing repeated TSTs. 
 
Early clearance of M. tuberculosis is most likely to be mediated by an effective 
innate immune response 
If individuals exposed to M. tuberculosis clear the infection, what could be the 
possible mechanism? The most plausible hypothesis is that EC is an innate immune 
response that occurs before adaptive immunity develops. Lurie demonstrated heritable 
resistance to M. bovis infection in rabbits in the 1940s [62]. In these studies the 
logarithmic growth of M. tuberculosis that preceded adaptive immunity in susceptible 





Inter-individual variability in quantitative assessment of innate immune responses, 
such as mycobacterial whole blood stimulation assays [63] and inhibition of 
mycobacterial growth in vitro [64], support the notion of variability in ability to clear 
M. tuberculosis between individuals. The Lubeck disaster in which 252 newborns 
were accidentally inoculated with virulent mycobacteria illustrates this variability 
most dramatically: approximately one third died, but another third remained well and 
the remainder were only slightly ill [65].  
 
Summary 
M. tuberculosis causes the world’s most deadly infection. Manipulating and evading 
immunity to establish a latent infection is key to this success. This latent infection is a 
reservoir of infection, creating a challenge for TB control as it limits the impact of 
case-based prevention measures. A vaccine that prevents M. tuberculosis infection is 
desperately needed, yet poor understanding of the causes of protective immunity to M. 
tuberculosis is a major barrier to progress. EC is hypothesised to occur when a person 
is exposed to M. tuberculosis yet remains uninfected. This is likely to occur early in 
infection, when the response to infection is mediated by innate defences. 
Epidemiological studies frequently identify an exposed uninfected group. Identifying 
biological correlates of EC could yield mechanistic insights to drive vaccine 






Chapter 2: Possible mechanisms of early clearance 
 
Introduction 
Knowledge of the early innate response to M. tuberculosis infection is largely based 
on animal and ex-vivo models. This chapter presents a narrative review of innate 
response to M. tuberculosis, firstly with respect to events within the alveolar 
macrophage (stage I), then interactions between cells that may occur in the granuloma 
(stage II). Possible modulators of EC are also discussed. The purpose of this review is 
to identify plausible correlates of EC for study in humans.  
 
Alveolar macrophages  
As the dominant phagocyte in the alveolar space, alveolar macrophages are likely to 
be first to encounter M. tuberculosis [67]. They could play a key role in EC, by 
phagocytosis and immune recognition of M. tuberculosis, and the subsequent 
inflammatory response and M. tuberculosis killing. Recognition by alveolar 
macrophages, and possibly epithelial cells, leads to pro-inflammatory cytokine 
production, chemokine secretion and antimicrobial peptides [68]. These early host 
responses may kill intracellular M. tuberculosis, or influence the activation state of 
other cells in the granuloma, thereby influencing the fate of M. tuberculosis infection. 
Mathematical models have been developed to understand host and pathogen 
interactions in early infection. These differ in their estimates of EC, primarily due to 
making differing assumptions about the killing capacity of alveolar macrophages [69, 
70]. Some authors have modelled alveolar macrophages as alternatively activated or 
promoting anergy [70, 71]. However Flynn and others argue that they may not fit in 
either category, particularly in early stages of infection, prior to cytokine activation 
[72]. Notwithstanding these controversies, a model of M. tuberculosis infection of 
alveolar macrophages can be advanced drawing on murine studies and ex vivo human 
studies.  
 





Uptake of M. tuberculosis by phagocytes occurs via specific receptors that can 
influence subsequent events within the cell. The Mannose Receptor (MR) is heavily 
expressed by alveolar macrophages and is the primary avenue for uptake of non-
opsonised M. tuberculosis in the alvolar space where complement is rare. Ligation of 
the MR by mannose-capped lipoarabinomannan (Man-LAM) induces phagocytosis. 
Opsonised M. tuberculosis is phagocytosed following ligation of the complement 
receptors 1 and 3 [73].  
 
When certain M. tuberculosis cell wall components bind to Pattern Recognition 
Receptors (PRRs) on the surface or in the cytosol of host innate cells, this shapes the 
subsequent immune response. Toll like receptors (TLRs), NOD like receptors (NLRs) 
and C-type Lectins recognise M. tuberculosis and drive cytokine signals that influence 
mycobacterial clearance [74]. Polymorphisms in TLR1 are associated with 
susceptibility to TB, and with reduced ex-vivo Tumor Necrosis Factor alpha (TNF-) 
production in response to M. tuberculosis lysate. TLR 2 binds the M. tuberculosis cell 
wall constituent lipoarabinomannan, and as a dimer with TLR6 binds a 19-kDa M. 
tuberculosis lipoprotein. These signals are transduced through MyD88 and 
transcription of Nuclear Transcription Factor kappa  (NF-) and thus promote 
inflammatory cytokine secretion, particularly TNF- [75]. TLR4 recognises heat-
labile cell-associated factor and also activates MyD88 and NF-, yet induces 
Interleukin-1 (IL-1) production [76]. TLR8 and 9 are endosomally located and thus 
able to detect the nucleic acids of intraphagosomal M. tuberculosis. Stimulation 
results in the expression of NF-B dependent cytokines as well as type 1 interferons 
[77, 78]. TLR8 expression is increased in patients with TB disease and in ex vivo cell 
stimulation experiments and genetic variants have been associated with susceptibility 
to TB disease in two populations [79].  
 
Similarly, ligation of nucleotide-binding oligomerisation domain 2 (NOD2), another 
PRR expressed by human alveolar macrophages, limits intracellular M. tuberculosis 
growth through up-regulation of autophagy and cathiliciden production [80], NOD2 
polymorphisms have been associated with TB in some populations [81], albeit not in 
others [82, 83]. 




NLR or Interferon-inducible protein AIM2 (AIM2) receptor ligation also activates the 
inflammasome; the multiprotein complex containing caspase-1 that activates IL-1b 
[84]. Polymorphisms in the inflammasome pathway, specifically Caspase recruitment 
domain-containing protein 8, are associated with risk of TB in HIV infected 
individuals [85].  
 
Besides MR, two other C type lectins may recognise M. tuberculosis: Dendritic cell 
specific intracellular adhesion molecule-3-grabbing non-integrin (DC-SIGN) and 
Macrophage C type Lectin (MCL). M. tuberculosis induces expression of DC-SIGN 
in alveolar macropahges, and binding of DC-SIGN to M. tuberculosis Man-LAM 
leads to an anti-inflammatory signal [86]. MCL (also called Clec4d) has recently been 
identified as a functional receptor for M. tuberculosis in experimental models [87], 
but genetic association studies in humans are needed.   
 
Recognition leads to the secretion of inflammatory signals, primarily cytokines and 
chemokines. Table 2 lists selected cytokines important to the control of Tuberculosis. 
 
 
Table 2. Innate cytokines with protective function in M. tuberculosis infection. 




IL-1 and IL-1 gene disrupted mice succumb to low dose aerogenic M. 
tuberculosis infection. M. tuberculosis infection of  IL-1 receptor 1 knock out 
mice develop necrotic granulomas that are permissive to mycobacterial 
replication [88]. In mice lungs IL-1 and IL-1 are co-expressed by 
inflammatory monocyte-macrophages and dendritic cell populations where 
they are regulated by type I interferons [89]. This susceptible phenotype can 
be reversed by host directed therapies targeting type 1 interferons via 
ecanosid mediators. Studies of IL-1 responses in humans are lacking, 
however polymorphisms in associated pathways have been linked to TB. 
Bone marrow derived macrophages from donors with gain of function 
polymorphisms in key inflammasome components control M. tuberculosis 




TNF- The importance of TNF- to human susceptibility to M. tuberculosis is 
illustrated by the risk of reactivation of latent infection in patients on anti-
TNF therapies [33]. Studies in zebrafish reveal that TNF- induces reactive 
oxygen species (ROS) production that enhances macrophage killing of 
intracellular M. tuberculosis but also causes macrophage necrosis through the 
RIP1-RIP3 kinase pathway, permitting M. tuberculosis to escape into the 
permissive extracellular space [91]. In zebrafish TNF- response to M. 
tuberculosis is determined by LTA4H expression and mediated by eicosanoid 
levels, and LTA4H promotor polymorphisms have been linked to treatment 
response in TB Meningitis [92], although this human finding has not been 
replicated [93]. The effects of IL-1β and TNF- are interdependent in 
establishing early control of infection in a mouse model [94]. 
IL-1RA IL-1RA binds the IL-1 receptor without inducing signaling. It is expressed by 
macrophages in M. tuberculosis and other granulomas [95]. One report of 
high IL-1RA genotypes being enriched in TST negative participants supports 
a positive role for IL-1RA[96]. Conversely M. leprae induces TOLLIP and 
thereby IL-1RA, potentially as a mechanism of evading IL-1β [97]. 
IL-10  Produced by macrophages, DC and neutrophils early in infection but later 
CD4+T cells.  
IL-10 maybe induced by M. tuberculosis as a block to phagolysosmal 
maturation, or it may serve the host by limiting excessive inflammation [98]. 
IL10 genotype is associated with TST positivity (but not TB disease) in a 
large study of Ghanaian case contacts [99], as well as TB disease in Tunisia 
and India [100-102].  
IL 6  IL-6 is produced by macrophages in response to mycobacterial stimulation of 
TLR2. IL-6 silencing in infected macrophages, permits M. tuberculosis 
growth and drives type 1 interferon signaling [103]. A single human study 
links IL-6 polymorphisms susceptibility to pulmonary disease [104]. IL-6 is 







Macrophages have a number of mechanisms to kill intracellular mycobacteria 
including oxidative killing, autophagy, antimicrobial peptide production. After 
phagocytosis the M. tuberculosis containing phagosome matures through interactions 
with the endocytic pathway. This includes acidification of the phagosome through 
expression of H+- ATPase as well as the hydrolytic enzyme cathepsin D [109]. 
Mycobacteria are subjected to further oxidative stress through up-regulation of 
Nicotinamide adenine dinucleotide phosphate oxidase and Nitric Oxide Synthase to 
produce reactive nitrogen intermediates (RNI) and possibly reactive oxygen 
intermediates (ROI). In mice this process is up-regulated by IFN- acting in synergy 
with TNF- [110, 111] whereas in humans 1,25-(OH)2 vitamin D3 is also required 
[112]. The importance of this defence for killing of intraphagosomal M. tuberculosis 
has driven both pathogen evasion strategies and host counter strategies to influence 
phagolysomal fusion. Man-LAM, through interaction with the MR, inhibits 
phagolysosomal fusion and, via peroxisome proliferator-activated receptor, down 
regulates transcription of NF-, activator protein-1, and Signal Transducer and 
Activator of Transcription (STAT), favouring an anti-inflammatory cytokine profile 
and blunted oxidative response [113, 114]. Cell wall constituents from more virulent 
mycobacterial strains achieve greater inhibition of phagolysosomal fusion [115]. 
Macrophages may counter this inhibition though deploying autophagosomes that 
engulf phagosomes and force lysosomal fusion [116, 117]. Autophagy is promoted by 
IFN-, vitamin D and TLR4 via Toll-interleukin-1 receptor domain-containing 
adaptor-inducing interferon-b (TRIF) signaling [116, 118]. Finally, M. tuberculosis 
infected macrophages produce hepcidin and catheliciden, which have direct activity 
against M. tuberculosis [119, 120]. 
 
Innate cells and the early granuloma   
Alveolar macrophages migrate to the lung interstitium where early granulomata form. 
Other myeloid cells including newly recruited monocytes, dendritic cells and 
neutrophils may engulf infected macrophages, now laden with bacilli [18]. Iterations 
of this process account for the logarithmic expansion of M. tuberculosis in early 




understood as a key pathogen virulence factor.  This stage represents a key juncture at 
which pathological findings in rabbits bred to resist infection diverged from 
susceptible rabbits [15].  
 
Macrophages in the granuloma  
Macrophages may die through apoptosis or necrosis, and experiments in macrophage 
cell cultures show that apoptosis inhibits M. tuberculosis replication. The apoptotic 
macrophage expresses ATP and phosphatidyl serine to promote its efferocytosis by 
other phagocytes that kill the bacterium [122]. Virulent strains of M. tuberculosis may 
evade apoptosis and induce necrosis through production of lipoxin A4, which blocks 
prostaglandin E2 synthesis and prevents repair of the plasma membrane [123]. This 
necrotic death favours membrane disruption and mycobacterial outgrowth. In a 
zebrafish M. marinum model the balance of pro and anti-inflammatory eicosanoids 
influenced macrophage necrosis and subsequent mycobacterial outgrowth [124].  
 
Neutrophils 
Neutrophils are an abundant innate cell type capable of rapid response to 
mycobacteria. They are capable of directly recognising and phagocytosing 
mycobacteria [125], and infected cells. Experimentally inducing neutrophilia in the 
lungs of rats reduces their susceptibility to aerosol M. tuberculosis infection [126]. 
Similarly neutrophil depletion of mice increases their susceptibility to experimental 
infection [127]. Neutrophils produce the antimicrobial peptides cathelicidin, human 
neutrophil peptides 1 and 3 and Lipocalin 2 [128]. Kisich observed that neutrophils 
from some donors killed mycobacteria spontaneously whereas others required TNF- 
activation; variability that may reflect varying capacities for EC [129]. The zebrafish 
model enables visualisation of neutrophils being recruited to the granuloma, 
potentially in response to signals from dying macrophages. In these studies 
neutrophils kill mycobacteria by oxidative mechanisms at a time that coincides with 
the formation of the early granuloma [130].  
 




Even less is known about the role of other immune cells in EC. Natural Killer (NK), 
Mucosa Associated Invariant T (MAIT) cells and  T cells express germ-line 
encoded PRRs that give them innate type functions. The early appearance of NK cells 
in M. tuberculosis suggests a possible role in EC. The germ line encoded receptors 
NKp46 on NK cells recognise infected monocytes [131]. NK cells produce IFN- and 
IL-22 that promote M. tuberculosis killing and macrophage apoptosis [132, 133]. NK 
cells in experimentally infected animals have a variable impact on the course of 
infection. 
 
MAIT cells are a recently described T cell population found in mucosal tissue 
including the lung. As they do not depend on clonal expansion, MAIT cells respond 
rapidly to danger signals and provide an early innate source of IFN- to drive 
macrophage activation. MAIT cell deficient mice challenged with aerosolised M. 
bovis have a significantly higher burden of infection at day 10. [133b] . 
 
 T cells may also play a role in the early response to M. tuberculosis as they are 
present in alveoli, and recognise mycobacterial phosphoantigens expressed on the 
surface of infected macrophage [133c]. Their activation results in killing of infected 
macrophages through cytotoxic granules, IFN- and TNF- signalling, and cell 
contact dependent help. As with other T cell sub-sets, the role of  T cell in the 
response to early M. tuberculosis infection needs to be defined.   
 
Acquired defects of early clearance 
A variety of clinical conditions could impair clearance of M. tuberculosis including 
diabetes mellitus, smoking [134], end stage renal disease, corticosteriod use and anti-
TNF- agents among others. Conditions where laboratory and clinical observations 
support impaired clearance are HIV infection and vitamin D deficiency.  
 
HIV 
HIV is an established risk factor for developing TB disease, and probably also a risk 




of CD4 T-cells [135]. Additionally, HIV impairs innate immunity in a manner that 
may impair EC: macrophage turnover is increased in HIV infection, and apoptosis is 
impaired [136, 137]; dendritic cell numbers are diminished and their autophagic and 
antigen presenting functions are suppressed [138, 139]; NK cells have low levels of 
glutathione and permit higher rates of mycobacterial growth in co-cultured monocytes 
[140]. Molecular epidemiological studies of M. tuberculosis suggest susceptibility to 
infection is a greater contributor to risk of TB in HIV positive persons than 
accelerated disease progression. HIV was strongly associated with reinfection in a 
study of previously treated South African miners [141]. Additionally, a metaanalysis 
of molecular epidemiological studies showed high rates of clustering of M. 
tuberculosis strains, supporting susceptibility to infection rather than reactivation of 
previously circulating strains [142]. A low baseline monocyte to lymphocyte ratio was 
associated with a higher risk of subsequent TB in HIV positive persons, and may 
reflect impaired clearance [143].  
 
Vitamin D 
Vitamin D deficiency may be a modifiable risk factor for M. tuberculosis infection. 
Vitamin D is a potent modulator of innate immunity and was a treatment for TB in the 
pre-antibiotic era.  
 
Following TLR2/1 activation, monocytes require vitamin 1,25 (OH)2vitamin D3 for 
the production of the antimicrobial peptides[120, 144] and up-regulation of autophagy 
[144, 145]. Vitamin D treated cells restrict M. tuberculosis growth [120]. Paracrine 
signalling by IL-1β drives the production of β -defensin by airway epithelial cells, 
which in turn promotes M. tuberculosis killing in co-cultured macrophages [146]. 
1,25 (OH)2vitamin D3 boosts cytokine signals associated with infection, particularly 
for IL-1β whose transcription is directly regulated by 1,25 (OH)2 vitamin D3. 
Activated macrophages drive the synthesis of active 1,25 (OH)2 vitamin D3 from 25 
(OH) vitamin D3 by up-regulating CYB27B1 [147], under the regulation of 
Interferon-g, IL-15 [148], and IL-32 [149].  
 
This effect occurs at physiologic concentrations: a single oral dose of vitamin D was 




TB case contacts [150]. Vitamin D receptor polymorphisms and vitamin D deficiency 
are associated with susceptibility to TB infection among Guajarati Indians living in 
the UK [151]. VDR polymorphisms have been linked to susceptibility to TB in 
several populations [152], response to treatment [153, 154] and to risk of drug 
resistant TB [155]. A study in two native Paraguayan populations also found the Fokl 
F allele protects against M. tuberculosis infection [156]. 
 
The effect of vitamin D may depend on the clinical stage of M. tuberculosis infection 
[157]. Profound vitamin D deficiency is associated with poor treatment response  
[158], however a randomised controlled trial of vitamin D supplementation did not 
shown significantly improved treatment response, as measured by sputum smear 
conversion with supplementation [159]. One study reported a non-significant 
reduction in days to sputum conversion overall (from 43·5 days in the placebo group 
to 36.0 in the intervention group; adjusted hazard ratio 1·39, 95% CI 0·90 - 2·16; 
p=0.14), but noted a strong interaction with genotype (pinteraction=0·03). Vitamin D 
resulted in significantly increased sputum clearance in patients with the tt genotype 
(8·09, 95% CI 1·36 - 48·01; p=0·02) [160].  
 
However, there is possibly greater evidence for vitamin D as a host directed therapy 
in earlier stages of M. tuberculosis infection. In a double blind placebo-controlled 
randomised controlled trial among 120 Mongolian child case contacts, those having 
vitamin D supplementation had a lower risk of TST-conversion than those on placebo, 
although the difference was of borderline significance (RR 0.41; 95% CI 0.16 to 1.09; 
P=0.06) [161]. An observational study of 247 initially TST negative TB case contacts 
in Spain found baseline serum 25 (OH) vitamin D was inversely associated with risk 
of M. tuberculosis infection after eight to ten weeks [162]. Following adjustment for 
grade of smear positivity of the index case, the relative risks (RR) according to 25 
(OH) vitamin D levels of 0-9ng/ml, 10-19 ng/ml, 20-29 ng/ml and >/=30 ng/ml levels 
were of 27.3% (RR 1.00), 16.0% (RR 0.52; 95% CI 0·14 - 1·99), 4.8% (RR 0·15; 
95% CI 0·03 - 0·77) and 5·4% (RR 0·15, 95% CI 0·03 - 0·71) for (P trend=0·005). 
The study estimated the attributable fraction of TB infections due to 25 (OH) vitamin 
D levels under 20 ng/mL as 45% (95% CI 20·6–55·2). Therefore, there is some 
evidence that vitamin D may influence EC, but more field studies in TB case contacts 





BCG vaccination and trained immunity 
BCG vaccination may modulate innate immune responses to enhance early clearance. 
The effect of BCG against M. tuberculosis infection was discovered recently, because 
of the improved specificity of IGRAs for detecting LTBI after BCG vaccination 
relative to the TST. A meta-analysis estimated the protective effectiveness of BCG 
against infection in children to be 19% (95% CI 8% to 29%) [163]. Adaptive 
recognition of BCG via CD4+ T cells does not correlate with protection against M. 
tuberculosis, contrary to long held expectations [48]. BCG vaccination has been 
shown to increase the production of IL-1 and TNF- responses to mycobacteria and 
other stimuli via epigenetic reprogramming of monocytes, a phenomenon called 
trained immunity [164]. 
  
Conclusion 
M. tuberculosis firstly infects alveolar macrophages and then other phagocytic cells in 
the early granuloma. Innate cells recognise M. tuberculosis via pattern recognition 
receptors that signal cytokine production. These signals may impact the cell 
phenotypes contained in early granulomata, thereby influencing the outcome of early 
infection. Innate responses to mycobacteria are modulated by HIV, vitamin D and 










Having established that an exposed but uninfected group is frequently observed in 
epidemiologic studies of TB case contacts (Chapter 1: Introduction) and reviewed 
possible innate immune mechanisms of EC (Chapter 2: Possible mechanisms of early 
clearance), the published literature was reviewed to identify reports of biomarkers 
linked to the EC phenotype in humans. Biomarkers of EC are needed to advance 
understanding of potential mechanisms of EC. The results of this specific review, and 
background knowledge of innate immune responses in the preceding chapter, 
informed the selection of candidate markers and the analytic approach of the present 
study.    
Method 
Search strategy 
As EC is a novel phenotype, investigators use a variety of terms to describe the group. 
Accordingly a search strategy was devised to identify a large number of potentially 
eligible reports that could then be assessed against eligibility criteria.  
 
To identify publications linking the EC phenotype to biomarkers in humans, the 
National Library of Medicine (Pubmed) database was searched for articles published 
before 22 March 2017. A first set of studies with the major topic or title 
“Tuberculosis” was filtered to exclude studies on animals only. Within this set of 
studies those containing the text “resistant to infection”, “resistance to infection”, 
“infection resistant”, “TST negative”, “tuberculin skin test negative”, “mantoux 
negative”, “heaf negative”, “heaf test negative”, “ppd negative”, “interferon gamma 
release assay negative”, “elispot negative” or “early clearance” and the subject 
headings “Immunity”, “Immunology”, “Genes” and in English. The search excluded 
studies with the major topics “Drug Resistance, microbial” or words “antimicrobial 




publications was manually reviewed for those that included comparison of biomarkers 
between infected and uninfected groups.  
 
The resulting list of publications was then reviewed to confirm reports met the 
following eligibility criteria: 
• original reports (not reviews)  
• published in English 
• included human subjects who were M. tuberculosis exposed yet uninfected 
• sought to link exposed yet uninfected individuals to a biomarker 
• was not a vaccine study  
• included a predominantly HIV negative population, due to the difficulty 
diagnosing LTBI in those with HIV.  
Studies were also identified through my own reading related to other chapters. Where 
they met the inclusion criteria they were included in the present review. Studies that 
sought to identify an intermediate phenotype such as TNF- or IFN-g production in 
response to mycobacterial antigens with genetic loci were not included [165, 166].  
Results 
Two hundred and forty-eight publications were identified by the search strategy. Of 
these 228 were excluded (Table 3).  
Table 3. Reason for exclusion for 228 studies. 
Reason for exclusion Frequency 
No human participants 31 
Report is not in English 9 
Report is not original (i.e. review). 25 
Study does not include an uninfected group 85 
No biomarker described in the study 5 
Study is on HIV infected participants 5 
Study is a clinical trial of a vaccine 7 
Study focuses on another phenotype 61 
Total excluded 228 





The most common reason for exclusion was lack of an uninfected group (82), 
followed by reports including but not describing the uninfected group (61). This latter 
group included studies that sought biomarkers of LTBI and used the uninfected group 
as controls. In total, 20 studies were identified for inclusion in the review.  
 
Summary of literature  
Studies of immune function in early clearers are reported in Table 4 and studies of 













Biomarkers and findings  Interpretation, strengths and limitations 
Multi-ethnic CC and 
HC in United 
Kingdom[167].  
 
All HIV negative.  
78% BCG vaccinated.  
QNF-GIT negative at 
recruitment.  
 
87 QNF-GIT positive. 
30 QNF-GIT negative.  
 
Longitudinal follow up of 
66 contacts and 29 
controls 6 weeks after 
recruitment. 
 
Design: Cross sectional.  
 
The phenotype is defined 
by baseline IGRA, follow 
up is to assess change in 
neutrophil count in each 
group over time  
Biomarker: Neutrophils. 
 
Findings: Low neutrophil count 
in  QNF-GIT positive case 
contacts, but not controls. Risk of 
conversion decreased by 40% for 
every 1 × 109 increase in 
neutrophils.  
 
Neutrophil count decreased from 
4.4 × 109/L at baseline to 4.1 × 
109/L; P = 0.02) in longitudinally 
followed contacts.  
 
BCG lux whole blood assay (an 
ex-vivo model ability of immune 
cells to restrict mycobacterial 
growth) was correlated with 
Interpretation: Neutrophil count is 
associated with EC, part of acute response 
to M. tuberculosis infection.  
 
Strength is use of longitudinal follow up to 
illustrate neutrophils in the QFN-GIT 
negative group reduce over time, consistent 
with reaction to acute infection. BCG lux 
findings support mechanistic role for 
neutrophils 
 
Moderate sample size.  
 
Limitations: is low prevalence setting, 
limits generalisability.  Assessed contact 
age as a potential confounder, but not M. 
tuberculosis exposure  
 






neutrophil count in the contacts 
only, but it was not correlated 
with  QNF-GIT result  
 
 
Household CC of smear 
positive TB cases in 
The Gambia [168]. 
All HIV negative 
52% BCG vaccinated 
 
Excluded contacts 
under 18 years of age  
TST performed at 
baseline and 6 months, cut 
off 10 mm. 
  
39 persistently TST 
negative at baseline and 6 
months  
26 convert TST negative 
to positive  





Biomarkers: Cytokine assays on 
PBMCs cultured with M. 
tuberculosis peptides overnight 
and for 6 days.  
 
Findings: Persistently TST 
negative had lower levels of 
responses for MCP–3, IL–13, IL–
17 (significant at P<0.05 level) 
and IFN–g, IP–10, MIP–1b, IL–
2RA, GMCSF (significant at P 
<0.01 level) than converters 
 
Interpretation: Higher results for  IFN–g, 
IL-17 reflect early delayed type 
hypersensitivity reaction that can be 
detected in PBMCs before TST conversion. 
i.e. study has discovered early biomarkers 
of infection  
 
Limitations: cytokine panel does not 
include key innate cytokines (IL–1b, IL-6, 
IL-8) 
 
Potential confounders reported but not 
adjusted for in analysis 
 
Excluded contacts under 18 years of age, 
who are most at risk of infection in 
endemic setting  
 




Moderate size study  
TB cases and contacts 
in the Gambia. 
 
HIV and BCG status of 
contacts not reported 
[169]. 
Contacts classified by 
TST; cut off ³10 mm  
 
19 TST negative 
20 TST positive,  
36 TB cases  
 
Design: cross sectional 
Biomarkers: cytokines production 
after PPD and EC fusion protein 
stimulation for 7 days  
 
Findings: PPD:  IFN–g , IL-13 
and IL-17 were all significantly 
lower in TST negative compared 
to TST positive contacts 
(p=0.003; p=0.02 and p=0.01 
respectively).  
 
EC Protein:  IFN–g and IL-13 
were both lower in TST negative 
contacts compared to TST 
positive contacts (p=0.0009 and 
p=0.03 respectively). 
Interpretation: Cross sectional comparison 
has led to discovery of correlates of 
adaptive immunity (i.e.  IFN–g and IL-17), 
which are known to be basis of delayed 
type hypersensitivity response measured by 
TST, and IL-13, correlate of a TH2 
response  
 
Small study. Cytokine panel does not 
include key innate cytokines (IL–1b, IL-6, 
IL-8). 
 
Excluded contacts under 18 years of age, 
who are most at risk of infection in 
endemic setting.  
 
Smear positive index 
cases and their 
household contacts >1 
Used TST (cut off 5 mm) 
PPD ELISPOT and 
ESAT6 ELISPOT.  
Biomarkers: Expression of TNF-
a dependent apoptotic genes 
(TNFR1, TNFR2, FLICE, FLIPs) 
Interpretation: Study concluded greater 
inhibition of apoptosis via FLIPs in TST 
positive, maybe an M. tuberculosis 




year of age and 
community controls  in 
Madagascar [170].  
 
All HIV negative.  
90% BCG vaccinated. 
 
34/128 TST negative 
21/95 PPD ELISPOT 
negative 
46/102 ESAT6 ELISPOT 
negative.  
HC and CC had no 
symptoms and negative x-
ray.  
 
Design: cross sectional. 
by real time RT-PCR of 
peripheral blood. 
 
Findings: TST negative contacts 
had lower mean levels of FLIPs 
(but also wider range).  ELISPOT 
negative contacts had lower mean 
level of FLIPs and narrower 
range.  
 
No difference in FLIPs 
expression in healthy controls 
according to TST.  
virulence factor. Alternative explanation, 
that FLIPs is upregulated in early clearers, 
can not be excluded without unexposed 
controls.   
 
Limitations: Multiple phenotype definitions 
analysed (TST, ELISPOTs) Unclear how to 
interpret when findings differ according to 
definition. No analysis of confounding 
factors including exposure. 
 
Strengths: Wide age range of participants 




Case contacts in The 
Gambia >6 months of 
age[171]. 
 
2% HIV positive.  
Comparison of contacts 
with concordant TST and 
ELISPOT results.  
 
Biomarker: FOXP3 and IL10 
expression by RT-PCR. 
 
Findings: FOXP3 expression, an 
indicator or Treg activity, was 
Interpretation: Regulatory T cells that 
express FOXP3 could be effectors of EC, 
or relatively depleted in the periphery in 
contacts with LTBI.  
 




77% BCG vaccinated.  
 
151 “double positives” 
(+/+) with TST > 10 mm 
and ESAT-6/CFP-10-
ELISPOT positive 
134 “double negatives” (-




Design: cross sectional 
higher in -/- contacts peripheral 




Strengths: large sample and analysis 
adjusted for age, sex, exposure to case 
(sleep proximity) and HIV status as 
confounders.  
 
Limitation: can not distinguish between 
two possible interpretations above without 
longitudinal follow up or unexposed 
controls.  
Strict phenotype definition may 
compromise representativeness of groups.  
 
23 HIV negative 
household CC from 
Addis Ababa [172]. 
 
All HIV negative. 
BCG status not 
reported.  
12 QFN-GIT positive, 11 
QFN-GIT negative. 
 
Design: cross sectional. 
Biomarkers: 45 genes associated 
with M. tuberculosis 
susceptibility or resistance in the 
literature. 
 
Findings: The expression levels 
of FOXP3, CCL4, CCL19, TGF
1 and LAG3 were significantly 
Interpretation: If differences observed in 
this small study are real, they appear to be 
associated with LTBI rather than EC.   
 
Limitations: Small number of participants, 
no multiple testing correction so findings 
could be due to chance. Cross sectional 
design means higher expression of genes in 
QFN-GIT positive group maybe 




higher (p < 0.05) in QFT-GIT 
positive than negative contacts. 
consequence of infection, not susceptibility 
factor that preceded infection. No analysis 
of potential confounding factors. 
Mexican CCs [173].  
 
Asymptomatic.  
None had HIV or 
diabetes mellitus. 
89% BCG vaccinated. 
QFN-GIT at baseline and 
again 12 and 18 months.  
 
9 persistently QFN-GIT 
positive 
10 persistently QFN-GIT 
negative. 
 
Design:  Most accurately 
described as follow up of 
cross-sectionally defined 
groups – QFN-GIT 
positive were not at risk 
of incident infection. 
Biomarker: PBMC collection, in 
vitro stimulation by M. 
tuberculosis antigens, then 
lymphocyte count by flow 
cytometry.  
 
Findings: Persistently QFN-GIT 
positive had increased TH1 and 
TH17 and regulatory T cells at all 
time points.  
Interpretation: Despite small size, finds 
latently infected group has consistently 
higher regulatory T cell responses.  
 
Limitations: Cross sectional design means 
may have discovered correlates of latent 
infection, rather than protective or 
susceptibility factors.  
Unclear what benefit of repeating 
stimulation assay is at multiple time points.  
Response does not change over time.  
No analysis of confounding.   
 
 
Ugandan TB household 
CCs [174]. 
 
TST cut off ³10 mm 
  
19 persistently TST 
negative. 
Biomarkers:  TNF- and IFN-g 
responses to whole blood 
stimulation with M. tuberculosis 
Interpretation: Does not find any difference 
between persistently TST negative and 
converters with respect to the markers 
studied.  




Aged over 15 and HIV 
negative.  
53% BCG vaccinated.  
 
42 TST converters. 
42 TST positive.  
 
Design: cohort followed 
for conversion for 2 years. 
 
bacilli, CF, 19 kDa LpqH, LPS 
and BrHPP. 
 
Findings: No difference in TNF-
a response to innate markers 
studies.  
 
IFN-g responses of converters to 
M. tuberculosis bacilli, CF, 19 
kDa LpqH increase are higher 
than PTST negative at baseline, 
and approach those of TST 
positive over time.  
 
No difference in Vd2+ gd T cell 
responses to 7-day stimulation of 
whole blood with three different 
concentrations of BrHPP plus IL-
2.  
 
Strengths: study explicitly designed to 
study EC, innate markers studied supported 
by good experimental evidence.  
 
Limitations: small study, no adjustment for 
confounding.  analysis of potential 
confounders. 
 
Long duration of follow up could be a 
strength, however also limits ability to link 
to index case, as late conversions unlikely 
to be due to original index.  
 




HCW at Respiratory 
Clinic in Malaysia for 
>10 years [175].  
 
BCG vaccination not 
reported. 
 
TST cut off ³10 mm. 
 
8 TST negative.  
7 TST positive. 
 
Design: cross sectional. 
 
Biomarkers: Deep sequencing of 
Immunoglobulin A D-J segments.  
 
Findings: VH3-23, D3-3, JH4 
segments of Immunoglobulin A 
are more common in TST 
negative group.  
 
Interpretation: Different composition of 
IgA antibodies between TST negative and 
TST positive HCWs. However not proof of 
causal role for IgA in EC as authors 
suggest because of limitations.  
 
Strength: use of deep sequencing as 
discovery method.  
 
Limitations: cross sectional design means 
differences between groups could arise via 
reverse causality. No evidence of M. 
tuberculosis specific IgA in the TST 
negative group. Other causes of differences 
between group antibodies not excluded 
(e.g. BCG vaccination, other mycobacterial 
exposure or just chance in small study).  
 
Household CCs in 
Greece.  Also 10 HC 
and 22 TB cases [176]. 
QFN-GIT. Biomarkers: Coronin-1, Sp110, 
TLRs-1,-2,-4 and -6 mRNA by 
quantitative PCR.  
Interpretation: No difference between 
uninfected contacts and HC means markers 





BCG status and HIV 
not reported.  
 
17 persistently QFN GIT 
negative, at baseline and 8 
– 10 weeks later. 
 
Design: cross sectional. 
 
Findings: Lower Coronin-1, and 
SP110 in the QFN-GIT negative 
group vs TB and LTBI groups 
but not HC.  
 
are not likely to be associated with EC, but 
are increased in conversion.  
 
Strengths: selection of biomarkers with 
evidence for role in innate response. 
 
Limitations: Small study risks type I errors 
and poor phenotype definition, no analysis 
of potential confounders.  
 
HCW in Brazilian 
Central Hospital [177].  
 
Previous BCG 60-70%.  
HIV negative.  
Two step TST  with cut 
off <10 mm. 
 
43 converters.  
159 uninfected. 
211 LTBI.  
Biomarkers:  IgG and IgM to M. 
tuberculosis epitopes HspX and 
GlcB.  
 
Findings: No difference in 
antibodies between the phenotype 
groups 
No relationship between antibody 
level and BCG vaccination. 
 
Interpretation: anti HspX and GlcB 
antibodies are not correlated with EC.    
 
Strengths: large size, prospective design, 
findings independent of BCG status.  
 




CC in USA, treated 
pulmonary and 
extrapulmonary [178].  
TST cut off <10mm 
 
20 TST negative.  
19 LTBI. 
21 Pulmonary TB. 
11 Extrapulmonary TB. 
 
Design: cross sectional. 
Biomarkers: Cytokine responses 
of M. tuberculosis infected 
macrophages cultured with and 
without monocyte depleted 
PBMCs.  
 
Findings: For IFN–g (P < 0.01), 
TNF-a (P < 0.04), IL-10 (P < 
0.001), and IL-6 (P < 0.03) 
uninfected persons producing the 
lowest levels, followed by 
extrapulmonary TB cases, 
pulmonary TB controls, and 
persons with LTBI.  
 
Analysis tested for trends across 
disease phenotypes of increasing 
severity.  
Interpretation: Differences across groups 
likely to be dominated by TB disease 
group.  
 
Limitations: Differences between TST 
negative and LTBI groups not directly 
tested, therefore can not draw conclusions 
about EC.  
 







19 kDa LqpH: The 19-kDa lipoprotein of M. tuberculosis; BCG: Bacillus Calmette-Guérin; BrHPP: Bromohydrin pyrophosphate; CC: 
Case contact; CCL: Chemokine (C-C motif) Ligand; CF: culture filtrate; EC: Early Clearance; EC Protein: ESAT6-CFP10 fusion 
protein; HC: Healthy Control; HCW: Health Care Worker; HIV: Human Immunodeficiency Virus; LTBI: Latent TB Infection; PBMCs: 
Peripheral Blood Mononuclear Cells; PPD: Purified Protein Derivative;QFN-GIT: Quantiferon Gold In tube test; RT-PCR; reverse 
transcriptase polymerase chain reaction; LPS: Lipopolysaccharide; TGFB1: Transforming Growth Factor B1; TST: Tuberculin Skin 
Test; TB: Tuberculosis disease.   
 
South Africans 
aged 12 to 18 
years [179].  
 







19 TST=0 mm 
and QFN-GIT 
negative.  






Biomarker:  M. tuberculosis lipid 
specific CD4+ T cells.   
 
 
Findings: CD4+ T cell responses 
to mycolic acid did not differ 
between infected and uninfected 
groups.  
Interpretation: Focus of study is on describing the 
response to mycolic acid, and not comparisons between 
the groups.  
 
Unclear meaning of presence of responses to mycolic in 
the TST negative group could be due to BCG vaccination 
or environmental mycobacteria or reflect memory to a 
cleared infection. 
 
Limitation: no analysis of confounding.  
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Table 5. Genetic studies of the early clearance phenotype. 
Study & Setting Phenotype definition 
& design 
Biomarkers and findings  Interpretation 
128 families (186 parents and 
350 children), 2 – 6 children 
per household. Set in hyper-
endemic Western cape of South 
Africa. States BCG vaccination 
is at birth but does not record 
whether participants vaccinated 
[180].  
 
TST analysed two 
ways: binary (zero vs 
nonzero) and 
quantitative (in 
millimeters - i.e. as a 
quantitative trait locus 
QTL). 
 
140 children TST=0.  
 
Design: cross sectional. 
Remainder normally 




QTL phenotypes were 
all adjusted on previous 
Genome wide linkage scan.  
 
TST1, mapped to chromosome 
region 11p14 associated with 
binary TST and presumably, T 
cell–independent innate 
resistance to M. tuberculosis.  
 
TST2 associated with the 
intensity of TST reactivity as a 
quantitative trait and, 
presumably, the intensity of T 
cell–mediated DTH to 
tuberculin. Fine mapping shows 




Interpretation: TST1 and TST2 are 
correlated with EC phenotype in this 
study.  
 
Potential limitation: the use of the zero 
vs non-zero phenotype definition, 
rather than the 10mm cut off which is 
associated with risk of progression to 
M. tuberculosis. However, as this alters 
the classification of fewer than 20 (6%) 
of children, the impact maybe limited.  
 
Strength: adjustment for confounders.   
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clinical TB, sex and 
age. 
Colombian household CC of 
smear positive cases without 
history of TB disease [181].  
 
BCG and HIV rates not stated 
but presence of BCG scar 
included in analysis.  
TST in mm (i.e. 
quantitative).  
 
371 contacts with 
median TST of 13 mm.  
 
Design: cross sectional. 
 
Effects of age, BCG vaccine 
scar, and sleep proximity were 
modelled by GLM. Best fit of 
model to data achieved when 
co-dominant mode of 
inheritance modelled 
(determined by likelihood ratio 
test).   
Segregation analysis suggested 
a co-dominant gene would 
explain 65% of TST variability.  
Interpretation: Strictly speaking no 
single biomarker studied, though 
findings do support genetic basis for 
EC.  
 
Strength: adjustment for confounders. 
273 household CC of culture 
positive cases in France [182]. 
 
HIV prevalence not stated.  
97% BCG vaccinated.  
 
Mean age (±SD) of contacts 
24.1 ± 18.0 years.  
TST as a binary 
variable 0 or >0mm, 
performed twice, 8-10 
weeks apart. Those 
with discordant TSTs 
were excluded.  
 
84 TST 0 mm, 
Effects of cavitation, smear 
grade, age, sex, days spent with 
case in last 3 months prior to 
diagnosis were modelled by 
GLM. Genome wide linkage 
scan performed on the residuals.  
 
Interpretation: Validates the association 
of TST1 with EC found in South Africa 
by the same group [180]. The nearest 
gene is WT1, also linked to TB disease 
by Thye [183]. 
 
Strength: Confounders adjusted for 
well.  
 Table 5 continued on next page 
 
37 
189 TST >10. 
 
Design: cohort. 
Findings: linkage at 11p15, and, 
when combined with South 
African data association was 
strengthened. [180]  
Limitations: Combined with preceding 
study provides compelling proof of EC 
phenotype, but without fine mapping to 
identify specific gene, does not advance 
understanding of EC mechanism.   
HIV negative TB cases and 
exposed CC from Ghana, West 
Africa [99]. 
 
Unrelated CC from households 
and neighbours, negative PPD 
and x-ray.  
 




TST cut off not stated.  
2010 TB cases,  
2217 TST positive 
129 TST negative 
household contacts. 
 
Design cross sectional. 
IL-10 promotor genotypes by 4 
SNPs, reconstructed haplotypes, 
then categorised as low or high 
IL-10 producers.  
 
The IL-10 low-producer 
haplotypes were more common 
among PPD negative controls 
than among cases (OR 2.15; 
95% CI 1.3–3.6) and PPD-
positive controls (OR 2.09, CI 
1.2–3.5).  
Haplotypes are correlated with 
plasma IL-10 levels.  
Interpretation: Investigators conclude 
IL-10 production in early infection may 
result in M. tuberculosis specific 
anergy. Alternative explanation, not 
discussed by authors, is a pro-
inflammatory phenotype favours EC. 
 
Strength: Large study though the TST 
negative group is only 3% of 
participants. Plausibility of result 
strengthened by also correlating to 
functional result (IL-10 plasma levels).  
Limitation: lack of adjustment for 






Household CC of 
culture positive cases in 
Uganda. 14% HIV 
positive. BCG coverage 
“high” [184].  
 
 
TST negative defined as 
<5 mm for children under 
5 years or HIV positive 
individuals and <10 mm 
for all others.  
 
75 “resistors” (early 
clearers) with persistently 
negative TST 
 Controls were group of 
both 240 cases and 520 
TST + contacts. 
 
Design: cohort followed 
for two years.  
546 haplotype- tagging SNPs 
within 29 candidate genes 
identified from literature.  
 
Genotype modelled for its 
relationship with resistor trait, 
using a GEE that accounted for 
clustering, with sex and age 
included as covariates. 
 
EC associated with total of 17 
SNPs at P<0.05 threshold. 
Strongest effects in 2 SNPs in 
NOD1, two in NOD2 and three 
SNPs in SLC6A3 (P<0.05) 
Interpretation: SLC6A3 is at same locus as 
TST2, so further validates locus identified in 
South Africa and France. [182]. Other 
associations plausible because genes studied 
already linked to TB susceptibility in 
literature.  
 
No correction made for multiple testing, 
therefore findings could be due to chance. 
 
Strength: Does adjust for some confounders, 
although this does not include BCG status 
nor M. tuberculosis exposure. 
 
HIV: Human Immunodeficiency Virus; BCG: Bacillus Calmette-Guérin; EC: Early Clearance; TST: Tuberculin Skin Test; PPD: Purified 
Protein Derivative; HC: Healthy Control; CC: Case Contact; HCW: Health Care Worker; LTBI: Latent TB Infection; TB: Tuberculosis 






Studies of the immunology of early clearance 
Overall the immunology studies had a number of methodological flaws that limit the 
ability draw conclusions about biological correlates of early clearance (EC).  
 
Firstly, nine out of 14 studies had fewer than 30 participants in the exposed uninfected 
group, risking type II errors. Studies to identify correlates of EC may need to be larger 
than studies of active TB disease phenotypes, as EC is asymptomatic and changes in 
biomarkers maybe less pronounced. Studies that used multiplex methods where 
multiple biomarkers were studied were small despite the need for increased sample 
size to address multiple testing.  
 
Secondly, few of the studies sought to address confounders such as HIV infection, 
BCG vaccination or age. Burl et al did adjust for age, sex, exposure to the index case 
(sleep proximity) and HIV status as confounders [185]. The study of FOXP3 
expression included 285 participants and adjusted for these factors in a multivariable 
model. The prospective study of anti-mycobacterial antibodies in health care workers 
by Rabahi et al did not adjust for confounders, but did address potential confounding 
by BCG vaccination through a stratified analysis [177].   
 
Thirdly, the interpretation of studies with a cross-sectional design is complicated. 
Findings can arise by reverse causality, for example the association of higher IFN-g 
and other markers of an adaptive response with baseline TST positivity are likely to 
be a consequence of LTBI infection [169], rather than a factor associated with either 
susceptibility or immunity. An exception is the study of London TB case contacts by 
Martineau et al, which shows an association between high neutrophil count at 
baseline and baseline QFN-GIT [167]. The uninfected group have higher neutrophil 
counts and these decline in the weeks after their exposure, but unexposed controls had 
no change. This pattern of findings favours the interpretation that neutrophil counts at 
baseline are protective, over the alternate explanation, that reduced peripheral 
neutrophil counts are associated with infection. Even when a cohort design is used, in 
which participants at risk of infection are followed for either conversion or remaining 





example, the cohort study in the Gambia found contacts who subsequently converted 
their TST had higher levels of cytokines with adaptive immune functions at baseline 
than those who remained uninfected [168]. It is likely this reveals earlier detection of 
the evolving adaptive response by the PBMC stimulation study than can be achieved 
by the TST or ELISPOT. Differences between the groups still need to be interpreted 
with respect to knowledge of the marker’s function, or in comparison to a set of 
uninfected controls.  
 
Fourthly, the literature includes studies focused on adaptive cellular or cytokine 
responses to M. tuberculosis and the selected biomarkers were not necessarily 
relevant to innate immunity. Studies by Mahan [174], Rakotosamimanana[170], and 
Martineau et al [167], are exceptions and test hypotheses about specific innate 
mechanisms and EC. 
 
Finally, many studies were limited by the representativeness of the groups they 
studied. As children, and to a lesser extent adolescents, represent a high risk group for 
infection, their exclusion limits the ability of investigators to detect differences in 
immune function correlated with susceptibility. In contrast the study of FOXP3 
expression by Burl et al included all participants over 6 months of age, and included 
age as a confounder [185]. Studies conducted in low prevalence settings could be 
limited by lack of generalisability to settings were M. tuberculosis transmission is 
high. Hosts in low prevalence settings may differ with respect to BCG vaccination, 
nutrition, and potentially environmental mycobacteria exposure. 
 
Given these limitations it is unsurprising that the results of studies have not been 
consistent. Martineau’s finding with respect to neutrophils represents the biomarker 
most clearly associated with EC, but this association has not been replicated. Burl et 
al [185] found higher FOXP3 expression in the TST and ELISPOT negative group 
was, compared to contacts for whom both tests were positive; was not replicated in a 
small study of Ethiopian case contacts [172]; nor were FOXP3 expressing T cells 
more frequent in QFN-GIT negative case contacts in Mexico [173]. Other studies 
tended to discover correlates of existing or developing latent infection, or were 






Genetic studies findings 
All of the genetic studies found loci or polymorphisms associated with remaining 
uninfected. Two associations were replicated in different populations. TST1 (the 
binary phenotype defined as TST of 0mm or TST greater than 0mm) was identified in 
South Africa and validated in France [182]. The nearest gene to the locus is WT1, a 
gene also associated with susceptibility to TB [183]. TST2 was associated with 
quantitative TST response South Africa [182] and SNPs in the nearest gene SLC6A3 
were associated with TST using 10mm threshold by Hall et al [184].  
 
This illustrates early clearers are a biologically distinct group, as biomarkers would 
not be expected to be found and replicated if the uninfected group were merely 
insufficiently exposed to be infected. However, the associations are not with genes 
with known immune functions, so they do not directly advance our mechanistic 
understanding of EC. Hall et al took an alternative approach and studied candidate 
genes with innate immune functions that were associated with a persistently TST 
negative phenotype. However, the large number of candidate genes analysed means 
the study was underpowered to detect any real differences that might exist.  
 
Overall the genetic studies were better designed to study EC than the immunology 
studies. Many of the studies of genetic correlates of EC accounted for confounding 
variables such as age, sex and sometimes exposure to the case and BCG vaccination. 
They included larger sample sizes than the immunology studies, and were able to 
detect some differences between the groups, however there is still a risk of type II 
errors. For example the genome wide linkage study by Cobat et al in South Africa had 
only 140 children in the TST=0 group, and while one linkage peak was significantly 
associated with the trait after multiple testing correction a further 6 peaks were not 
[180]. Even the study of 29 candidate genes in the Uganda cohort had only 75 
persistently TST negative contacts, and was insufficiently powered once multiple 
testing is accounted for.  
 
 
Unlike studies of markers of immune function, reverse causality is not a concern as 
genotype is known to precede the development of the phenotype.  This permits the 





African study [180], provided M. tuberculosis transmission in the community is 
sufficiently high for the study population to be considered exposed even if they are 
not known case contacts. The Ugandan study used a long term follow up of the TST 
negative group to demonstrate the stability of the phenotype over time.  
 
The genetic studies all used TST to define the EC phenotype, and associations were 
replicated despite using different cut points for TST positivity. This suggests the 
precise cut point does not matter, perhaps because TST distributions tend to be 
bimodal and a minority of subjects’ classification is changed when the cut-point is 
changed from zero to 10mm. None of the genetic studies used IGRAs.  
 
Conclusions 
Genetic markers of EC have been identified and replicated, findings which show early 
clearers are a biologically distinct group. However, these have not identified genetic 
associations that advance mechanistic understanding of EC. Neutrophil count is the 
only marker of immune function linked to EC, and that is yet to be replicated. Studies 
of immune function require careful study design including definition of an appropriate 
study population, definition of early clearers and controls, measurement and analysis 
of confounding variables, and a design that captures changes in rapidly changing 
parameters. Addressing these challenges is the subject of a later chapter (Chapter 5: 









A further review of the published literature was performed to identify candidate genes 
to be measured in a pilot of RNA sequencing of early clearers and converters. We 
sought to mitigate the risk of false discovery posed by a whole genome approach by 
selecting a limited panel of candidate genes with known protective functions in M. 
tuberculosis infection. The methods and outcome of the literature review are 
described in this chapter, and the pilot itself is reported in Chapter 12.   
 
Methods literature review 
Search strategy 
The following process was used to identify genes with experimental evidence for a 
protective innate immune function during M. tuberculosis infection. Firstly, based on 
the literature review (Chapter 2: Possible mechanisms of early clearance), we 
searched for genes involved in the following protective innate responses to M. 
tuberculosis:  
1. M. tuberculosis recognition. 
2. M. tuberculosis recognition signal transduction  
3. Cytokine signalling. 
4. Intracellular killing. 
5. Disposal of infected cells by phagocytes. 
6. Vitamin D related mechanisms. 
7. Cellular response to infection. 
 
This search began with listings in the KEGG database, which groups human genes 
according to pathways or modules they have been implicated in [186]. Where the 
KEGG database appeared incomplete, published reviews were sought for listings of 
genes associated with the mechanism, as was the case for autophagy [187]. Further 





(RvC, AvL). For each gene, the Pubmed database was searched for reports containing 
the gene name and “M. tuberculosis” in the title or abstract. I reviewed the resulting 
reports for evidence that the gene had a protective role in the response to M. 
tuberculosis. The criteria for inclusion in the final list was a published report 
documenting any of the following:  
1. Manipulation of gene function by inhibition, knockout or RNA silencing 
increases susceptibility to M. tuberculosis in experimental animal.  
2. Manipulation of gene function by inhibition, knockout or RNA silencing 
impairs ability of cultured cells to contain M. tuberculosis growth. 
3. Increased gene expression associated with protective response to vaccination 
in an experimental animal.  
4. Gene expression was associated with other correlates of protective cellular 
response in experimental studies and polymorphisms in the gene are 
associated with TB disease risk.  
 
In summary, genes were retained in the final list if there was experimental evidence 
for their expression influencing known mechanisms of innate immune protection from 
M. tuberculosis. Merely being associated with TB disease was not sufficient for 
inclusion under criteria (4) as factors other than failed ECmay lead to the association 
(i.e. increased risk of disease progression once infected). A gene was not considered a 
candidate if it was merely induced by M. tuberculosis, as this does not necessarily 
constitute a protective response.  
 
Results 
A total of 45 genes were retained in the final list, these and the evidence supporting 
their inclusion are listed in Table 6.  
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Table 6. Genes with evidence for a protective role in innate response to M. tuberculosis. 
Gene Name 
(other names) 
Description and function Evidence for protective function, references 
 M. tuberculosis recognition 
 
TLR1 Toll-like receptor 1. Recognition 
of triacylated lipopeptides.  
Stimulation of TLR1 enhances macrophage and monocyte inhibition of M. tuberculosis 
growth and up-regulates expression of the vitamin D receptor, the vitamin D-1–
hydroxylase genes, and antimicrobial peptide cathelicidin [144]. TLR1- polymorphisms 
is associated with susceptibility to TB in Indian population [188]. 
TLR2 Toll-like receptor 2. Recognition 
of lipoarabinomannan.  
As for TLR1 (above) [144] TLR2 is required for MyD88 induced TNF- response to M. 
tuberculosis in murine macrophage cell line [75]. 
TLR4 Toll-like receptor 4. Recognition 
of heat-labile cell-associated 
factor.  
Expression is upregulated in BCG vaccinated and M. tuberculosis infected cynomolgus 
macaques, but not unvaccinated and infected controls [189]. 
NOD2 Nucleotide-binding 
oligomerization domain 
containing 2. Cytoplasmic 
recognition of N-glycolyl-
muramyl dipeptide (GMDP). 
NOD2 stimulation restricts M. tuberculosis growth in ex-vivo human alveolar 
macrophages and promotes inflammatory cytokine production [80]. M. tuberculosis 






3-Grabbing Non-integrin. A C-
Knock out of CD209 homologues impairs resistance to M. tuberculosis infection in mice 
[191]. 
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Description and function Evidence for protective function, references 
type lectin on dendritic cells that 
recognises M. tuberculosis 
lipoarabinomannan.  
CD209 is the ligand for receptor mediated endocytosis of M. tuberculosis in human 
dendritic cells [192, 193]. A meta-analysis of human studies has found CD209 
polymorphisms are associated with TB disease [194].  
AIM2 Absent in melanoma 2. 
Component of inflammasome. 
Recognises of cytosolic DNA.  
AIM2 knockout mice had increased susceptibility to intra-tracheal infection with M. 
tuberculosis and diminished IL-1 and IL-18 production [195]. 
CLECSF8 
(CLEC4D) 
C-type lectin domain family 4 
member D. Recognition of 
trehalose- 6,60-dimycolate 
(TDM or cord factor). Signalling 
via CARD9 to drive neutrophil 
mediated pulmonary 
inflammation.  
CLECSF8 knock out mice exhibit higher bacterial burdens and increased mortality upon 
M. tuberculosis infection. Polymorphisms in this gene are associated with TB disease in 
humans [196].  
Signal transduction 
 
TOLLIP Toll interacting protein. 
Negative regulation of TLR 
signal following M. tuberculosis 
recognition.  
TOLLIP suppresses TNF- and IL-6 and induces IL-10 production after stimulation 
with TLR2 and TLR4 ligand. Polymorphisms in TOLLIP are associated with TB 
susceptibility in Vietnam [197]. 
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Description and function Evidence for protective function, references 
NFKB1 NF-kB signaling pathway . 
Antimicrobial peptide 
transcription factor.  
NF-B p50 knockout mice were more susceptible to M. tuberculosis infection than wild 
type. They developed multifocal necrotic pulmonary lesions or lobar pneumonia and had 
reduced IFN-g, and TNF- mRNA. [198] Has a role in antimicrobial peptide production 
[146].  
MyD88 Myeloid differentiation primary 
response 88 
Transduction of IL-1 and toll 
like receptor signals. 
MyD88 knockout mice do not survive infection with mutant M. smegmatis, wild type do 
[199]. 
CARD9 Caspase recruitment domain 
family member 9. Signaling 
from TLRs, NOD2 and dectin-1. 
Regulation of apoptosis.  
Card9 knock out mice succumb early after aerosol infection with M. tuberculosis. This 
was associated with pyo-granulomatous pneumonia and a proinflammatory cytokine 
profile [200].  
Cytokine Signalling 
IL1B Interleukin-1. Proinflammatory 
cytokine.  
Macrophages from donors with polymorphisms in inflammasome genes CARD8 and 
NLRP3 demonstrated enhanced M. tuberculosis control in vitro, an effect that was 
reversed by addition of IL-1 antagonist anakinra [90]. 
1,25, OH2 vitamin D stimulated IL-1 production is associated with improved control of 
M. tuberculosis in cell culture [146]. Expression is upregulated in BCG vaccinated and 
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Description and function Evidence for protective function, references 
M. tuberculosis infected cynomolgus macaques, but not unvaccinated and infected 
controls [189]. 
TNF Tumor necrosis factor- 
Proinflammatory cytokine. 
TNF- deficiency and TNF- excess are associated with dysregulated control of 
mycobacteria in mutant zebrafish M. marinum model [92]. 
IL17A Interleukin-17. Proinflammatory 
cytokine produced by activated 
TH17 cells. Activates neutrophils 
recruitment.  
Higher IL-17 production in BCG vaccinated cynomolgus macaques that controlled M. 
tuberculosis infection compared to those who did not [201]. IL-17A knock out mice 
failed to develop granulomas in response to BCG infection. 
IL18 Interleukin -18. Activates NK 
cells, and stimulates IFN gamma 
in TH1 cells 
Mice deficient for IL-18 and MyD88 rapidly succumb to M. tuberculosis infection in 
contrast to wild type and TLR-2/-4 double knock out mice (the TLR-2/-4 control  
required to demonstrate this effect is due to IL-18, as both IL-19 and TLR2/4 signalling 
is through MyD88) [202]. 
IL6 Interleukin-6. Acute 
inflammatory cytokine.  
Silenced expression of IL-6 permits increased growth of M. tuberculosis in cultured 
macrophages [103]. 
IL12 Interleukin-12. Expressed by 
activated macrophages to induce 
TH1 cell development.   
IL12 expression is upregulated in BCG vaccinated and M. tuberculosis infected 
cynomolgus macaques, but not unvaccinated and infected controls [189]. 
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IL32 Interleukin-32. Induction of 
vitamin D dependent 
antimicrobial peptides 
Transgenic mice expressing human IL-32 have lower M. tuberculosis burden following 
experimental infection [203]. Note protective effects vary according to splice variants 
[204].  
CXCL8 Interleukin-8. Granuloma 
formation and neutrophil 
chemoattractant.  
Exogenous CXCL8 reduces the survival of M. tuberculosis within cultured 
macrophages, and inhibition of CXCL8 is associated with intracellular mycobacterial 
proliferation [205].  
CXCL2  C-X-C motif chemokine ligand 
2. Neutrophil chemoattractant. 
Distinguishes resistant from susceptible mice in an experimentally infected population of 
outbread mice with multiple biomarkers measured. Correlates of resistance identified by 
machine learning approaches [206].   
CXCL1 C-X-C motif chemokine ligand 
1. Neutrophil chemoattractant 
Distinguishes resistant from susceptible mice in an experimentally infected population of 
outbread mice with multiple biomarkers measured. Correlates of resistance identified by 
machine learning approaches [206].   
CXCL5 C-X-C motif chemokine ligand 
5. Neutrophil chemoattractant 
Distinguishes resistant from susceptible mice in an experimentally infected population of 
outbread mice with multiple biomarkers measured. Correlates of resistance of resistance 
identified by machine learning approaches [206].   
PPBP  Pro-platelet basic protein (or 
CXCL7). Neutrophil 
chemoattractant. 
Stimulation of human monocyte-derived macrophage with CXCL7 inhibits intracellular 
growth of M. tuberculosis [207]. 
Intracellular killing 
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Description and function Evidence for protective function, references 
CAMP Cathelicidin. Antimicrobial 
peptide. 
Inhibits M. tuberculosis growth in cultured macrophages. Effector of the vitamin D 
induced antimicrobial response [208]. Potentially upregulates autophagy [209]. 
 
NOS2 Nitric oxide synthase 2, 
inducible. (iNOS) Nitric Oxide 
production in human 
macrophages. 
Mediates antimycobacterial activity of NOD2, which restricts M. tuberculosis growth in 





Cytochrome b-245 beta chain. 
Production of reactive oxygen 
species. 
Macrophages cultured from CYBB knockout mice have impaired vitamin D dependent 
inhibition of M. tuberculosis in culture [208]. Polymorphisms in CYBB are associated 
with TB in a study of Chinese TB patients and healthy controls [210].   
LCN2 Lipocalin 2. Acute phase 
response including iron 
sequestration, neutrophil 
chemoattractant [211]. 
Lcn2 knockout mice were highly susceptible to intrathecal infection with M. tuberculosis 
and died. These mice had histopathological evidence of a stronger inflammatory 
response [212].  
ATP6V1B1 ATPase H+ transporting V1 
subunit B1. Proton pump for 
phagosomal acidification.  
Inhibition of ATPase using bafilomicin reduced capacity of human macrophages to 
inhibit growth of M. tuberculosis H37Rv in culture [109]. 
CTSD Cathespin D. Lysosomal 
peptidase. 
Inhibition of Cathespin D using pepstatin reduced capacity of human macrophages to 
inhibit growth of H37Rv in culture [109]. 
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Autophagy 
 
ATG5  Autophagy related gene 5. 
Assists in autophagosomal 
elongation.  
Aerogenically infected transgenic mice deficient in ATG5 in myeloid lineage had 
increased bacterial burden than normal littermates with low M. tuberculosis dose and 
high rates of death at high doses [213].  
BECN1 BCL-2-binding protein; forms a 
regulatory complex with class III 
phosphatidylinositol-3-kinas 
(VPS34) 
Mediates vitamin D dependent upregulation of autophagy.  
ATG7 Autophagy related 7. E1 
ubiquitin conjugase-like 
enzyme; facilitates conjugation 
of ATG8 proteins to PE, acts as 
an E1 enzyme for ATG12 
conjugation to ATG5 and 
ATG3.   
ATG7 knock out mice have higher bacterial loads following M. tuberculosis and BCG 
infection [214]. Silencing of ATG7 inhibits ability of RAW264.7 cells to control M. 
tuberculosis growth [215]. 
IRGM Immunity related GTPase M. 
Regulates autophagy in relation 
to intracellular pathogens. 
IRGM RNA silencing abrogates autophagy and control of BCG growth in infected U937 
cells [216].  
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Apoptosis/disposal of infected cells 
 
CASP3 Caspase 3. Activates 6, 7 and 9. Inhibition of CASP3 abrogated IL-1 mediated control of M. tuberculosis in cultured 
murine macrophages [217]. 
CASP8  
(FLICE) 
Caspase 8. Apoptosis. Inhibition of CASP8 abrogated IL-1 mediated control of M. tuberculosis in cultured 
murine macrophages [217]. Expression of CASP8 is higher in PPD ELISPOT positive 
household contacts than PPD ELISPOT negative [170].  
CFLAR 
(FLIPs) 
CASP8 and FADD like 
apoptosis regulator.  
Regulates apoptosis. Significant. 
Higher expression in PPD ELISPOT positive and ESAT-6 ELISPOT positive household 
contacts than their negative counterparts [170].  
CASP7 Caspase 7. Induces apoptosis. Inhibition of caspase 3/7 abolishes apoptosis and elimination of mycobacteria by IFN- 
activated murine bone marrow derived macrophages [218].  
CASP1 Caspase 1. apoptosis and 
activates IL-1. 
Inhibition of caspase-1 significantly abrogates the IL-32-mediated reduction in the 
quantity of intracellular M. tuberculosis and of the percentage of GFP- M. tuberculosis -
infected human THP-1 macrophages [219].  
TNFRSF1A TNF receptor superfamily 
member 1A. Binds TNF- to 
induce apoptosis.  
Tim-3 and IL-1 mediated M. tuberculosis control was abolished in TNFR1 knock out 
murine derived macrophages [217]. Higher expression in PPD ELISPOT positive 
household contacts than PPD ELISPOT negative [170].  
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TNFRSF1B TNF receptor superfamily 
member 1B. Complexes with 
TNF-receptor 1. Antiapoptotic.  
Higher expression in PPD ELISPOT positive household contacts than PPD ELISPOT 
negative [170]. 
LTA4H Leukotriene A4 hydroxylase. 
Metabolism of ecanosids. 
Using morpholino oligonucleotides to inhibit LTA4H translation in zebrafish larvae 
phagocytes lead to increased susceptibility to M. marinum, increased extracellular 
bacterial growth and cording [92]. LTA4H polymorphisms are associated with TB 
meningitis in Vietnam.    
Vitamin D related mechanisms 
 
VDR Vitamin D receptor. 
Transduction of vitamin D 
signal.  
VDR antagonist ZK 159 222 (VAZ) blocked TLR2/1-induced DEFB4 production in 
monocytes [220]. Vitamin D receptor expression is induced by M. tuberculosis infection 
of cultured macrophages [146] VDR polymorphisms are associated with TB disease in 
humans [152]. 
CYP27B1 Cytochrome P450 family 27 
subfamily B member 1. 
Hydroxylates 25-OH vitamin D3 
to produce the active form. 
Inhibition of CYP27B1 blocks TLR2/1L activation of cathelicidin mRNA, and this is 
associated with antimycobacterial effects in cell culture [144].  
Cellular response to infection 
 
Table 6 continued 





Description and function Evidence for protective function, references 
FOXP3 Forkhead box P3. Regulatory T 
cells  from TB patients inhibit 
M. tuberculosis in Monocyte 
derived Macrophages. 
FOXP3 is downregulated in household contacts with recent LTBI relative to TB cases 
and uninfected contacts [185] CD4+CD25+Foxp3+ cells inhibit growth of M. 
tuberculosis in monocyte derived macrophages via production of a Rho GDP 
dissociation inhibitor (D4GDI) [221].  
TNF-α: Tumor necrosis factor –α; BCG: Bacillus Calmette-Guérin; iNOS: inducible Nitric oxide synthase; PPD: Purified Protein 







This review of the literature identifies a number of genes that are important to the 
innate immune response to mycobacteria. The studies included in the review were 
predominantly experiments on animals or human cells, with only Foxp3, LTA4H, 
TOLLIP and the regulators of apoptosis studied in humans.   
 
These transcripts are suitable for inclusion in a panel of candidate transcripts that are 
expected to be up regulated in early clearers relative to susceptible controls. By 
studying these candidate transcripts we can reduce the risk of false discovery that 






Chapter 5: Considerations in study design 
 
Introduction 
Studies of the EC phenotype are complicated by the difficulty in identifying a group 
of Early clearers to study. Experimental infection studies are ethically unacceptable 
and observational studies can not distinguish with certainty individuals who are 
exposed and uninfected (Early clearers) from those who are uninfected due to lack of 
exposure. Lack of a gold standard test for M. tuberculosis infection is also a 
complicating factor. Only a handful of the studies reviewed in the literature review 
(Chapter 3: Review of literature on biomarkers of early clearance) have used methods 
that address these limitations. This chapter discusses challenges in the design of 
studies of EC ahead of a detailed discussion of the study method (Chapter 6: 
Methods).  
 
Defining a group of interest 
A definition of EC is required to enable further study. This definition could be 
considered a “case definition” that identifies a group that contains a high proportion 
of early clearers but acknowledges that some degree of misclassification is inevitable. 
The definition must address two characteristics of Early clearers; namely being 
exposed to and uninfected by M. tuberculosis. 
 
Diagnosing M. tuberculosis infection 
During M. tuberculosis infection non-replicating bacilli are dormant inside 
macrophages. Diagnosis by direct detection of M. tuberculosis would only be possible 
by necropsy. Therefore infection is routinely diagnosed indirectly, by measuring the 
host response to infection, an approach that has inherent inaccuracies. Lack of an 
acceptable “gold standard” means the sensitivity and specificity of both tests can only 
be evaluated indirectly. A meta-analysis of both IGRAs and TSTs included studies 
comparing performance of the two tests [222]. Specificity, estimated by studies in low 
prevalence countries, was 100% (95% CI 97.6 – 100%) for IGRAs and 88.7% (95% 




expected to be higher with a more sensitive test, was 2.3-3.3% for TST and 2.8-14.3% 
for QFN-GIT. IGRA results also had a stronger association with M. tuberculosis 
exposure in analytic studies. Imperfect sensitivity and specificity of LTBI tests will 
lead to non-differential misclassification in studies of EC. To address this limitation, 
studies of EC may need to select “extreme” or high probability phenotypes in which 
the diagnosis is more certain (see below: Defining early clearers according to M. 
tuberculosis exposure). If false negative or positive results actually arise from a 
different phenotype they can be a source of more systematic error. For example, 
anergy, defined as immune non-response to M. tuberculosis antigens, can result in 
false negative TST and IGRA results. This clearly occurs in people with HIV and 
hemodialysis patients, who are at risk of disease at lower levels of Tuberculin 
reactivity and lower IFN- g levels on IGRA test than healthy people. Anergy is clearly 
distinct from an uninfected phenotype as illustrated by a TB outbreak in an anergic 
Amazonian population [223]. Anergy is thought to be the basis of associations 
between polymorphisms in anti-inflammatory cytokines IL10 [99] and IL-1RA [96] 
and negative TST, although the case definition would include early clearers. This type 
of misclassification can not be addressed through study design, but the impact can be 
mitigated by using the tests in populations where their performance is optimal, i.e. in 
immunocompetent individuals and in the setting of recent exposure. Finally, 
correlates of EC identified through research studies in humans should be validated as 
protective in experimental studies or in human cohorts followed for TB disease. 
 
Test reversions, where a positive test becomes negative, are observed more frequently 
with IGRAs than with the TST [224]. Unlike false negatives due to anergy the 
biological meaning of reversions is unclear. In low pre-test probability settings 
reversions may reflect random variation in a continuous variable around the cut-off 
for positivity. Where exposure has been documented reversions are less frequent 
[225]. Others have speculated it reflects “delayed clearance” (as defined in Chapter 2: 
Possible mechanisms of early clearance), although this seems unlikely as IGRA 
reversions are no more frequent in people treated for LTBI than those who are not 
[226]. Hill et al speculate that IGRA reversions reflect low expression of the two 
antigens tested by the IGRA during latency, whereas the TST, that tests responses to a 




clearers as those with a negative test on two separate occasions could reduce the 
chance of misclassifying infected contacts with a reverted IGRA as early clearers.   
 
Defining early clearers according to M. tuberculosis exposure 
A key challenge in studies of EC is distinguishing early clearers from those merely 
insufficiently exposed to be infected. Studies of infection in case contacts have 
verified several of measures of M. tuberculosis exposure that influence risk of 
infection. These include time with the case [227], proximity [228, 229], and crowding 
[230]. Selecting within the most heavily exposed uninfected contacts increases the 
probability that they are genuinely early clearers. The importance of a “gradient of 
exposure” to EC study design is illustrated in Figure 2. Infection of susceptible 
contacts increases along the gradient and therefore, early clearers who are not 
susceptible, comprise an increasing proportion of the uninfected contacts. In the most 
heavily exposed strata misclassification will be minimal, whereas it may be frequent 
in the least exposed strata. Correlates of EC will be more readily detected among 
uninfected contacts in the highest strata of exposure, and this will be reflected in 
stronger associations. A trend of increasing effect sizes across increasing strata of 
exposure would be expected for correlates of EC. The most highly exposed strata 
could be the most efficient group for study for more expensive or difficult assays.  
 
Figure 2. Schematic diagram of expected prevalence of phenotypes according to 







Contacts with a positive IGRA or TST, or those who convert from a negative to a 
positive IGRA or TST are possible susceptible controls for studies of EC. Baseline 
samples from those who converted during follow up reflect the early innate response 
prior to the development of adaptive immunity. IGRA or TST conversion following a 
high-risk exposure can be considered highly specific for new M. tuberculosis 
infection. Those with a positive IGRA or TST at baseline are also susceptible, but 
their immune responses reflect a later period, after adaptive immunity has developed. 
A cross-sectional comparison according to baseline IGRA or TST risks discovery of 
factors associated with Latent TB infection and adaptive responses. A recently 
infected group can be identified by selecting converters and those with a positive 
IGRA who lack risk factors for infection (i.e. those who are younger and lack prior 
TB exposure). This group has increased likelihood of being recently infected at initial 
testing.   
 
Contacts who had TB disease in the past or who have TB co-prevalent to the index 
case could be used as controls in studies of EC genetics, as TB cases are susceptible 
to infection by definition. However, they are a poor choice of control for studies of 
immune function as their immune responses are likely to be dysfunctional during 
illness. Efforts should be made to identify and remove cases of TB disease from 
among latently infected controls, as even a few could substantially impact average 
measures across the group. As identified in the literature review (chapter 3) a third 
comparator group of unexposed healthy controls may be useful when dynamic 
measures of immune function are studied. Higher innate immune responses in early 
clearers than unexposed controls would confirm they were in fact responding to M. 
tuberculosis, whereas similar responses between the groups would suggest the 
uninfected group was insufficiently exposed to be infected.  
 
Other factors influencing EC 
To identify immune mechanisms or biomarkers implicated in EC, factors that 
influence the risk of M. tuberculosis infection (or EC) but are unrelated to M. 




confounders. Figure 3 conceptualises factors influencing the outcome of M. 
tuberculosis exposure as host factors (factors of interest in studies of EC) and 
pathogen or environmental factors that are potential confounders. Host factors include 
the array of innate immune mechanisms reviewed previously (Chapter 2: Possible 
mechanisms of early clearance), and their modulators such as BCG vaccination, 
vitamin D deficiency, nutrition and HIV infection.  
 
 
Figure 3. Conceptual model of factors influencing risk of infection. 
 
Theoretically pathogen factors could also confound studies of EC. However, 
epidemiological evidence for M. tuberculosis genotype influencing risk of infection is 
scant. A large case contact study in the Gambia found no difference in risk of 
infection according to M. tuberculosis genotype of index case, although genotyping 
studies of clustered isolates suggests it might [231]. M. tuberculosis transmissibility 
could be enhanced through two broad strategies: evasion of protective immunity in 
the (new) host and inducing a pro-inflammatory disease phenotype in the index case 
to enhance aerosolisation and thereby M. tuberculosis dose (Figure 3).  
 
M. tuberculosis has a phylogeographical population structure that may have arisen 






hypothesis predicts that effective host protection mechanisms could be specific to 
certain M. tuberculosis lineages. Measuring M. tuberculosis genotype in studies of EC 
would enable it to be understood as a confounder, or potential effect modifier of the 
relationship between correlates of EC and outcome. It may also promote 




Figure 4. Hypothesised causal pathway for M. tuberculosis infection or early 
clearance.  
BCG: Bacillus Calmette-Guérin; HIV: Human Immunodeficiency Virus; DM: 
Diabetes Mellitus; BMI: Body mass index. Pathogen factors could promote 
transmission either by inducing an index case disease phenotype that facilitated 
transmission, for example by inducing cavity formation, or by successfully evading 
host defences in the contact.  
 
Study population 
Selection of the study population should seek to identify a highly exposed group 
whose M. tuberculosis exposure can be quantified. Of potential study populations 
household case contacts stand out as having the key advantage of linking contacts to 
an index case in time and space [232]. This enables more accurate measurement of M. 
tuberculosis exposure than other designs, and the index case isolate can be cultured 





Occupationally defined cohorts could include highly exposed groups such as health 
care workers in high burden settings. In situations where the mean age of infection is 
high, this may be an efficient study design. However, an occupational cohort will not 
contain children, who represent the population most in need of protection from M. 
tuberculosis [49]. Prisons could be high transmission intensity settings where a cohort 
study could be based provided concerns about research on vulnerable groups could be 
addressed.   
 
In certain settings the force of infection may be high enough for a negative TST or 
IGRA to be strongly suggestive of the EC phenotype. This appears to be the case in 
the Western Cape where Cobat et al identified and validated markers associated with 
a negative TST [180].  
 
Study setting 
An endemic country setting is desirable as it increases the generalisability of findings 
to settings where M. tuberculosis transmission is highest. The prevalence of potential 
modulators of host susceptibility, such as BCG vaccination, smoking, HIV infection, 
vitamin D deficiency, malnutrition, diabetes and air pollution including occupational 
dust exposure should be considered.  
 
Study design 
In cohort studies measurements made at baseline are studied for their association with 
a subsequent outcome, such as “conversion” from a negative to a positive TST or 
IGRA. An advantage of cohort studies is that they establish that putative correlates of 
EC preceded the outcome. A limitation is that participants shown to be infected on 
initial screening are excluded, potentially excluding a large pool of susceptible 
contacts.  
 
Cross-sectional studies collect samples and measure infection status at the same time. 
Reverse causality is a particular limitation of cross sectional studies of functional 
immune responses, as the CD4+ TH1 cells probed by LTBI diagnostic tests alter the 




control and cross-sectional studies is that the baseline positive participants who would 
have been excluded from a prospective cohort study count towards the analysis. In 
population based studies it is important to consider the risk of M. tuberculosis 
infection by age, as recruiting young participants risks including a large number who 
have not yet been exposed.  
 
Case contact studies may contain both a cross sectional analysis of infection at 
recruitment and a prospective analysis of contacts uninfected at baseline, some of 
whom will convert their test for infection over time. Findings will need to be 
interpreted with respect to the known strengths and limitations of each analytic 
approach.  
 
Duration of follow up 
Long term follow up of early clearers can demonstrate the stability of the phenotype, 
if high exposure continues, as would be expected in cohorts of health care workers. 
For household case contacts exposure would usually diminish rapidly after 
recruitment, following treatment of the index case, towards the exposure levels of the 
general population. So there are diminishing returns in follow up beyond three months 
for evidence of infection in case contact studies.  
 
Measuring correlates of early clearance 
As summarised earlier (Chapter 3: Review of early clearance literature) genetic loci 
associated with EC have been discovered and validated, but efforts to identify 
differences in the immune function of early clearers have mostly yielded negative 
results. Firstly this might be because few studies specifically pose hypotheses about 
innate immune mediated EC and study biomarkers with known innate immune 
functions. In this thesis the review of potential mechanisms of EC (presented in 
chapter two) leads to specific hypotheses about the mechanism of EC that leads to the 
selection of specific cells and cytokines for study. The review of genes associated 
with EC (chapter four) in laboratory experiments enables selection of a high 





Secondly, real differences in the innate responses of ECs and susceptible controls 
maybe difficult to detect because EC is a transient response to a small quantity of 
bacilli and occurs in the lungs. Sampling lung tissue is invasive and not practical in a 
large scale study and methods for quantifying immune cells and cytokines in lavage 
fluid are not well established. Peripheral blood is much easier to sample but it is 
unknown if EC can be detected in peripheral blood. Stimulation assays, in which 
blood immune cells are stimulated ex-vivo, standardize participants’ exposure to a 
large quantity of antigen, but the cell culture conditions only approximate those in the 
lung.  
 
Initial studies of EC will have to take a pragmatic approach to selecting biologically 
plausible biomarkers that can be measured in samples collected in a large scale field 
study. Studies of EC should anticipate smaller effect sizes than seen in studies of TB 
disease phenotype and calculate target sample sizes accordingly. Study procedures 
can be optimised to recruit contacts as close as possible to M. tuberculosis exposure, 
although this can never be totally standardized across contacts except in rare “point 
source” type exposures [51].  
 
Conclusion 
Genetic studies have demonstrated early clearers are a biologically distinct group. 
Identifying mechanisms of EC would represent an important advancement in our 
understanding of this phenotype. To do this, a working definition of EC that 
minimises misclassification, while acknowledging it can not be eliminated, is 
required. Studies need to anticipate potentially small effect sizes through large sample 
sizes. Other important considerations in study design include the measurement of 
confounders and, for measures of immune function, the timing of sample collection. 
Using a prospective study design and a gradient of exposure may assist in identifying 
correlates of EC.  
 
Other areas of uncertainty about the phenotype, such as excluding anergy as its cause, 
might only be definitively addressed through complementary studies that validate a 
protective role for correlates of EC. Functional correlates could be validated in ex-




against TB disease as well as latent infection, so could be validated in the many 






Chapter 6: Methods 
 
Aim, objectives, hypotheses 
Aim: 
To identify host nutritional, genetic and immunological factors associated with EC. 
 
Objectives: 
1. To identify peripheral blood cell populations associated with EC. 
2. To test if serum vitamin D is associated with EC. 
3. To characterise the innate cytokine responses of early clearers. 
4. To test whether contacts with a PN QFN-GIT and those who convert their 
QFN-GIT differentially express 45 candidate genes measured by RNA 
Sequencing. 
5. To provide data to guide sample size calculations for future RNA Sequencing.  
6. To determine whether lineage of M. tuberculosis a contact is exposed to 
influences their risk of M. tuberculosis infection.     




Based on the preceding literature the following specific hypotheses were defined:  
1. Contacts with a persistently negative (PN) QFN-GIT have a higher peripheral 
neutrophil count than those that convert their IGRA during follow up. 
2. Contacts with a PN QFN-GIT have higher 25-OH vitamin D levels at baseline 
than those who convert their IGRA during follow up. 
3. Contacts with a PN QFN-GIT have a stronger inflammatory cytokine response 
after whole blood stimulation by mycobacterial stimuli than is seen in those 
who convert their IGRA during follow up. 
4. A PN QFN-GIT is associated with a stronger inflammatory cytokine response 
to whole blood stimulation by mycobacterial and non-mycobacterial stimuli 




5. The PN group would have higher expression of candidate transcripts with a 
demonstrated protective function in M. tuberculosis infection, than converters. 
6. Contacts with a positive QFN-GIT at baseline or follow up are more likely to 
have been exposed to a lineage two isolate of M. tuberculosis than those who 
have a PN QFN-GIT. 
 
Design 
To identify and characterise early clearers we sought a group that was highly exposed 
to M. tuberculosis. Of various possible study populations, household case contacts 
were selected because they can be linked to a known index case in time and space 
[232], whereas this is harder for other highly exposed populations. Linkage to a 
known case enables analysis that accounts for index case disease phenotype and 
pathogen genotype as possible confounders or effect modifiers of transmission risk. 
Measures of M. tuberculosis exposure have been validated for household contacts 
both internationally [228] and in Bandung [229].  
 
The case contact design also identifies contacts at the time of, or very soon after, their 
exposure to M. tuberculosis. This allows prospective study of a group at baseline who 
are uninfected, or in the very early stages of infection, and can be followed for risk of 
incident infection. In this group we can be confident that new infection is from the 
index case, and can measure confounding variables related to the case or pathogen. 
The measured  exposures will also usually have preceded the outcome. Additionally 
this design enables studies of dynamic host factors like cellular responses [128] and 
changes in gene expression during infection and EC[233].    
 
Setting 
The study was conducted in Bandung, West Java, Indonesia (Figure 5). Recruitment 
occurred between February 2014 and February 2016, and follow up concluded three 
months later in May 2016. The official population of Bandung is 2.4 million people. 
The city is situated in a volcanic basin and is at an elevation of 768 metres. This 
elevation means the average temperature is approximately 23°C despite being only 





Figure 5. Map of Indonesia showing the study site in Bandung, West Java, Indonesia. 
 
Tuberculosis prevalence in Bandung 
At the time of the commencement of this study, in 2013, Indonesia was estimated to 
have the 5th highest burden of Tuberculosis [234]. The prevalence of bacteriologically 
confirmed TB was 759 per 100,000 people aged ³ 15 years [7]. This high prevalence 
setting enables recruitment of a large number of cases and contacts needed to study 
the phenotype, as well as providing findings which are generalisable to settings where 
M. tuberculosis has a high impact. However, a high prevalence setting also increases 
the probability that case contacts are already infected at baseline.  
 
Tuberculosis care in Bandung 
TB care in Indonesia relied on radiography and hospitalisation well after the invention 
of anti-tuberculosis drugs. Eventually, in 1977 Indonesia was one of the first countries 
to trial short course TB treatment, and nationwide adoption of modern rifampicin 
containing regimens occurred with the adoption of DOTS in 1995 [235]. Case 
detection rates were beneath 30% until 2002 but increased steadily to 76% in 2006.  
 
In 2013, compulsory national health insurance (Jaminan Kesehatan Nasional) was 
introduced [236], redirecting patients who had previously self-referred to specialist 




practitioners and usually diagnose TB by x-ray and sputum smear microscopy. A 
minority of puskesmas have facilities for sputum smear microscopy on site. Active 
contact tracing and, where indicated, prophylactic treatment of contacts is 
recommended by the national tuberculosis programme but physicians struggle to 
implement this in practice. A study of child case contacts in Bandung reported that 
only 8% of child contacts are screened for LTBI, and only 40% of contacts identified 
as eligible had isoniazid preventive therapy initiated [237]. 
 
Figure 6. Aerial map of Bandung showing location of study clinic and puskesmas. 
 
BCG vaccination in Bandung 
BCG vaccination campaigns targeting all ages were conducted in Indonesia between 
1952 and 1962 [238]. From 1969 a programme to vaccinate all children under 16 was 
in place. Vaccination was deliberately suspended for a period in the 1970s [239], until 
1977 when Indonesia implemented the World Health Organization’s Expanded 
Programme on Immunisation [240]. Estimates of BCG coverage increased from 60% 




produced BCG (Mycobacterium bovis strain Paris No. 1173-P2, Biofarma, Bandung, 
Indonesia) though other strains have been used in the distant past.  
 
Host factors in Bandung  
Diabetes mellitus is a risk factor for TB disease [241] with increasing prevalence in 
Indonesia [242]. A case-control study in Bandung found 13.2% of TB cases had 
diabetes mellitus compared to 3.2% of neighbourhood controls (OR 4.7; 95% CI 2.7– 
8.1) [243]. Outside of Papua, Indonesia does not have a generalised HIV epidemic 
[244]. The prevalence of HIV in Indonesian adults aged 15 to 49 is estimated at 0.4% 
and infection is concentrated in high risk groups. In the case-control study mentioned 
above 1.5% of the patients had HIV and none of the controls. There are no published 
reports of population based studies of vitamin D deficiency in Indonesia, but a study 





We identified cases of pulmonary TB over 15 years of age from within the TANDEM 
cohort. TANDEM is a European Union funded multi-centre study on the relationship 
between TB and diabetes [246]. TANDEM activities in Bandung included recruiting a 
cohort of TB cases who were screened for diabetes, a subset of whom were included 
in a randomised trial of intensified diabetes management. Puskesmas referred people 
with suspected pulmonary TB to the study clinic at Universitas Padjadaran. Suspected 
TB was defined as those with cough for 2 weeks or more. Here a physician performed 
a history and examination, a postero-anterior chest x-ray was taken and up to three 
sputum samples were submitted for microscopy and culture. X-rays were reviewed by 
radiologists at the adjacent hospital Rumah Sakit Hassan Sadikin and the film was 
stored for a more detailed reading.  
 
INFECT clinic nurses reviewed the results of these investigations and offered index 
cases the opportunity to participate if suspects were found to have pulmonary TB. 




participation in the trial, meaning index cases were drawn from a population of 
community TB cases.  
 
We defined TB cases as suspects who had a positive sputum smear and typical x-ray 
findings for TB. This definition combines the performance of sputum smear and x-ray 
to maximise certainty of a TB diagnosis, and does not require waiting for positive 
cultures, enabling rapid recruitment contacts as close to the beginning of their 
exposure to M. tuberculosis. Selecting only smear positive cases also promotes the 
selection of highly infectious cases [247]. The full inclusion criteria for index cases 
were as follows: 
• Sputum smear was positive for acid-fast bacilli; 
• Chest x-ray typical of TB; 
• Aged over 15 years; 
• Lives in the study area (Bandung City); 
• Lives with more than one other person; and  
• If already on TB treatment, for less than 2 weeks at the time of the home visit. 
Case contacts 
Household contacts of TB cases, were eligible for inclusion if they: 
• Lived with the index case for more than 5 hours a week; 
• Had never had TB; and 
• Were aged over 5 years.  
 
Contacts under five years of age were excluded because they require preventive 
treatment that could theoretically prevent IGRA conversion despite their 
susceptibility, thereby biasing against discovery of susceptibility factors. In addition, 
the volume of blood collected was large for young children. Contacts who reported 
previously having TB were excluded because they were not suitable controls for a 







Identifying early clearers and controls 
A combination of IGRA testing and clinical assessment was used to assign the 
outcome of M. tuberculosis exposure.  
 
Diagnosis of M. tuberculosis infection  
Both the Tuberculin Skin Test (TST) or Interferon Gamma Release Assays (IGRA) 
are validated diagnostic tests for LTBI. The performance characteristics of IGRA and 
TST are broadly similar. A positive test conferred a similar risk of TB disease to a 
positive TST in a large scale study of household case contacts in the Gambia [248].  
 
QFN-GIT (an IGRA) was selected over TST primarily because in this longitudinal 
study there was a risk of a false positive follow up TST being positive due to boosting 
of non-specific previously acquired mycobacterial immunity [222]. Additionally, the 
TST can have a false positive result in contacts who were recently vaccinated with 
BCG (within 10 years of testing) [249]. Finally prior research in child case contacts in 
Bandung had shown IGRA was capable of detecting a gradient of infection within 
household contacts whereas TST did not [229].  
 
Identification of co-prevalent cases 
Approximately 1.5% of household case contacts could be expected to be “co-
prevalent” TB cases [250]. Contacts with TB disease or in whom TB could not be 
excluded were not included in the comparator groups because they reflect a distinct 
phenotypic group. While they may reasonably be included in groups of susceptible 
controls for genetic studies of early clearance, markers of immune function are likely 
to be heavily influenced by their current illness.  
 
TB was diagnosed as definite, probable or possible according to the criteria in Table 
7. If a participant’s symptoms resolved or their investigations negative, they were no 






Table 7. Case definitions for co-prevalent TB cases identified among household 
contacts. 
Clinical findings Investigations Group Name 
Symptomatic Culture or gene expert positive or 
histopathology. 
Definite TB disease 
Symptomatic X-ray and smear positive, culture 
negative or not done.  
Probable TB disease 
Symptomatic X-ray negative, sputum smear 
positive, culture and geneXpert 
negative or not done. 
OR X-ray possible TB, sputum 
smear negative, geneXpert 
negative or not done. 
OR X-ray typical TB, sputum 
smear negative, geneXpert 
negative or not done. 
Possible TB disease 
 
Definition of outcome 
Based on the QFN-GIT result at baseline and 14 weeks participants without TB 
disease were classified as QFN-GIT positive at baseline (BP), converters negative at 
baseline and positive at follow up (conv) or persistently negative on both occasions 
(PN). The assignment of outcome according to IGRA result is illustrated in the 
schematic (Figure 7). 
Figure 7. Assignment of outcome according to QFN-GIT in the INFECT study. 






To address the hypotheses the following host factors were assessed as putative 
correlates of early clearance: 
• Peripheral blood cell populations at baseline; 
• 25-OH vitamin D;  
• Cytokine expression; and  
• Gene transcription. 
 
Other host factors associated with risk of infection were studied as potential 
confounders of early clearance, namely: 
• Age – as there are age-related differences in M. tuberculosis exposure within 
the home, and outside the home. Also, it is speculated that early adolescence 
may be a time of relative protection from M. tuberculosis [49]. 
• BCG vaccination – studies conducted since the advent of IGRAs reveal BCG 
is effective against M. tuberculosis infection in children [163].  
• Smoking – is associated with LTBI in cross sectional population based studies 
in the USA and China [251, 252].  
• Body mass index – has a log-linear association with incident TB [253], it is 
primarily considered a confounder in this study because vitamin D is 
negatively associated with BMI [254, 255]. 
• Diabetes mellitus – is potentially related to M. tuberculosis susceptibility 
[256], and could be a confounder of any relationship between vitamin D and 
M. tuberculosis risk [257]. 
HIV testing was not done because of the low prevalence of HIV mentioned above.  
 
M. tuberculosis exposure as a potential confounding variable 
The degree of exposure to M. tuberculosis is known to influence a contact’s risk of 
infection, and therefore is an important confounder in studies of early clearance. Risk 
of M. tuberculosis infection is known to be associated with exposure to the index 
case, including waking hours spent with the case,[227] and sleep proximity [228, 229] 
to the index case. Aspects of index case disease phenotype are also associated with 




case are associated with increased aerosolisation of bacilli. Namely the presence of 
lung cavities [258] and extent of x-ray disease have been correlated with conversion, 
as has smear grade of the index case. The following variables quantifying M. 
tuberculosis exposure were also measured:  
• Smear grade; 
• Extent of x-ray disease; 
• Presence of lung cavities on x-ray; 
• Cough duration; 
• Hours spent with the case the day before enrolment; and 
• Sleep proximity to the index case. 
An index case isolate’s M. tuberculosis lineage was considered as a possible effect 
modifier in an exploratory analysis. The presence of a co-prevalent case of 
Tuberculosis in the household was not considered an exposure variable as these were 




Patients with proven or suspected TB were referred from primary care to the clinic for 
TB diagnosis in a separate study of TB and diabetes mellitus (TANDEM). TB cases 
identified via TANDEM were screened for eligibility and consented to enter the 
present study. If the patient consented, a nurse completed a questionnaire designed to 
gather demographic data, cough characteristics and number of cohabitants. A home 
visit was scheduled as soon as possible, and always within two weeks of index case 
diagnosis. All TB cases eligible for inclusion in INFECT were commenced on anti-
tuberculosis treatment as part of the TANDEM study, as were cases diagnosed on 
culture.  
 
Procedures for home visit – baseline 
Nurses completed a questionnaire with the head of each household to characterise the 
house, family composition, employment, assets, education and their knowledge of 




to participate in the study. Participants under 18 years of age had study procedures 
explained to them and their parents and informed consent was given by their parent. A 
questionnaire to record demographic data, and reported history of smoking, diabetes 
or HIV was administered. BCG vaccination was assessed by checking for the 
presence of a scar. Symptoms of TB were screened for and were defined as any one of 
cough, fever, night sweats, weight loss, loss of appetite, chest pain or a mass in the 
neck. Where present their duration was recorded. Height and weight were measured 
and a random capillary blood glucose was performed and the result recorded.  
 
In addition to three QFN-GIT tubes, a further 20 mL of blood was collected in EDTA 
containing blood tubes for HbA1c, haematology and DNA extraction, Paxgene™ 
tubes for RNA extraction, heparin for whole blood stimulation assays and sterile clot 
activator tubes for biochemistry and micronutrients.  
 
Procedure for home visit follow up 
Participants with a negative IGRA at baseline were visited again at 14 weeks. 
Screening for symptoms of TB disease was repeated, and blood drawn for a second 
QFN-GIT. Nurses attempted to reach contacts three times before assigning anyone as 
lost to follow up.  
 
Follow up for active disease 
Participants who reported any symptom of TB disease, or had an indeterminate IGRA 
were offered evaluation for TB at the study clinic. At the evaluation visit symptom 
screening was repeated, and if symptoms had resolved, no further assessment was 
performed. Participants whose symptoms persisted were offered a chest x-ray, and if 
their cough was productive, three sputum samples were submitted for microscopy and 
culture. Results were collated by a structured questionnaire at the study clinic. 
Contacts in whom disease was confirmed were referred to Puskesmas for care. If TB 
was excluded no further follow up was arranged and a physician review was arranged 









Figure 8. Recruitment and follow up of household case contacts QFN-GIT = 
Quantiferon Gold In Tube test.  
 
Measurements and Data sources  
Smear grade 
Microscopists assigned each index case a smear grade based on the WHO/IUTLD 
classification, explained in Table 8 [259].   
 
Table 8. WHO/IUTLD grading of sputum smear. 
Grade Definition 
Negative  No acid-fast bacilli in at least 100 fields  
Scanty 1 to 9 acid-fast bacilli in 100 fields  
1+ 10 to 99 acid-fast bacilli in 100 field  
2+ 1 to 10 acid-fast bacilli per fields in at least 50 fields  




Questionnaires were developed in Bandung and trialled on patients and their families 
attending study clinic and improvements incorporated into the final design. The 
questionnaires allowed for numeric coding of responses.    
 
Index case radiology 
Index cases had a full size posteroanterior chest x-ray, which was read by a physician 
(AV) who characterised the dominant abnormality in each of six lung zones and the 
extent of disease estimated using a standardised form [260, 261]. This reading was 
performed after the required radiologists reading for entry into the study.  
The following definitions were used:  
• Cavity: a lucency with a well-defined inner border was visible within a patchy 





• Patchy lesions: heterologous densities of varying size with irregular and ill-
defined borders; 
• Consolidation: virtually confluent and homogenous infiltration >2 cm in 
diameter;  
• Nodules: multiple discrete, rounded opacities; and  
• Bullae: small lucencies, often present in clusters, with ill-defined walls.  
 
Whenever lung cavities were present, these were coded as the dominant abnormality 
in the zone. In addition, hilar lymphadenopathy, pleural effusion, pericardial effusion, 
retraction and the presence of a miliary pattern were recorded. These were defined as:  
• Hilar lymphadenopathy: large or lobulated pulmonary artery or loss of 
concavity of aorto-pulmonary window; 
• Pleural effusion: uniform radiolucent in dependent part of thorax, includes 
blunting of costophrenic angle; 
• Pericardial effusion: cardiothoracic ratio >50%; 
• Right upper lobe collapse: horizontal fissure displaced up, raised right 
diaphragm; 
• Left upper lobe collapse: raised left diaphragm; and 
• Miliary pattern: diffuse nodules 1-3 mm in all lung zones. 
 
Anthropometrics 
Participants were asked to remove shoes and heavy clothing before being weighed on 
calibrated scales and having their height measured using a Seca 217 stadiometer.  
Height was measured twice, or a third time when differences of more than 0.7 cm 
were observed. Weight was measured on electronic scales twice and a third time when 
recordings differed by more than 0.1 kg. All measurements were recorded. Calculated 
body mass index (weight/height2) was categorised as very severely underweight 
(<15.0), severely underweight (15.0-15.9), underweight (16.0-18.4), Normal (18.5-
24.9), overweight (25.0-29.9), Obese (³30.0). 
Specimen transport 
The time from blood collection to centrifugation of serum was recorded and transport 




were refrigerated at 4˚C until separation. From the lithium heparin tube whole blood 
was transferred to the three blood tubes for the Quantiferon Assay. A drop of blood 
from the EDTA tube was used for a point of case measurement of glycosylated 
haemoglobin. A full blood count was performed and the remaining blood was stored 
for DNA extraction. Serum from plain and sterile micronutrient collection tubes was 
extracted by centrifugation and stored at -80˚C. Stored specimens are summarised in 
Table 9.  
 
Laboratory procedures 
Microbiology (index case and suspect co-prevalent cases) 
TB case sputum smear grade was assessed by florescence microscopy [262]. Sputum 
culture was performed by the microscopic observation broth–drug susceptibility 
(MODS) method [263]. 
 
Interferon-gamma release assays 
Quantiferon-Gold™ tests were performed according to the manufacturer’s 
instructions to assess for M. tuberculosis infection (QFT-GIT; Qiagen, Australia). 
Specifically a three tube test was run with a positive test was defined as IFN-g 
production in the TB antigen tube that is both ³ 0.35 IU/mL and 25% more than the 
nil tube, with IFN-g production ≤ 8 IU/mL in the nil tube. An indeterminate result was 
reported if IFN-g in the mitogen tube was less than <0.50 IU/mL greater than that in 
the nil tube, or if the nil tube had over 8 IU/mL. As most indeterminate tests arise 
from errors in specimen collection, blood was drawn again and the QFN-GIT repeated 
in participants with indeterminate results, and the result of the second test used. 
Quality control standards included assessing each ELISA plate of results for adequate 
optical density of the highest standard, measures of variation between replicate 
standards and the correlation coefficient of the standard curve. Furthermore three 
recombinant human IFN-g controls of known concentrations were included as 
controls in each batch and their measured concentration compared against the 




reanalysed using the remaining supernatant. The assay was performed weekly to 
enable decisions to be made about the follow up of participants. 
 
Diabetes testing 
A random capillary blood glucose (RCBG) was performed by Accu-Chek™ 
glucometer, and if RCBG was greater than 100mg/dl (5.5 mmol/L) glycosylated 
hameoglobin (HbA1c) was measured. Diabetes is rare beneath this threshold [264]. 
HbA1c was measured in venous blood by a Hemocue analyser (Hemocue, Sweden) 




DNA was extracted from blood in EDTA tubes, divided into two labelled aliquots and 
stored at -80°C. Serum was centrifuged and labelled aliquots and stored at -80°C. 
Paxgen tubes were stored at -80°C.  
 
Table 9. Samples archived on participants. 
Collection Storage 
M. tuberculosis isolate Isolate stored 
Quantiferon test Remaining supernatant stored after ELISA 
Blood in lithium heparin Whole blood stimulation assay supernatant 
Blood in EDTA DNA extracted by Qiagen mini kit 
Sterile serum micronutrients tube Serum 
 
 
Data management  
Index cases were identified by their TANDEM study number, and contacts by a 
unique seven-digit number. An online study register linked index cases to the study 
contacts, and could be modified in real time by the field and laboratory staff to reflect 





Specimens and questionnaires were labelled with sequential pre-printed barcoded 
freezer-proof labels that also bore the participant number. Field staff labelled 
questionnaires as they were completed, and checked the participant’s study number 
against the date of birth on the questionnaire at specimen collection to prevent 
mislabeling specimens.  
 
After data collection was completed for a household questionnaire data were entered 
in a purpose designed Microsoft Access database. Data were entered twice, and 
discrepant missing or illogical results resolved. Index case data were merged with 
data from the microbiology lab to produce a database of index case characteristics. 
Data from contact questionnaires were merged with laboratory results (IGRA, WBSA, 
vitamin D).  
 
Ethics  
The study was approved by the Health Research Ethics Committee Universitas 
Padjadjaran (14/UN6.C2.1.2/KEPK/PN/2014) and reviewed by the Southern Health 
and Disability Ethics Committee New Zealand (13/STH/132).  
 
Role of the funding source 
The funders of the study had no role in study design, data collection, data analysis, 
data interpretation, or writing of the report. The author had full access to all the data 
in the study and had final responsibility to submit for publication.  
 
Analysis 
Differences in characteristics of the participant groups were compared by t-tests 
(continuous variables), chi-squared (binary variables) or wilcox-rank-sum (ordered 
categorical variables).  
 
The defined outcome groups enabled three comparisons of uninfected putative early 
clearers and susceptible controls: 1) a comparison of final IGRA in those initially 




QFN-GIT (BP vs Converters and PN), and 3) a comparison of those with a positive 
QFN-GIT at baseline or follow up to persistently negative (BP and Converters vs PN). 
These comparisons are shown in Error! Reference source not found..   
 
The first comparison of final IGRA in those initially QFN-GIT negative (PN vs 
Conv). In this cohort-type analysis measures of M. tuberculosis exposure performed 
at baseline are most likely to reflect their true value during the risk period for 
infection. Because conversions in this group are almost certain to result from 
exposure to the isolate cultured from the index case, the classification of pathogen 
factors such as M. tuberculosis lineage will be most accurate in this group. Thus a 
strength of this approach is the ability to measure and therefore account for exposure 
and pathogen factors, enabling accurate assessment of the role of host factors.  
 
The main limitation of this approach stems from the large number of contacts who are 
positive at baseline. Their exclusion from this comparison represents a loss of 
statistical power for the primary analysis directed at detecting correlates of EC. It is 
also a potential source of bias, as the most susceptible contacts will be infected first. 
For this reason, findings should be interpreted alongside those from other 
comparisons. For dynamic measurements of immune function made at baseline, such 
as cell counts or gene expression, this comparison reflects values during exposure 
when early clearers are expected to be mounting a protective response and converters 
developing an adaptive response, though individuals will be at various stages in that 
process.  
 
The second comparison, based on the baseline IGRA result, compares recently 
exposed contacts with a positive baseline IGRA, to those who were negative at 
baseline in a cross sectional study design. For dynamic or functional measurements, 
this comparison reveals differences between infected contacts and uninfected contacts 
who are recently exposed. The BP group will comprise both contacts exposed in the 
distant past and recently infected contacts. The BN group contains both early clearers 
and susceptible contacts who will subsequently convert. By definition the groups 
differ with respect to adaptive immune memory of M. tuberculosis antigens as 
measured by IGRA. Including this analysis enables comparison with other studies that 




comparison is the misclassification of converters in the uninfected group, resulting in 
bias towards the null. Secondly, as some members of the baseline positive group were 
infected, weeks or years, prior to inclusion in the study, measures of M. tuberculosis 
exposure may correlate poorly with actual exposure, limiting the ability to adjust for 
confounding.  
 
The third comparison of contacts with a positive QFN-GIT at baseline or follow up to 
persistently negative (BP and Converters vs PN) makes use of the full cohort but 
addresses the misclassification of future converters in the second. It is not appropriate 
for studying dynamic events during exposure, as the infected group is heterogeneous 
(including those with and without adaptive responses to M. tuberculosis) at baseline. 
This approach is useful for studying the factors that definitely preceded infection, 
such as genes or BCG vaccination, and potentially their impact on the current and 
potentially past exposures to M. tuberculosis. This analysis reveals differences in 
baseline blood count parameters in infected and uninfected contacts, giving insights 
into the immune response to infection. 
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Table 10. Comparisons made in the study.  
PN: Persistently IGRA negative; Conv: IGRA converters; BP: IGRA positive at baseline. 
Definition Susceptible Protected Strengths Limitations 
• IGRA at 14 wks for 




• PN • Better measurement of confounding factors 
• Samples collected at baseline during EC or 
conversion  
• Smaller numbers  
• Reverse causality minimised  
• Excludes susceptible BPs, causing 
possible bias 
• Baseline IGRA 
•  
• BP • Converters 
and PN 
• Consistent with existing literature that takes a 
cross sectional approach 
• Functional/dynamic markers differ between 
uninfected and recently infected with adaptive 
response to M. tuberculosis 
• Large numbers 
• Misclassification of susceptible 
converters  
• Index case not necessarily source of 
infection, unmeasured confounding by 
pathogen factors  
 
• Final IGRA 
•  
BP & Conv 
 
PN • Large numbers 
• Those who convert are not misclassified. 
• Appropriate for studying static correlates of EC 
e.g. BCG vaccination, genetics 
• Index case not necessarily source of 
infection,  








The PN group may include some contacts who are susceptible but insufficiently 
exposed to be infected. This misclassification risks biasing results towards the null. A 
sensitivity analysis that restricted early clearers to a high exposure group was 
performed to assess the impact, if any, of this bias. High exposure was defined by 
identifying those variables that have been associated with exposure in Indonesian 
studies and elsewhere (discussed earlier in this chapter), assessing correlation between 
the exposure variables in the dataset using Spearman’s correlation coefficient and 
then selecting up to three minimally correlated variables to define a high exposure 
group.  
 
Sample size calculation 
Sample size calculations were performed for the vitamin D study. We estimated the 
rate of IGRA conversion over 14 weeks could be as low as 10% in vitamin D replete 
contacts and calculated the sample size required to detect a doubling of that risk to 
20% in vitamin D deficient or insufficient participants with 80% power and a 
significance of 5%. A total sample of 398 was required, based on the assumption that 
50% of contacts were vitamin D insufficient or deficient. To identify 398 participants 
for a prospective study, we estimated approximately 800 case contacts were required 
as prior research in Bandung found 54% of household contacts were QFN-GIT 







Chapter 7: Characteristics of the cohort including 
phenotype classification   
Introduction 
This chapter presents the clinical and epidemiological characteristics of both index 
cases and contacts. The assignment of phenotype to each contact is explained and the 
baseline characteristics presented according to phenotype. Analysis of host or 
pathogen factors and their association with phenotype are presented in later chapters. 
A highly exposed group is defined that will be the focus of detailed laboratory studies 
to identify correlates of early clearance.  
Derivation of the cohort 
Of the 1,533 contacts of 340 index cases, 1,170 were eligible for inclusion (Error! 
Reference source not found.). Three hundred and eighty-one were ineligible because 
they did not usually live with the index case for more than 5 hours a week (174), were 
aged under 5 years (149) or previously had TB (58). Of these, 941 (80%) were present 
at the time of the home visit and gave consent to be included in the study.  
 
Figure 9. Derivation of the study sample.  







Characteristics of index cases  
Clinical and microbiological characteristics 
The median age of the index cases was 37 years (range: 17 to 87) and 178 (54%) were 
male. Sunda was the most common ethnicity, reported by 287 (87.5%) patients. Three 
hundred and twenty-two index cases (98.2%) reported cough, six did not report cough 
at the time of recruitment to INFECT but had at the time of recruitment to the 
TANDEM study. The median cough duration was 30 days (IQR 30-60). The majority 
of patients, 273 (83.2%), had not started anti-tuberculosis therapy at the time of 
recruitment to INFECT. Forty-eight (14.6%) had taken treatment for less than a week 
and seven (2.1%) for more than 1 week but less than two weeks. As detailed in Table 
11, 104 (31.7%) index cases had scanty or 1+ acid-fast bacilli seen in sputum, 93 
(28.4%) had 2+ and 131 (39.9%) had 3+. M. tuberculosis was detected by culture in 
301 index cases (91.8%), and by GeneXpert in 3 cases (0.9%). These three cases were 
smear positive (grade 1+ or 2+) and had patchy opacities on over thirty percent of 
their x-ray, consistent with TB disease. Nine were culture negative in (2.7%) and 15 
(4.6%) did not have culture performed. All index cases met the case definition on the 
basis of radiology and acid-fast bacilli in their smear.  
 








 Median (range) 37 (17 – 87) 
 
<30 87 26.5% 
 
30-59 208 63.4% 
 




Female 150 45.7% 
 




Sunda 287 87.5% 
 
Jawa 29 8.8% 
 
Batak 2 0.6% 
 
West Sumatra (Minang) 3 0.9% 
 




No 6 1.8% 
 
Yes 322 98.2% 
Cough duration (days)  
  
 Median (IQR) 30  (7 – 240) 
 
<14 54 16.6% 
 
14-60 192 58.9% 
 
61+ 80 24.5% 
Is the cough productive? 
 
 
No 12 3.7% 
 
Yes 316 96.3% 
Days of TB treatment  
 
 
None 273 83.2% 
 
<7 48 14.6% 
 





Highest sputum smear grade 
 
 
Scanty or 1+ 104 31.7% 
 
2+ 93 28.4% 
 
3+ 131 39.9% 
Culture and GeneXpert result 
  
 
Positive culture  301 91.8% 
 
Negative culture and positive GeneXpert 3 0.9% 
 
Negative culture 9 2.7% 
 
Not done 15 4.6% 
 
Radiological characteristics 
A detailed reading of the x-ray was possible for 317 of 328 x-rays (96.6%). The 
dominant abnormality in each of six lung zones, and overall, was coded according to 
the hierarchy already defined (Chapter 6: Methods). Findings are presented in Table 
12. An abnormality could be coded in all but one x-ray. Radiographic abnormalities 
were present in both lungs in 205 (65%) cases; confined to the right lung in 70 (22%) 
cases and confined to the left lung in 53 (17%) cases. Cavities were present in 162 
(51.1%) of index cases, and were more frequent in the upper lung zones 133 (42%) of 
cases. Patchy opacity was the dominant abnormality in 85 (26.8%) of x-rays, and it 
was the exclusive abnormality in 76 cases (23.2%). Consolidation was the dominant 
abnormality in a further 66 (20.8%) x-rays and the exclusive abnormality in 23 cases 







Table 12. Dominant index case x-ray abnormality overall and by zone.  
Lung Zone 
 
Any Upper Mid Lower 
Abnormality n (%) 
No abnormality 1 (0.3) 29 (9.1) 42 (13.2) 113 (35.6) 
Cavity 162 (51.1) 133 (42.0) 55 (17.4) 8 (2.5) 
Consolidation 66 (20.8) 48 (15.1) 56 (17.7) 39 (12.3) 
Patchy Lesion 85 (26.8) 97 (30.6) 150 (47.3) 147 (46.4) 
Nodules 2 (0.6) 2 (0.6) 4 (1.3) 2 (0.6) 
Bullae 1 (0.3) 8 (2.5) 10 (3.2) 8 (2.5) 
     
Total 317 (100.0) 317 (100.0) 317 (100.0) 317 (100.0) 
 
The median estimated extent of abnormalities was 40% of visible lung (range 1-
100%). Other x-ray findings are presented in Table 13. Pleural effusions were present 
in 25 index cases and were small (11 being less than one anterior rib-space in height, 
maximum 5 rib spaces high). Upper lobe collapse was present in 89 (28.1%) index 
cases in total (56 right upper lobe only, 19 left upper lobe only, 14 both). For the five 
index cases with miliary pattern, lung cavities were the dominant abnormality in 







Table 13. X-ray characteristics of 317 index cases. 
Abnormality Frequency (%) 
Right paratracheal adenopathy 73 (23.0) 
Hilar adenopathy 73 (23.0) 
Aorto-pulmonary window convex 57 (18.0) 
Pleural effusion 25 (7.9) 
Pleural thickening 15 (4.7) 
Pleural calcification 3 (0.9) 
Cardiothoracic ratio >50% 3 (0.9) 
Tracheal deviation 33 (10.4) 
Right upper lobe collapse or volume loss 70 (22.1) 
Left upper lobe collapse or volume loss 33 (10.4) 
Miliary pattern 5 (1.6) 
Calcified granulomata 273 (86.1) 
Multiple calcified nodules 27 (8.5) 
 
Household characteristics  
Participants were drawn from 328 households. In 197 (60%) households all eligible 
contacts participated. In 82 households (25%) one contact declined to participate, this 
number ranged up to six. Table 14 reports the number of contacts recruited per 
household. The 941 participants were drawn from 1,155 eligible household contacts, 
corresponding to a response rate of 81.5%. The median number of contacts recruited 






Table 14. Number of contacts recruited per household. 
Contacts per 
household 




1 93 28.4 28.4 93 
2 88 26.8 55.2 176 
3 50 15.2 70.4 150 
4 44 13.4 83.8 176 
5 21 6.4 90.2 105 
6 13 3.4 94.2 78 
7 9 2.7 97.0 63 
9 5 1.5 98.5 45 
10 1 0.3 98.8 10 
11 3 0.9 99.7 33 
12 1 0.3 100.0 12 
Total 328 100 100.0 941 
 
Characteristics of contacts 
Table 15 reports the baseline characteristics of the case contacts. Contacts had a 
median age of 28.9 years (range 5 to 84 years) and 527 (56%) were female. Sunda 
was the most frequent ethnicity, reported by 869 contacts (92.3%). Six hundred and 
seventy-nine (72.2%) contacts slept in a different room from the index case. Contacts 
spent a median 4 hours with the index case on the day before recruitment (range 0 - 
15 hours). Overall 729 (77.5%) of contacts were BCG vaccinated, and this did not 
decrease with age: 80.0% of contacts aged 5 to 24 were vaccinated; 65.7% of contacts 
aged 25 to 44 years; and 85.6% of contacts aged over 45 years. Current smoking was 
reported by 273 (29.0%) of contacts. Males were more likely to smoke: 224 (51.1%) 







Figure 10. Smokers and non-smokers by age (years) and sex for 941 contacts. 
 
A random capillary blood glucose greater than 100 was recorded in 599 case contacts 
(63.7%). Of these 40 had an HbA1c>6.4%, of whom only 12 reported knowing that 
they had diabetes. Fifty-eight had an HbA1c between 5.7% and 6.4%, none of whom 
reported a prior diagnosis of diabetes. The proportion of contacts with diabetes 
(HBA1c>6.4%) increased with age: 4/422 (1%) of contacts aged 5 to 24; 5/262 
(1.9%) of contacts aged 25 to 44; and 31/257 (12.1%) of contacts over 45 years of 
age. Mean body mass index increased from childhood to middle-age, and then was 
relatively constant (Figure 11). Obesity (BMI>30 kg/m2) was identified in 69 contacts 
aged 16-64. Only three contacts reported knowing they had HIV, all had a positive 
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Table 15. Clinical characteristics of 941 case contacts.  
Characteristic N* % 
Age (years) 
   
 Median (IQR) 28.9 14.8 – 46.3 
 
5 to 24 422 44.8% 
 
25 to 44 262 27.8% 
 
45+ 257 27.3% 
Sex 
   
 
Female 527 56.0% 
 
Male 414 44.0% 
Ethnicity 
   
 
Sunda 869 92.3% 
 
Jawa 43 4.6% 
 
Cirebon 2 0.2% 
 
Batak 1 0.1% 
 
West Sumatra Minang 4 0.4% 
 
Other 22 2.3% 
Sleep proximity to index case 
 
different room 679 72.2% 
 
same room 82 8.7% 
 
same bed 180 19.1% 
Hours spent with case the day before enrolment 
 Median (IQR) 4 1 - 10 
 
0 59 6.3% 
 
1-5 493 52.4% 
 




No 212 22.50% 
 




No or do not know 926 98.4% 
 









never 637 67.7% 
 
current 273 29.0% 
 




<5 102 11.0% 
 
5 to 9 80 8.6% 
 
10 to 14 76 8.2% 
 
>14 35 3.8% 
 




No 67 7.1% 
 
Yes 3 0.3% 
 




RBCG<101 599 63.7% 
 
HbA1c <5.7 244 25.9% 
 
HbA1c 5.7-6.4 58 6.2% 
 
HbA1c>6.4 40 4.3% 
Body mass index 
  
 Mean, sd (kg/m2) 21.6 5.3 
 
Very severely underweight (<15.0) 83 8.8% 
 
Severely Underweight (15.0-15.9) 56 6.0% 
 
Underweight (16.0-18.4) 157 16.7% 
 
Normal (18.5-24.9) 408 43.4% 
 
Overweight (25.0-29.9) 167 17.8% 
 
Obese (³30.0) 69 7.3% 
Results are number and percentage of contacts unless otherwise stated.  
IQR: Interquartile range; HIV: Human Immunodeficiency Virus; RCBG: random 






Figure 12. Assignment of outcome based on QFN-GIT result at baseline and 14 weeks and symptom evaluation. QFN-GIT: Quantiferon 




Figure 12 summarises the assignment of outcome based on QFN-GIT results at 
baseline and 14 weeks and evaluation for TB disease. Of 586 baseline QFN-GIT 
positive participants, 497 were asymptomatic and 89 (15.2%) had symptoms of TB. 
Three of the asymptomatic contacts with a positive QFN-GIT were later found to 
have TB disease. Of the 89 with symptoms, 63 underwent clinical evaluation, at 
which TB disease was identified in 13. TB was excluded in 50, because their 
symptoms resolved (41), or they were x-ray negative (nine). Ultimately 544 contacts 
were classified as baseline positive (BP), comprising 494 asymptomatic, 41 with 
symptoms that resolved and 9 with symptoms but negative x-rays.  
 
Of fifteen contacts with indeterminate QFN-GITs at baseline, seven (46.7%) were 
symptomatic. Six with symptoms and five without symptoms were evaluated. Four 
contacts (26.7%) with an indeterminate QFN-GIT were found to have TB disease, all 
were symptomatic.  
 
Of 340 contacts with a negative QFN-GIT at baseline two (0.6%) had active disease. 
Both (age 6 and 14 years) had lymphadenopathy and a chest x-ray consistent with TB 
disease. Repeat QFN-GIT was not performed for these two. Of 76 converters, six had 
symptoms at baseline (7.9%) but all had resolved by 14 weeks. One was evaluated on 
the day of recruitment and found to have a normal x-ray. Of 224 contacts with 
persistently negative (PN )QFN-GIT results, 29 (12.9%) had symptoms at baseline. 
These had resolved in all but 7 contacts at the 14 week visit and six of these seven 
were then evaluated at the clinic. The symptoms had resolved in five and one other 
had a negative x-ray.  
 
Predictors of active tuberculosis 
Overall 22 (2.3%) of contacts had TB disease. The prevalence of TB according to 
symptoms and QFN-GIT result is presented in Table 16. Of 139 participants with one 
or more symptoms, 19 (13.7%) had TB. Of 586 with a positive QFN-GIT 15 (2.6%) 
had TB disease. Of 15 participants with an indeterminate QFN-GIT, 4 (26.7%) had 
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TB disease. Eighty-nine participants had a positive QFN-GIT and symptoms, a 
finding associated with TB disease in 13 (14.6%) of the participants (Figure 13).  
 
 
Table 16. Prevalence of TB disease among contacts according to their 
characteristics. 
 




   
Negative 2 340 0.6% 
Positive 15 586 2.6% 
Indeterminate 4 15 26.7% 
Number of symptoms 
   
0 2 802 0.2% 
1 12 91 13.2% 
2 1 35 2.9% 
3 3 8 37.5% 
4 3 4 75.0% 
5 0 1 0.0% 
Any 19 139 13.7% 
Specific Symptoms 
   
Cough for 2 weeks 6 33 18.2% 
Productive cough 6 68 8.8% 
Haemoptysis 0 1 0.0% 
Fever 3 9 33.3% 
Night sweats 1 8 12.5% 
Weight loss 4 21 19.0% 
Loss of appetite 2 15 13.3% 
Chest pain 4 27 14.8% 
Lymphadeopathy 9 24 37.5% 
Any symptom and negative QFN-GIT 2 43 4.7% 
Any symptom and positive QFN-GIT 13 89 14.6% 







Figure 13. Venn diagram of number of contacts with active Tuberculosis (TB), 
symptoms of Tuberculosis and a positive QFN-GIT. 
 
Characteristics of contacts with TB disease 
Of the 22 TB cases identified among the 941 household contacts, eighteen were co-
prevalent cases whereas four were diagnosed more than 90 days after their enrolment 
in the study (incident cases). The prevalence of TB disease during 90 days of contact 
recruitment was 1,860 per 100,000 contacts (95% CI 1158 to 2974). Eight of the 22 
were less than 15 years old, corresponding to a prevalence of 3% (95% CI 1.4 - 6.3), 
higher than the 1.5% prevalence in adults (95% CI 0.8 - 2.7).  
 
Cases of TB disease in children under fifteen years frequently had lymphadenopathy 
(7 of 8), usually as their only clinical finding (6 of 8), and a positive x-ray. Cough was 
uncommon and therefore sputum smears or culture were not performed and all were 
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considered possible cases. The QFN-GIT was positive in 5/8 cases under 15 years and 
indeterminate in one and negative in two.  
 
Of the 15 cases of TB in contacts over 15 years of age, all had an x-ray consistent 
with TB disease, six were sputum smear positive and five were also culture positive. 
Accordingly there were five definite cases, one probable case and seven possible 
cases of TB among contacts over 15. The QFN-GIT was positive in 11 of 14 cases 
over 15 years and indeterminate in three.  
 
Based on the preceding work-up the final outcome is presented Table 17. The largest 
group was the BP group that was comprised of 544 contacts (57.8%). Two hundred 
and twenty-three contacts (23.7%) were persistently QFN-GIT negative. Seventy-six 
contacts converted from a negative to a positive QFN-GIT during follow up 
representing 8.1% of the overall cohort or 25% of those whose baseline QFN-GIT 
was negative. Eighteen contacts (1.9%) had an indeterminate test at baseline or follow 
up as their outcome.  
 
Table 17. Outcome based on baseline and 14 week QFN-GIT and symptom 
evaluation.  
Outcome n % 
Baseline Positive 544 57.8 




Indeterminate 18 1.9 




Lost to follow up 31 3.1 
Total 941 100.0 
 
The median TBAg-Nil at 14 weeks was 0.85 IU/ml for converters (IQR 0.49 to 2.44). 
41 (54.0%) of converters had a TBAg-Nil greater than 0.7 IU/mL at 14 weeks. For 
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converters the median change in TBAg-Nil from baseline to 14 weeks was 0.68 IU 
(IQR 0.35 to 2.38).  
 
The number of contacts contributing to the three different comparisons (defined in 
Chapter 6: Methods) are described in Table 18. The comparison of the prospectively 
defined group includes 76 converters and 223 PN. The cross-sectional comparison of 
baseline QFN-GIT includes 544 BP and 299 BN. The comparison of contacts with a 
positive QFN-GIT at either time point with those without includes 630 BP and conv, 
versus 223 PN.  
 
Table 18. Contacts contributing to the three different analyses. 
 Definition N 
Comparison Infected Uninfected Infected Uninfected 
QFN-GIT at 




Conv PN 76 223 
Baseline 
QFN-GIT 





PN 630 223 
 
Characteristics of phenotype groups 
Table 19 summarises the characteristics of the phenotype groups. The baseline 
positive contacts were older than converters and PN (mean age 32.9, 27.4 and 29.2 for 
BP, converters and PN respectively). The PN group had lower exposure to M. 
tuberculosis: 30.9% were exposed to a 3+ positive case, versus 43.9% of BP and 
53.9% of converters and 45.7% of PN were exposed to index cases with lung cavities 
versus 55.9% of BP and 54.8% of converters. Fewer PN contacts reported spending 
more than 5 hours with the case the day before enrolment (31.8%) than BP (44.5%) or 
converters (40.8%) or sleeping in the same room as the case (21.1% versus 31.8% BP 
and 19.7 converters). 
 
Table 19 continued on next page 
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Index case age (years) 
        
Mean (sd) 39 14.3  39.5 14.6  40.3 14.7 















Index case sex 
        










Index case ethnicity 
        











        










highest smear grade 
        















Contact age (years) 
        
Median (IQR) 31.8 16.8 – 50.0  22.8 16.8 –35.5  23.3 12.3 – 43.2 
















        












   
 
Table 19 continued on next page 
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Hours spent with case the day before enrolment 
Median (IQR) 1 1- 2  1 1- 2  1 1- 2 















Sleep proximity to index       
Different Room 371 68.2%  61 80.3%  176 78.9% 
Same room 55 10.1%  2 2.6%  15 6.73% 
Same bed 118 21.7%  13 17.1%  32 14.4% 
Diabetes - self reported 
      
















        















HIV infection - self reported 
      
















        











        






















BMI kg/m2 22.0 5.3  21.9 5.2  21.0 5.0 
Very severely 











Underweight 80 14.7% 11 14.5% 44 19.8% 




















Table 20 shows the correlation between measures of index case infectivity. Highest 
smear grade was correlated with both the presence of lung cavities (rho=0.20; 
P=0.0001) and extent of x-ray disease (rho=0.18;P=0.0001). Cough duration was not 
correlated with lung cavities and had a weak correlation with smear grade. The two 
measures of a contact’s exposure to the case, hours spent with the case the day before 
enrolment and sleep proximity were also strongly correlated (rho=0.24;P <0.0001).  
 
Of 223 PN contacts, 69 (31%) were exposed to a 3+ case, 47 (21%) slept in the same 
room as the index case and 104 (47%) were either exposed to a 3+ case or slept in the 
same room. Based on these relationships high exposure was defined as exposure to a 
case with a 3+ smear grade or sleeping in the same room or bed as the case.  
 
































Cavities       
Extent x-ray abnormal (%) 0.14     
Cough duration (days) 0.06 0.17   




Overall the cohort comprises household contacts highly exposed to M. tuberculosis. 
Index cases were included on the basis of x-ray and smear positivity, while M. 
tuberculosis was detected by GeneXpert and/or culture in 98% of cases. Radiological 
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findings are consistent with advanced disease in the majority of index cases at the 
time of presentation. Two thirds of patients had bilateral disease and over half had 
lung cavities, similar to the proportions reported in other high burden settings [260, 
266]. Case contacts were required to live with the index case for five hours a week, 
above this threshold we measured a range of exposure to the case.  
 
Assigning phenotype to contacts  
We found 57% of contacts were QFN-GIT positive at the baseline visit, 8% converted 
during follow up and 24% remained persistently QFN-GIT negative at 14 weeks and 
TB disease was diagnosed in 2.3% of contacts. TB disease was more likely in those 
with a positive or indeterminate QFN-GIT. These proportions are similar with other 
large series of TB case contacts published in endemic settings, discussed below.  
 
Hill et al published longitudinal follow up results for 558 Gambian household case 
contacts phenotyped by ELISPOT and TST [224]. Fewer had a positive ELISPOT at 
baseline (40%) but a similar proportion of initially negative contacts (25%) converted 
their ELISPOT over three-months follow up. Data from the same cohort document a 
similar rate of co-prevalent disease in contacts to that recorded in the present study 
[267]. The study recruited 2,381 contacts and all contacts that were TST positive or 
symptomatic were offered diagnostic evaluation. Evaluation was complete on 2,186 
contacts. Gastric aspirates were available for children who were not able to produce 
sputum. The study identified co-prevalent disease (defined as within 2 months of 
index case recruitment) in 1.52% (95% CI 0.9-2.0%), a similar rate to the present 
study. It appears limiting x-ray evaluation to symptomatic contacts in the present 
study did not result in a lower rate of diagnosis of co-prevalent disease.   
 
A Ugandan study of 1,210 TB case contacts followed for between 1 to 2 years found 
74.4% were TST positive at baseline, 13.8% converted and 11.7% were persistently 
TST negative. The cohort included contacts of any age, and 24% were under 5 years 
of age, and seven percent of the cohort were HIV positive.   
 
An earlier study of child case contacts (aged 6 months to 9 years) in Bandung found 




Indeterminate QFN-GIT results were infrequent in this cohort (1.9%). Much higher 
rates of indeterminate results have been reported in other cohorts, particularly in 
extremes of age or those HIV positive [268]. This could reflect good specimen 
collection practices, rapid specimen processing and our practice of repeating 
indeterminate tests. Of the few remaining indeterminate results, many (26%) were 
associated with TB disease.  
Exposure 
We defined a sub-group of highly exposed persistently uninfected contacts 
pragmatically. Analysis of correlations between variables revealed smear grade 
category was correlated with other measures of index case infectivity, as was sleep 
proximity with respect to the other measure of exposure to the index case. High 
exposure was defined as either exposure to a 3+ smear grade case or sleeping in the 
same room as the index case, to achieve a balance between high exposure and an 
adequately sized group. These measures of high exposure were less frequently 
encountered in the PN group, underlying the importance of adjusting or stratifying for 
exposure in subsequent analyses.  
 
Host factors 
A high proportion of the cohort is BCG vaccinated (76%). BCG vaccination was 
interrupted in Indonesia in the 1970s [235], possibly explaining the lower prevalence 
in the 25-44 age group (born 1970 – 1989). Smoking is highly prevalent in adolescent 
and adult men but not women. The prevalence of diabetes in the cohort was 4.25% 
overall and 12.1% of contacts over 45 years. In 2009 a national health survey found a 
prevalence of 5.6% in people over eighteen years [269]. Eighteen percent of the 
cohort was overweight and 7.3% obese.  
 
Discussion of other findings 
Other radiological findings in index cases 
X-ray based categorisation of TB disease phenotype is not clear cut. We found 28% 
of index cases had signs of upper lobe collapse, consistent with established or 
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reactivation TB. Overall a classification of reactivation versus primary disease could 
not be made with certainty. Rathman et al proposed infiltrates as a novel phenotype 
and we also find a substantial subset of index cases only have patchy infiltrates (23%) 
[260]. 
 
Symptoms among case contacts 
Symptoms of TB were reported by 15% of baseline positive contacts, but resolved in 
65% of this group who returned for evaluation. Symptoms at baseline were also 
reported by 12.9% of the PN group, and resolved in all but two, one had a negative x-
ray and another who was excluded on the basis of unresolved symptoms. Persistent 
and multiple symptoms were associated with TB disease but a transient productive 
cough was common and not associated with a diagnosis of disease. As expected co-
prevalent cases were rare and most were smear negative, justifying use of index case 
characteristics as measures of M. tuberculosis exposure.  
 
Mild and transient symptoms have been observed in the early stages of M. 
tuberculosis infection. As previously mentioned these were documented in case 
contact studies in the Faroe Islands (Chapter 1: Introduction). More recently Fijikawa 
et al diagnosed “early active” TB in 24 out of 884 soldiers exposed to six pulmonary 
TB cases in barracks [270]. These early active cases were identified by positive chest 
computer tomography in contacts with a positive QFN-GIT or x-ray. Ten of the cases 
were culture positive. None of the cases had TB symptoms but almost all subjects 
reported a “mild passing cough similar to a common cold”. All cases were treated, so 
it is not clear whether these cases represent the period of bacterial replication prior to 
a latent infection being established or the early stages of primary progressive TB. In 
the present study cough was reported by similar frequency by PN and BP contacts. 
This suggests symptoms result from early stages of infection common to both early 
clearers and those with latent infection, or cough arising from causes other than M. 





The cohort comprises highly exposed contact suitable for studies of EC. The high 
proportion of BP contacts suggest cases may present late meaning many susceptible 
contacts are lost from the prospective comparison of PN and converters. This is an 
issue for the statistical efficiency of the study, and also a potential source of bias. 
Thus the primary comparison is accompanied by an analysis that includes the baseline 
positive group. 
 
Measures of M. tuberculosis exposure differed across the phenotype groups, meaning 
exposure needs to be accounted for in subsequent analyses, either as a confounder or 
by stratification. Because exposure measurements were correlated, exposure to a 3+ 
index case or sleeping in the same room as the index case is proposed as a pragmatic 
definition of high exposure.   
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Chapter 8: Results of multivariable modelling of clinical and 
haematological parameters 
Introduction 
To identify differences in blood cell populations between early clearers and controls, 
each participant had an extended automated blood count performed at baseline. Blood 
parameters, along with clinical characteristics of the contact and case were modelled 
for their association with QFN-GIT result. As described earlier (Chapter 6: Methods), 
the primary analysis was a comparison of final QFN-GIT for those at risk of infection 
at baseline (PN vs Conv). Secondary analyses included the cross-sectional 
comparison of QFN-GIT result at baseline (BP vs Converters and PN), and the 
comparison of those with a positive QFN-GIT at baseline or follow up to persistently 
negative QFN-GIT (BP and Converters vs PN).  
 
The analysis of haematological parameters focuses on main blood cell populations. 
The results may direct planned future analysis of cell sub-populations using stored 




To identify peripheral blood cell populations associated with EC. 
 
Hypothesis 
Based on the findings of Martineau et al, (discussed in Chapter 2: Possible 
mechanisms of early clearance), we sought to replicate the association between 
neutrophil count and a negative IGRA. Specifically we hypothesised that:  
Contacts with a PN QFN-GIT have higher peripheral neutrophil count than 





The following haematology parameters were included in the analysis: hemoglobin, 
hematocrit, mean corpuscular volume (MCV), reticulocyte count, reticulocyte 
hemoglobin, total leucocytes, neutrophils, immature granulocytes, lymphocytes, 
monocytes and platelets. Age and sex for index cases and contacts were included in 
the model. Measures of M. tuberculosis exposure including index case smear grade, 
x-ray lung cavities, extent of disease on x-ray, sleep proximity, and hours spent with 
the case on a representative day were also included. Host (contact) factors considered 
as potential confounders included BCG vaccination, smoking, BMI and diabetes.  
 
Sample selection 
The analysis was performed for all cohort members.    
 
Laboratory methods 
Haematology parameters were measured by an automated haematology system 
(Sysmex XE-5000; Sysmex Corp, Kobe, Japan) that uses flow cytometry to count cell 
populations in whole blood.  
 
Form of variables included in the model 
All continuous variables were studied in their original form and as a fractional 
polynomial, and the form with the best fit (lowest p-value) when modelled against 
QFN-GIT result included in the model. This approach enables modelling of non-linear 
relationships between exposures and outcomes [270b], meaning the final model will 
better specify exposures of interest and confounding variables. Because different 
outcomes were modeled in the primary and secondary analyses, the variables may 
take different forms in each model.  
 
Where necessary continuous variables were scaled to aid interpretation. Categorical 
variables defined as follows: 
 BCG vaccination binary: vaccinated versus not vaccinated or not sure 
Sleep proximity binary: same room or different, where same includes 
same bed or different bed 
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Smoking binary: current smoker versus never, or smokers who 
quit >6 months ago  
 Smear grade   categorical: (1+ or scanty, 2+, 3+)   
Other variables remained in their original form. The variable form used for all three 
analyses is summarised in the appendix (Table 60). 
 
Statistical methods 
The association between haematology parameters and other variables with binary 
QFN-GIT result was modelled by a generalised estimating equation that accounted for 
clustering within households using an independence working correlation and robust 
standard errors. A log-link was used to estimate relative risks or prevalence ratios. 
Index and contact age and sex were retained in the model, other terms were removed 
in a stepwise fashion until remaining terms had a p-value <0.2. Lines of best fit were 
plotted for cell types and their relationship with the outcome of interest, based on raw 
data. For selected continuous variables post-estimates of the relative risk or 
prevalence ratio are presented for representative values.  
 
The primary analysis was the prospectively defined group PN vs conv. The 
hematological parameters modelled were measured at baseline, during M. 
tuberculosis exposure. Two secondary analyses were also informative. The cross-
sectional analysis of baseline QFN-GIT compared the BP and BN (PN and conv) 
group. Cell populations associated with the baseline positive group followed recent 
infection and the development of adaptive responses to M. tuberculosis. The final 
comparison of contacts with a positive QFN-GIT at either baseline or follow up with 
the PN group was not helpful for studying dynamic responses like cell types, but is 
included to allow comparison of other variables, such as BCG vaccination and 
smoking, across the three analyses.  
 
Results 
The characteristics of the three phenotype groups were presented in the preceding 
chapter (Table 19, Chapter 7: Characteristics of the cohort including phenotype 
classification  ). X-ray data for the eleven index cases whose x-ray was unavailable 
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for review were coded as missing. Otherwise a full dataset was available for all 
participants.   
 
Distribution of hematology parameters by phenotype  
The distribution of blood count parameters by phenotype is presented in Table 21. 
Mean hemoglobin in the converters was 14.3 g/dL compared to 13.9 g/dL for PN but 
this was not significant. Similarly the hematocrit was not higher in converters than PN 
(42.2% vs 41.2%). The concentrations of neutrophils and leucocytes were similar 
across the phenotype groups. 







Hemoglobin g/dL 13.9 (1.6) 14.3 (1.5) 13.9 (1.6) 
Haematocrit (%) 41.3 (4.3) 42.2 (4.1) 41.2 (4.2) 
MCV (fL; median (IQR))  83.7 (78.7 - 86.8) 82.9 (79.6 - 87.2) 82.7 (78.4 - 86.2) 
Ret (1000/uL; median 
(IQR)) 
50 (38 - 64) 52 (39 - 65) 49 (39 - 61) 
Ret He  
(pg; median (IQR)) 
34 (32 - 36) 34 (31 - 36) 34 (31 - 35) 
Leucocytes (/mm3) 7809 (1915) 7633 (2069) 7713 (2006) 
Neutrophils (1000/µL; 
median (IQR)) 
4.09 (3.36 - 4.97) 4.10 (3.01 - 5.07) 3.96 (3.25 - 4.99) 
Immature Granulocyte 
(1000/µL) 
0.18 (1.20) 0.01 (0.02) 0.10 (0.71) 
Lymphocytes (1000/µL) 2.7 (0.8) 2.7 (0.8) 2.6 (0.8) 
Monocytes (1000/µL) 0.45 (0.20) 0.40 (0.19) 0.43 (0.19) 
Monocyte to 
Lymphocyte Ratio 
0.2 (0.1) 0.2 (0.1) 0.2 (0.1) 
Platelets (1000/mm3) 299 (76) 301 (83) 304 (78) 
Results are mean (standard deviation) unless otherwise stated. MCV: Mean Cell 
Volume; Ret: Reticulocytes; Ret He: Reticulocyte Hemoglobin; IQR: Interquartile 
range. P-value for primary comparison groups PN vs converter. Note immature 
granulocytes are not scaled.  
 
116 
Primary comparison: Clinical and haematological parameters and 
final QFN-GIT  
 
Neutrophils was the only variable whose factional polynomial terms fitted better 
(P=0.3) than the linear term (P=0.8). However there was no evidence of any 
relationship (since p>0.05) and including fractional polynomials in the model 
produced unstable coefficients. The fractional polynomial curve (Figure 14) revealed 
a horizontal J-shaped curve with an inflection point at approximately 4 x 103 cells/µL. 
To allow for a non-linear relationship contacts were scored according to which 
quartile their neutrophil count fell in, with the lowest risk quartile (second quartile) 
serving as the reference.   
 
 
Figure 14. Fractional polynomial of neutrophil and risk of conversion for those 
originally QFN-GIT negative. 
 
Univariate associations 
Table 22 shows factors associated with risk of infection at 14 weeks for the primary 
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index case associated with QFN-GIT conversion (Univariate RR=2.47, 95% CI 1.42 - 
4.28; P=0.001). sleep time nor day time proximity to the index case were associated. 
 
BCG vaccination was strongly associated with a reduced risk of QFN-GIT conversion 
(RR 0.51; 95% CI 0.34 - 0.75; P=0.001). The risk of infection declined with 
increasing contact age, but the association was not significant. Smoking was not 
associated with risk of infection (RR=1.39; 95% CI 0.93 - 2.08; P=0.1). Only 13 
contacts in this analysis had an HbA1c >6.4%, and there was no association between 




Table 22. Univariate relative risk of infection at 14 weeks according to contact and 
index case factors 
Characteristic PN 
 N       % 
Conv 
N       % 
RR 95% CI P 
Index age (mean, sd)  40 15 40 15 0.97 0.84 - 1.13 0.7 
Index sex (M vs F) 112 50 33 43 0.82 0.54 - 1.23 0.3 
Cough (days, mean, sd) 59 61 58 52 1.00 1.00 - 1.00 0.9 
Highest smear grade        
1+/scanty 90 40 16 21 1.00 ref  
2+ 64 29 19 25 1.52 0.82 - 2.81 0.2 
3+ 69 31 41  2.47 1.42 - 4.28 0.001 
Cavities  
(present vs absent) 
96 46 40 55 1.31 0.87 - 1.98 0.2 
Extent of x-ray disease  48 29 47 26 0.99 0.93 - 1.06 0.8 
Age contacts (years) 
       
5-14 73 33 18 24 1.00 ref 
 
15-24 43 19 25 33 0.96 0.86 - 1.07 0.5 
25-34 27 12 13 17 0.92 0.74 - 1.15 0.5 
35-44 27 12 10 13 0.89 0.64 - 1.23 0.5 
45-54 28 13 4 5 0.85 0.55 - 1.32 0.5 
55+ 25 11 6 8 0.82 0.47 - 1.41 0.5 
Contact sex (M vs F) 104 47 36 47 1.02 0.67 - 1.56 0.9 
Contact eth. (Sunda vs 
other) 
202 91 71 93 0.96 0.86 - 1.07 0.5 
Sleep proximity 47 21 15 20 0.94 0.57 - 1.54 0.8 
Hours with case (mean, sd) 4 4 5 4 1.02 0.97 - 1.07 0.5 
BCG vacc (yes vs no) 192 86 53 70 0.51 0.34 - 0.75 0.001 
Smoking (current vs non-) 53 24 25 33 1.39 0.93 - 2.08 0.1 
BMI kg/m2 (mean, sd) 21 5 22 5 1.03 0.99 - 1.06 0.1 
Diabetes 
       
RCBG<100 149 67 49 65 1.00 ref 
 
HbA1c <5.7% 52 23 21 28 1.16 0.73 - 1.85 0.5 
HbA1c 5.7%-6.4% 12 5 3 4 0.81 0.27 - 2.38 0.7 
HbA1c>6.4% 10 5 3 4 0.93 0.34 - 2.59 0.9 
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Values are numbers and % unless otherwise stated. For binary exposures the 
frequency of the exposure (male sex, sunda ethnicity, BCG vaccination, current 
smoking) is presented. Data on the baseline category is in Table 19. BCG: Bacillus 
Calmette-Guérin vaccination; BMI: Body mass index; RCGB: Random capillary 
blood glucose; HbA1c: glycosylated haemoglobin; sd: standard deviation.  Note: 
contact age was modelled as a linear variable and the effect at representative values 
is shown in the table.  
 
Immature granulocytes were the only cell type associated with the primary outcome 
(Table 23). As immature granulocytes were scaled by a factor of ten the RR of 0.73 is 
interpreted as RR of conversion of 0.73 when the immature granulocyte count is 10 
cells/uL (95% CI 0.58 - 0.93; P=0.009) compared to when it is zero. When compared 
to the second quartile, risk of conversion was higher in all other quartiles of 
neutrophil count (1.72 for quartile 1, 1.38 for quartile 3 and 1.68 for quartile 4), 
however none were significantly different from the baseline category. The risk of 
QFN-GIT conversion increased with increasing lymphocyte counts and decreasing 
monocyte counts but neither association was statistically significant. Increasing 
haemoglobin was associated with an increased risk of QFN-GIT conversion, although 




Table 23 Univariate relative risk of infection at 14 weeks according to baseline 
haematology parameters, for those initially uninfected. 
Values are mean and standard deviation, except for neutrophils where number and 
percentage are presented. Abs. Retics: Absolute reticulocyte count; Ret haemoglobin: 
reticulocyte haemoglobin; Lympho: lymphocytes; Immat grans: Immature 
granulocytes (scaled). Note: contact age was modelled as a linear variable and the 
effect at representative values is shown in the table.  
 
Results of multivariable model 
The process for developing the model is summarised in the appendix (Table 61). The 
final model adjusted for age, sex and smear grade of the index case, age and sex of the 
contact, hours spent with the case, BCG vaccination, smoking, BMI, and neutrophil 
and immature granulocyte counts. Factors associated with QFN-GIT conversion in the 









RR 95% CI P 
Hemoglobin g/dl  13.9 1.6 14.3 1.5 1.12 0.99 - 1.26 0.06 
Haematocrit (%) 41 4 42 4 1.04 0.99 - 1.09 0.08 
Mean Cell Volume (fL)  82 6 82 7 1.01 0.98 - 1.05 0.5 
Reticulocytes  1 3 1 2 0.99 0.94 - 1.06 0.9 
Abs. Retics (cells/µL)  56 63 52 22 1.00 0.99 - 1.00 0.4 
Ret hemoglobin (pg)  33 4 33 4 1.02 0.96 - 1.09 0.5 
Platelets (cells/µL)  304 78 301 83 1.00 1.00 - 1.00 0.8 
Neutrophils (quartiles)* 
       
1 61 27 26 34 1.72 0.95 - 3.12 0.08 
2 57 26 12 16 1.00 ref 
 
3 54 24 17 22 1.38 0.72 - 2.62 0.3 
4 51 23 21 28 1.68 0.89 - 3.16 0.1 
Lympho (1000 cells/µL) 2.6 0.8 2.7 0.8 1.10 0.86 - 1.40 0.5 
Monocytes (1000 cel/µL)  0.4 0.2 0.4 0.2 0.48 0.16 - 1.46 0.2 
Immat Grans (100 cells/µL)  0.01 0.0
7 
0 0 0.73 0.58 - 0.93 0.009 
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Table 24. Two sets of granulocytes were associated with outcome. Immature 
granulocyte count remained strongly associated with a persistently negative QFN-GIT 
in the multivariable model: RR 0.72; 95% CI 0.60 - 0.90; P=0.004, or a 28% 
reduction in risk of conversion for every 100 cells/µL increase. A neutrophil count in 
the lowest quartile was associated with an increased risk of conversion versus the 
second quartile (RR 1.91 95%CI 1.05 - 3.50; P=0.04). The estimate for risk of 
conversion was also increased in the 4th quartile but this was not significant (RR 1.49; 





Table 24. Adjusted relative risk of infection at 14 weeks, for those initially uninfected.   
RR* 95% CI P 
Index case age (scale: 1=10 years) 0.97 0.84 - 1.12 0.7 
Index case sex 0.83 0.57 - 1.22 0.3 
Highest smear grade 
   
 
2+ vs 1+/scanty 1.47 0.80 - 2.70 0.2 
 
3+ vs 1+/scanty 2.63 1.54 - 4.50 <0.0001 
Contact age (years) 
   
 
10 1.00 - 
0.2 
 
20 0.90 0.77 - 1.05 
 
30 0.81 0.60 - 1.10 
 
40 0.73 0.46 - 1.16 
 
50 0.66 0.36 - 1.22 
 
55+ 0.60 0.28 - 1.28 
Contact sex (Male vs Female) 1.04 0.67 - 1.63 0.9 
Hours with case  1.04 1.00 - 1.08 0.08 
BCG vaccination (yes vs no) 0.52 0.35 - 0.77 0.001 
Smoking (current vs non-smokers) 1.63 1.03 - 2.57 0.04 
Body Mass Index (kg/m2) 1.06 1.01 - 1.10 0.01 
Neutrophils quartile 
   
 
1 1.91 1.05 - 3.50 0.04 
 
2 1.00 - 
 
 
3 1.15 0.60 - 2.18 0.7 
 
4 1.49 0.81 - 2.75 0.2 
Immature granulocytes (cells/uL) 
  
 
0 1.00 - 
 
 
10 0.97 0.95 - 0.99 
0.004 
 
20 0.94 0.90 - 0.98 
 
50 0.85 0.76 - 0.95 
 
100 0.72 0.58 - 0.90 
 
200 0.52 0.33 - 0.81 
* Adjusted for age, sex and smear grade of the index case, age and sex of the contact, 
hours spent with the case, BCG vaccination, smoking, BMI, and neutrophil and 
immature granulocyte counts. Immature granulocytes and contact age were modelled 
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as a linear variable, and are presented as post-estimates of the effect at representative 
values. BCG: Bacillus Calmette-Guérin vaccination. 
 
Other host factors associated with the outcome included BCG vaccination (RR 0.52; 
95% CI 0.35-0.77; P=0.001), smoking (RR 1.63; 95% CI 1.03 - 2.57; P=0.04) and 
body mass index (RR=1.06; 95% CI 1.01 - 1.10; P=0.01). The post-estimate for obese  
contacts relative to contacts with a normal BMI was 1.79 (95% CI 1.14 - 2.81; 
P=0.01), based on the midpoint for each category (i.e. 32.5 kg/m2 vs 21.75 kg/m2; for 
full definitions of categories see Chapter 6, Methods). Multivariable modelling 
revealed an estimate for smoking that was 18% higher than the univariate estimate. 
The univariate RR may have been confounded by time spent with the case as smokers 
tended to spend less time with the case than non-smokers (mean 4.7 hours vs 5.5 
hours, P=0.012). 
 
Living with an index case with 3+ grade sputum positivity was the only measure of 
M. tuberculosis exposure significantly associated with developing infection in the 
univariate analysis (RR 2.36; 95% CI 1.54 - 4.50; P=0.001), and remained significant 
in the multivariate analysis (RR 2.67; 95% CI 1.58 - 4.54; P<0.0001).  
 
Testing for effect modification  
There was evidence of interaction between smear grade and quartile of neutrophils 
(Pinteraction=0.01) and smear grade and BCG (Pinteraction =0.001). Table 25 presents 
relative risk of QFN-GIT conversion by neutrophil quartile, stratified by smear grade 
of the index case. For those exposed to a 3+ smear grade case, relative risk of 
conversion was higher in the lowest and highest quartile, relative to the second 
quartile (RR=3.61; 95% CI 1.24 - 10.56; P=0.02) and 4.26 (95% CI 1.53 - 11.83; 
P=0.005) respectively. Contacts exposed to a 1+ case had a similar pattern with 
increased estimates for the relative risk of conversion in the highest and lowest 
quartiles, but these were not significant. A different relationship was seen for contacts 
exposed to a 2+ positive case, with those in the third quartile having a lower relative 
risk of QFN-GIT conversion (RR= 0.25; 95% CI:0.08 - 0.82; P=0.02) than those in 
the reference (second) quartile, but these were based on small numbers. Similarly 
post-estimates for the effect of BCG according to index case was significant when the 
case was smear grade 1 and 3 (RR 0.27; 95% CI 0.12 - 0.61; P=0.002 and RR=0.53; 
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95% CI 0.33 - 0.87; P=0.012), but not 2+ (RR=0.93; 95% CI 0.38 - 2.25; P=0.866) 
(Table 26). In both instances the estimates for contacts exposed to 2+ cases were 
based on small numbers of participants.     
 
Table 25. Post-estimates for relative risk of conversion by neutrophil quartile, 





PN Conv Conversion 
rate  
RR 95% CI p 
1+/scanty 1 31 8 0.21 3.63 0.95 - 13.83 0.06 
 
2 24 2 0.08 1.00 ref 
 
 
3 16 3 0.16 2.86 0.66 - 12.42 0.2 
 
4 19 3 0.14 1.41 0.29 - 6.77 0.7 
        
2+ 1 15 7 0.32 0.70 0.28 - 1.77 0.5 
 
2 15 7 0.32 1.00 ref 
 
 
3 16 3 0.16 0.25 0.08 - 0.82 0.02 
 
4 18 2 0.10 0.25 0.05 - 1.17 0.08 
        
3+ 1 15 11 0.42 3.61 1.24 - 10.56 0.02 
 
2 18 3 0.14 1.00 ref 
 
 
3 22 11 0.33 2.78 1.00 - 7.76 0.051 
 





Figure 15. Risk of QFN-GIT conversion according to neutrophil count at baseline, 
stratified by smear grade of index case. Fractional polynomial based on univariate, 
not multivariate model. 
 
 
Table 26. Relative risk of QFN-GIT conversion according to BCG vaccination 
stratified by smear grade of index case. 
Smear 
grade 






RR 95% CI P 
1+/scanty No 11 7 0.39 1.00 ref 
  
Yes 79 9 0.10 0.27 0.12 - 0.61 0.002 
2+ No 11 4 0.27 1.00 ref 
  
Yes 53 15 0.22 0.93 0.38 - 2.25 0.866 
3+ No 9 12 0.57 1.00 ref 
  
Yes 60 29 0.33 0.53 0.33 - 0.87 0.012 
BCG: Bacillus Calmette-Guérin vaccination; PN: Persistently QNF-GIT negative; 
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Secondary comparison: Clinical and haematological parameters and 
baseline QFN-GIT result  
Form of variables included in the model 
Contact age was modelled as a fractional polynomial because this fitted better than 
the linear term. (P=0.001 vs P=0.008, see Figure 16).   
 
Figure 16. Fractional polynomial for contact age and risk of positive QFN-GIT at 
baseline. 
 
Univariate associations  
Table 27 shows index case and contact factors associated with prevalence of infection 
at baseline. Sleeping in the same room as the index case was associated with an 
increased prevalence of infection (PR=1.23; 95% CI 1.11 - 1.36; P <0.0001). Other 
measures of exposure to M. tuberculosis also modestly increased the relative risk of 
infection. The prevalence ratio of infection associated with a 2+ smear grade case 
versus 1+ or scanty was 1.16 (95% CI 1.01 - 1.39; P=0.04) and for 3+ grade case 
versus 1+ or scanty was 1.18 (95% CI 1.01 - 1.31; P=0.03). Exposure to a case with 


























(PR=1.15; 95% CI 1.01 - 1.31; P =0.03). Each hour spent with the case the day before 
enrolment raised the prevalence of infection 2% (95% CI 1% - 3%; P=0.003). An 
HbA1c >6.4% was not associated with a positive QFN-GIT at baseline (PR=0.92; 
95% CI 0.70 - 1.21; P=0.6).  
 
Post-estimates of the PR of infection at baseline increased approximately 0.5% for 
each decade over 10 years of age of the contact (P=0.002). This is as anticipated from 
the graph of the fractional polynomial, which is linear between ages 5 – 55 years. The 
PR for infection at baseline in males was 0.91 (95% CI 0.83 - 1.00; P=0.05). BCG 
vaccination was associated with a decreased relative risk of infection in both the 




Table 27. Contact and index case factors associated with prevalence of infection at 
baseline.  
Characteristic PN & Conv 
N        %  
BP 
N        % 
PR 95% CI P 
Index age (mean, sd) 40 15 39 14 0.99 0.94 - 1.03 0.5 
Index sex (Male vs Female) 160 48 316 55 1.11 0.98 - 1.26 0.1 
Cough (>15 days vs 0-14) 271 82 487 85 0.91 0.75 - 1.10 0.3 
Highest smear 
       
1+ or scanty 115 35 148 26 1.00 ref 
 
2+ 92 28 175 31 1.16 0.97 - 1.40 0.1 
3+ 124 38 248 43 1.18 1.01 - 1.39 0.04 
Cavities (present vs absent) 149 47 310 57 1.15 1.01 - 1.31 0.03 
Extent of x-ray (mean; sd) 48 28 51 28 1.02 1.00 - 1.04 0.1 
Contact age (years) 
       
5-14 96 29 130 23 1.00 ref 
<0.0001 
 
15-24 76 23 100 18 1.01 1.00 - 1.01 
25-34 47 14 94 17 1.01 1.00 - 1.02 
35-44 38 12 76 13 1.02 1.01 - 1.03 
45-54 34 10 93 16 1.02 1.01 - 1.03 
55+ 40 12 78 14 1.03 1.01 - 1.04 
Contact sex (M vs F) 157 47 235 41 0.91 0.83 - 1.00 0.05 
Cont eth (Sunda vs other) 301 91 533 93 0.98 0.95 - 1.01 0.2 
Sleep prox (diff vs same) 264 80 389 68 1.23 1.11 - 1.36 <0.0001 
Hours with case  4.6 3.9 5.6 4.3 1.02 1.01 - 1.03 0.003 
BCG (yes vs no) 268 81 431 76 0.89 0.81 - 0.99 0.03 
Smoking (current vs non-) 90 27 175 31 1.06 0.96 - 1.18 0.3 
BMI (kg/m2; mean, sd) 21 5 22 5 1.01 1.00 - 1.02 0.1 
Diabetes 
       
RCBG<100 216 65 365 64 1.00 ref 
 
HbA1c <5.7% 83 25 147 26 1.02 0.90 - 1.15 0.8 
Hba1c 5.7-6.4% 16 5 37 7 1.11 0.93 - 1.33 0.3 
Hba1c>6.4% 16 5 22 4 0.92 0.70 - 1.21 0.6 
Note: values are numbers and percentages unless otherwise stated. For binary 
exposures the frequency of the exposure (male sex, sunda ethnicity, BCG vaccination, 
current smoking) is presented. Data on the baseline category is in Table 19.PN: 
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Persistently Negative QFN-GIT; Conv: Converter; BP: Baseline Positive QFN-GIT; 
Cont eth: contact ethnicity; Sleep prox: sleep proximity, different room versus same 
room; BCG: Bacillus Calmette-Guérin vaccination; BMI: Body mass index; RCGB: 
Random capillary blood glucose; HbA1c: glycosylated haemoglobin. 
 
Higher monocyte and lymphocyte counts were associated with increased prevalence 
of infection at baseline but neither relationship was statistically significant (PR=1.27; 
95% CI 0.97 - 1.67; P= 0.08 and PR=1.05 95% CI 0.99 - 1.11; P=0.1 per 1000 cells/ 
uL) (Table 28). Immature granulocytes had an PR of 1.002 per 1000 cells/ uL (95% 
CI 1.001 - 1.003; P<0.0001). The number of neutrophils were not related with a 




Table 28. Haematological parameters associated with positive QFN-GIT at baseline 
Characteristic PN & Conv 
mean     sd  
BP 
mean    sd 
PR 95% CI P 
Hemoglobin  g/dl  14.0 1.6 13.8 1.7 0.98 0.95 - 1.01 0.2 
Haematocrit   (%) 41.5 4.2 41.2 4.4 0.99 0.98 - 1.01 0.4 
Mean Cell Volume  (fL) 82 7 82 7 1.00 0.99 - 1.01 0.8 
Reticulocyte  2 4 1 3 0.99 0.97 - 1.02 0.6 
Abs retics  (1000/uL) 57 59 56 60 1.00 1.00 - 1.00 0.8 
Ret hemoglobin   (pg) 33 4 33 4 0.99 0.98 - 1.00 0.2 
Platelets  (/1000) 301 78 299 77 1.00 1.00 - 1.00 0.7 
Neutrophils   (1000/uL) 4.34 1.60 4.34 1.50 1.00 0.97 - 1.03 0.9 
Lymphocytes  (1000/uL) 2.67 0.79 2.76 0.85 1.05 0.99 - 1.11 0.1 
Monocytes  (1000/uL) 0.43 0.19 0.45 0.20 1.27 0.97 - 1.67 0.08 
Immat grans  (1000/uL )  0.09 0.6 0.24 1.76 1.02 1.01 - 1.03 <0.0001 
Note: values are numbers and percentages unless otherwise stated. PN: Persistently 
Negative QFN-GIT; Conv: Converter; BP: Baseline Positive QFN-GIT; BCG: Abs. 
Retics: Absolute reticulocyte count; Ret haemoglobin: reticulocyte haemoglobin; 
Immat grans: Immature granulocytes, not scaled. Post-estimate for contact age >55 
is based on a contact age of 60 years.  
 
Multivariable analysis  
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The steps for developing the model are described in the appendix (Table 62). The 
final model included age, sex, lung cavities of the index case, as well as age, sex, 
ethnicity of the contact, hours spent with the case, sleep proximity to the case, BCG 
vaccination, smoking status and haemoglobin; as well as neutrophil, immature 
granulocytes lymphocyte, and monocyte counts measured in 1000 cells/uL. 
 
Table 29 shows factors associated with a positive QFN-GIT at baseline. The effect of 
a 1 x 103 increase in monocytes increased from 1.27; (95% CI 0.97 - 1.67; P=0.08) in 
the univariate analysis by 18% to an adjusted PR of 1.52 (95% CI 1.11 - 2.07; 
P=0.008). In contrast to the univariate analysis lymphocytes were significantly 
associated with risk of infection in the final model (PR=1.06; 95% CI 1.00 - 1.12; 
P=0.04). Immature granulocytes were associated with infection at baseline in the 
univariate analysis but not in the final model. Haemoglobin concentration was 
retained in the model but its relationship with infection at baseline was not significant.  
 
Cavities remained associated with infection in the final model (PR 1.17; 95% CI 1.04 
- 1.32; P=0.009) whereas smear grade was not retained in the model. Sleeping in the 
same room as the index was associated with an increased prevalence of infection at 
baseline (PR 1.16; 95% CI 1.04 - 1.29; P=0.009) as was each additional hour spent 
with the case (PR 1.01; 95% CI 1.00 - 1.03; P=0.045).  
 
Contact age was positively associated with prevalence of infection with the PR 
increasing approximately 0.5% for each decade over 10 years of age (P=0.002). BCG 
vaccination remained associated with a decreased prevalence of infection in the 
multivariate analysis (PR 0.87; 95% CI 0.78 - 0.96; P=0.007). Smoking was not 
significantly associated with an increased prevalence of infection at baseline 
(PR=1.12; 95% CI 0.98 - 1.28; P=0.09).   
 
 
Table 27 continued on next page 
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Table 29. Contact characteristics and adjusted prevalence ratio of infection at 
baseline.  
  
PR* 95% CI P 
Index case age (years)  0.98 0.94 - 1.02 0.3 
Index case sex (M vs F) 1.11 0.98 - 1.26 0.1 
Cavities (present vs absent) 1.17 1.04 - 1.32 0.009 
Contact age (fractional polynomial; years) 
   
 5-14 1.00 ref  
 
15-24 1.01 1.00 - 1.01 
0.002 
 
25-34 1.01 1.01 - 1.02 
 
35-44 1.02 1.01 - 1.03 
 
45-54 1.02 1.01 - 1.04 
 
55+ 1.03 1.01 - 1.05 
Contact sex (M vs F) 0.93 0.82 - 1.05 0.2 
Contact ethnicity (Sunda vs other)  0.97 0.94 - 1.01 0.1 
Hours with case the day before enrolment 1.01 1.00 - 1.03 0.05 
Sleep proximity (same vs different room)  1.16 1.04 - 1.29 0.009 
BCG vaccination (yes vs no) 0.87 0.78 - 0.96 0.007 
Smoking (current vs non-smoker) 1.12 0.98 - 1.28 0.09 
Hemoglobin g/L 0.97 0.93 - 1.01 0.1 
Immature granulocytes (cells per uL) 
 
 
0 1.00 ref 
 
 
10 1.00 1.00 - 1.00 
0.1 
 
20 1.00 0.99 - 1.99 
 
50 1.00 0.99 - 1.99 
 
100 1.00 0.99 - 1.97 
 
200 1.00 0.99 - 1.91 
Neutrophils (1000 cells/uL) 
  
 
2.83 1.00 ref 
 
 
3.72 0.98 0.94 - 1.41 0.1 
 
4.54 0.95 0.89 - 1.61 
 




Monocytes (1000 cells/uL)  
 
0.23 1.00 ref 
 
 
0.37 1.06 1.02 - 1.11 0.008 
 
0.49 1.11 1.03 - 1.21 
 
0.66 1.20 1.05 - 1.37 
Lymphocytes (1000 cells/uL) 
 
1.87 1.00 ref 
 
 
2.35 1.03 1.00 - 1.26 0.04 
 
2.87 1.06 1.00 - 1.12 
 
3.62 1.11 1.01 - 1.23 
* Estimates adjusted for age, sex, lung cavities of the index case, as well as age, sex, 
ethnicity of the contact, hours spent with the case, sleep proximity to the case, 
neutrophil, lymphocyte, and monocyte counts. Blood parameters were modelled as 
continuous variables but are presented here as post-estimates for either mid points of 
quartiles (neutrophils, monocytes lymphocytes) or representative values (immature 
granulocytes). Post-estimate for contact age >55 is based on a contact age of 60 
years. BCG: Bacillus Calmette-Guérin vaccination; BMI: Body mass index.
 
Effect modification 
Tests for interaction were positive for lymphocyte count and the presence of index 
case lung cavities, and monocyte count and the presence of index case cavities 
(P=0.0006 and P=0.0007).  
Table 30 presents the stratum-specific estimates for both cell types, among those 
exposed to index cases with and without lung cavities. In both cases, the relationship 
with baseline QFN status was only statistically significant in those exposed to cases 
with lung cavities (PR=1.78; 95% CI 1.29 - 2.45; P<0.0001 and 1.09; 95% CI 1.03 - 
1.15; P=0.002 for monocytes and lymphocytes respectively). Figure 17 shows the line 
of best fit for the relationship between the cell counts and prevalence of conversion, 
based on original, not modelled, data. There is a positive relationship between both 
lymphocytes and monocytes and a positive QFN at baseline among contacts exposed 




Table 30. Post-estimates of prevalence ratio of infection at baseline according to 
monocyte and lymphocyte count, stratified by lung cavities.  
PR 95% CI p-value 
Monocytes (1000 cells/µL) 
   
No cavities 1.28 0.91 - 1.81 0.2 
Cavities 1.78 1.29 - 2.45 <0.0001 
Lymphocytes (1000 cells/µL) 
   
No cavities 1.03 0.96 - 1.10 0.4 





Figure 17. Lines of best fit and 95% confidence interval for association of baseline 
lymphocyte and monocyte count according to presence of cavities in the index case  
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Secondary analysis: Clinical and haematological parameters and 
positive QFN-GIT at baseline or follow up  
Variable form 
All continuous variables were studied in their original form and as a fractional 
polynomial, and p-values compared to gauge whether fractional polynomial terms 
correlated better with outcome. This was only the case for contact age, where the 
fractional polynomial terms fitted better (P=0.041) than the linear term (P=0.042), 
although the difference was slight.   
 
 
Figure 18. Fractional polynomial of relationship between contact age and positive 
IGRA at baseline or follow up. 
 
Univariate analysis 
Table 31 shows factors associated with prevalence of infection at either baseline or 14 
weeks versus being persistently uninfected. The prevalence ratio for vaccination with 
BCG was 0.85 (95% CI 0.79 - 0.92; P <0.0001). Smoking was also associated with a 





















There was a linear relationship with BMI and prevalence of infection (1% increase for 
each kg/m2 increase in BMI). Diabetes was not associated with a positive QFN-GIT.  
 
Sleeping in the same room as the index case was associated with an increased 
prevalence of infection (PR=1.12; 95% CI 1.04 - 1.21; P <0.003). The prevalence 
ratio of infection associated with a 2+ smear grade case was 1.16 (95% CI 1.00 - 1.35; 
P=0.04) for a 2+ grade case versus 1+ or scanty and 1.25 (95% CI 1.10 - 1.43; 
P=0.001) for a 3+ case versus a 1+ or scanty case. Exposure to a case with lung 
cavities was associated with a modest increase in prevalence of infection (PR=1.12; 
95% CI 1.01 - 1.23; P=0.03). Each hour spent with the case the day before enrolment 
was associated with an increase in the prevalence of infection of 2% (95% CI 1% - 




Table 31. Univariate prevalence ratio of infection at baseline or 14 weeks versus 
remaining uninfected at 14 weeks according to index and contact characteristics. 
 PN 
(N    %) 
BP & Conv 
(N    %) 
PR 95% CI P 
Index case age  40 
 
39 14 0.99 0.95 - 1.02 0.5 
Index sex (M vs F) 112 50.2 349 53.9 1.04 0.94 - 1.15 0.4 
Cough (>15 vs	£15 days) 180 80.7 553 85.5 0.91 0.78 - 1.06 0.2 
Highest smear 
       
1+ 90 40.4 164 25.3 1.00 ref 
 
2+ 64 28.7 194 30.0 1.16 1.00 - 1.35 0.04 
3+ 69 30.9 289 44.7 1.25 1.10 - 1.43 0.001 
Cavities (present vs absent) 96 45.7 350 56.5 1.12 1.01 - 1.23 0.03 
Extent of x-ray (mean, sd,) 48 29 51 28 1.01 0.99 - 1.02 0.3 
Age contacts 
       
5-14 73 32.7 148 22.9 1.00 ref 
 
15-24 43 19.3 125 19.3 1.00 1.00 - 1.01 0.02 
25-34 27 12.1 107 16.5 1.01 1.00 - 1.01 0.02 
35-44 27 12.1 86 13.3 1.01 1.00 - 1.02 0.02 
45-54 28 12.6 97 15.0 1.01 1.00 - 1.02 0.02 
55+ 25 11.2 84 13.0 1.02 1.00 - 1.03 0.02 
Contact sex (M vs F) 104 46.6 271 41.9 0.95 0.87 - 1.04 0.2 
Contact ethnicity 202 90.6 604 93.4 0.98 0.96 - 1.01 0.2 
Sleep prox (diff vs same) 176 78.9 450 69.6 1.12 1.04 - 1.21 0.003 
Hours with case  4 4 5 4 1.02 1.00 - 1.03 0.004 
BCG vacc (yes vs no) 192 86.1 484 74.8 0.85 0.79 - 0.92 <0.0001 
Smoking (current vs non) 53 23.8 200 30.9 1.09 1.01 - 1.18 0.03 
BMI (kg/m2; mean, sd) 21 5 22 5 1.01 1.00 - 1.02 0.01 
Diabetes 
       
RCBG<100 149 66.8 414 64.0 1.00 ref 
 
HBA1c <5.7% 52 23.3 168 26.0 1.04 0.94 - 1.15 0.5 
HBA1c 5.7-6.4% 12 5.4 40 6.2 1.05 0.89 - 1.23 0.6 
HBA1c >6.4% 10 4.5 25 3.9 0.97 0.78 - 1.21 0.8 
Note: values are numbers and percentages unless otherwise stated. For binary 
exposures the frequency of the exposure (male sex, sunda ethnicity, BCG vaccination, 
current smoking) is presented. Data on the baseline category is in Table 19. PN: 
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Persistently Negative QFN-GIT; Conv: Converter; BP: Baseline Positive QFN-GIT; 
Index case age in years, scaled 1:10; Extent x-ray disease scaled 1:10; Sleep prox: 
sleep proximity, different versus same room)BCG vacc: Bacillus Calmette-Guérin 
vaccination; BMI: Body mass index. 
 
The association of heamatological parameters with prevalence of infection at baseline 
or 14 weeks is shown in Table 32. Lymphocytes were positively associated with 
infection (PR=1.04 95% CI 1.00 - 1.08; P=0.04) as were monocytes, but the latter was 
not significant (PR=1.10; 95% CI 0.89 - 1.37; P=0.4). Immature granulocytes were 
also positively associated with infection but neutrophils were not. None of the red cell 
indices were related to infection at baseline or follow up.   
 
Table 32. Univariate prevalence ratio of infection at baseline or 14 weeks versus 
remaining uninfected at 14 weeks according to haematological parameters 
 PN 
(N    %) 
BP & Conv 
(N    %) 
PR 95% CI P 
        
Hemoglobin g/dl  13.9 1.6 13.9 1.6 1.00 0.97 - 1.03 1 
Haematocrit (%,)) 41 4 41 4 1.00 0.99 - 1.01 0.7 
MCV (fL)  82 6 82 7 1.00 1.00 - 1.01 0.4 
Reticulocytes  1 3 1 3 1.00 0.98 - 1.02 0.8 
Abs Retics (1000/uL,) 56 63 56 57 1.00 1.00 - 1.00 0.9 
Ret hb (pg,) 33 4 33 4 1.00 0.99 - 1.01 0.8 
Platelets (/1000,) 304 78 300 78 1.00 1.00 - 1.00 0.4 
Neutrophils (1000/uL,) 4.3 1.6 4.3 1.5 1.00 0.98 - 1.03 1 
Lympho (1000/uL) 2.6 0.8 2.8 0.8 1.04 1.00 - 1.08 0.04 
Monocytes (1000/uL,) 0.4 0.2 0.4 0.2 1.10 0.89 - 1.37 0.4 
Immat grans (1000/uL,) 0.1 0.7 0.2 1.7 1.00 1.00 - 1.00 0.04 
PN: Persistently Negative QFN-GIT; Conv: Converter; BP: Baseline Positive QFN-
GIT; BCG: Bacillus Calmette-Guérin vaccination; MCV: mean corpuscular volume; 
Abs. Retics: Absolute reticulocyte count; Ret hb: reticulocyte haemoglobin; Lympho: 
Lymphocytes; Immat grans: Immature granulocytes. 
 
Building the model 
The model building steps are summarised in the appendix (Table 63). The final model 
included age, sex, smear grade, lung cavities of the index case, as well as age, sex, 
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ethnicity of the contact, hours spent with the case, sleep proximity to the case, BCG 
vaccination, smoking, neutrophil, lymphocyte, and monocyte counts. 
 
Multivariate associations 
Lymphocytes were the only cell population associated with a positive QFN-GIT at 
either baseline or follow up (Table 33), with PR of infection of 1.05 (95% CI 1.01 - 
1.20; P=0.02) for each 1000 cell/uL, similar to the association seen in the comparison 
of QFN-GIT at baseline. Monocytes were not significant in this analysis. (PR=1.24; 
95% CI 0.98 - 1.57; P=0.07). Neutrophils were retained in the model but they did not 
have a significant association with outcome, immature granulocytes were not retained 
in the model.  
 
Cavities and a smear grade of 2+ and 3+ were associated with increased risk of 
infection at baseline in the univariate analysis, but only 3+ smear grade remained a 
significant risk factor in the final model (PR 1.21; 95% CI 1.07 - 1.37; P=0.003). 
Similarly, sleep proximity and hours spent with the case were both associated with 
infection in the univariate but only hours with the case in the adjusted analysis, with 
each additional hour raising the risk of infection by 1% (P=0.01).  
 
Contact age was positively associated with prevalence of infection with the PR 
increasing approximately 2% for each decade over 10 years of age (P=0.01). BCG 
vaccination decreased the risk of infection in both the univariate and adjusted analysis 
(PR and adjusted PR 0.85; 95% CI 0.79 - 0.92; P<0.0001). Smoking was associated 
with increased prevalence of infection (PR 1.13; 95% CI 1.03 - 1.23; P=0.01). BMI 




Table 33 continued over page 
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Table 33. Prevalence ratio of positive QFN-GIT at baseline or 14 weeks according to 
contact characteristics.  
PR* 95% CI P 
Index age (scale: 1=10 years) 0.98 0.95 - 1.02 0.3 
Index case sex (M vs F) 1.03 0.94 - 1.13 0.5 
Highest smear grade 
   
2+ vs 1+/scanty 1.09 0.94 - 1.25 0.3 
3+ vs 1+/scanty 1.21 1.07 - 1.37 0.003 
Cavities 1.09 0.99 - 1.20 0.09 
Contact age (years) 
   
10 
   
20 1.02 1.00 - 1.03 
0.01 
 
30 1.04 1.01 - 1.07 
40 1.06 1.01 - 1.10 
50 1.08 1.02 - 1.14 
60 1.10 1.02 - 1.18 
Contact sex (M vs F) 0.91 0.83 – 1.01 0.082 
Hours with case the day before enrolment 1.01 1.00 - 1.03 0.01 
Sleep Proximity (diff room vs same) 1.08 0.99 - 1.17 0.08 
BCG vaccination (yes vs no) 0.85 0.79 - 0.92 <0.0001 
Smoking 1.13 1.03 - 1.23 0.01 
Neutrophils (1000 cells/uL)    
2.83 1.00 ref 
0.1 
3.72 0.98 0.95 - 1.81 
4.54 0.97 0.92 - 1.21 
5.98 0.94 0.86 - 1.12 
Monocytes (1000 cells/uL)    
0.23 1.00 ref 
0.07 
0.37 1.03 0.99 - 1.77 
0.49 1.06 0.99 - 1.12 






   
1.87 1.00 ref 
0.02 
2.35 1.03 1.00 - 1.45 
2.87 1.05 1.00 - 1.19 
3.62 1.09 1.02 - 1.18 
PR: Adjusted prevalence ratio. * Estimates adjusted for age, sex, smear grade, lung 
cavities of the index case, as well as age, sex, ethnicity of the contact, hours spent 
with the case, sleep proximity to the case, BCG vaccination, smoking, neutrophil, 
lymphocyte, and monocyte counts.  
 
Discussion 
Cell populations associated with the primary outcome 
Two granulocyte population measurements at baseline were associated with 
subsequent QFN-GIT conversion at 14 weeks, and are possible correlates of EC. 
Immature granulocytes were infrequently detected, but when present were strongly 
associated with remaining uninfected. A neutrophil count in the lowest quartile was 
also associated with an increased risk of conversion in the multivariable analysis. A 
U-shaped relationship between neutrophil count and risk of conversion was 
statistically significant among contacts with the highest exposure to M. tuberculosis. 
 
Immature granulocytes are most likely immature neutrophils, so called “band forms” 
drawn into the circulation during the acute response to bacterial infection [271]. 
Studies in immature granulocytes collected from septic patients reveal immature 
neutrophils are capable of phagocytosis and production of reactive oxygen species 
and have a pro-inflammatory phenotype with higher TNF-/IL-10 ratio than mature 
neutrophils. Alternatively the immature granulocytes identified may be myeloid 
derived suppressor cells (MDSC), a population previously identified following LTBI 
infection and in TB disease. MDSC inhibit CD4+ (and CD8+) T cells, promote IL-1b, 
IL-6 and IL-8, GCSF, MCP-1 and reduce GMCSF [272]. The inverse relationship 
between immature granulocytes and risk of conversion is evidence of an acute 




We found contacts had a significantly higher relative risk of conversion if their 
neutrophil count was in the lowest quartile. Among contacts exposed to index cases 
with a 3+ smear grade, the risk of conversion was significantly higher in both the first 
and fourth quartile of neutrophil count relative to the reference second quartile.  
 
The present study suggests both extremes of neutrophil count could favour infection 
following M. tuberculosis exposure. This is more complex than the inverse 
relationship reported by Martineau et al. The London study was smaller than the 
present study, adjusted for fewer confounders and analysis was according to baseline 
QFN-GIT meaning the timing of sample collection may not be comparable to the 
present study [128]. A U-shaped relationship between neutrophils and risk of 
infection has not previously been reported, but neutrophils are often described as 
having both protective and pathological functions in response to M. tuberculosis 
[273]. Neutrophil count is positively associated with poor outcome in active disease 
[274], pulmonary cavitary disease [275], and paradoxical deterioration of TB 
meningitis patients receiving antiretroviral treatment [276, 277]. Increased neutrophil 
gene expression is also a dominant feature of TB disease, relative to latent TB [278]. 
A mechanistic role for neutrophils in early innate response to M. tuberculosis 
infection is supported by a zebrafish larvae – M. marinum model. Studies in 
transparent zebrafish larvae show neutrophils are drawn to signals from apoptotic 
macrophages in granulomata, and a sub-population of highly motile neutrophils 
dispose of infected cells and kill M. tuberculosis through oxidative mechanisms [130]. 
The zebrafish model also illustrates that excessive or insufficient TNF- mediated 
inflammation can permit mycobacterial growth, potentially the basis of the U-shaped 
relationship between neutrophils and infection risk observed in the present study 
[279]. Future studies on the cohort should test whether neutrophil phenotype differs at 
the two extremes of neutrophil count.  
 
 
Cell populations associated with infection at baseline  
A positive QFN-GIT at baseline was associated with higher monocyte and 
lymphocyte counts, compared to a negative QFN-GIT. This effect was detected in the 
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multivariable analysis, and interacted with the measure of M. tuberculosis exposure in 
the model (lung cavities). The effect size was greater in the most heavily exposed 
group.  
 
There were no other published reports on monocyte or lymphocyte counts among case 
contacts at the time of writing this thesis. Sutherland et al found no difference in 
blood count parameters between household case contacts who progressed to TB 
disease versus those that did not. However, differences in lymphocyte subsets were 
identified by flow cytometry [280]. Extremes of the ratio of peripheral blood 
monocyte to lymphocyte has been associated with incident TB in patients with 
advanced HIV [143]. This differs from the linear relationship with monocyte and 
lymphocyte count seen in the present study, perhaps because of expected 
lymphopenia in HIV infection. 
 
The increased lymphocyte count in case contacts with a positive QFN-GIT may 
reflect CD4+ T cell proliferation as many of the BP group will be recently infected. It 
might also reflect proliferation of other innate like T cells.  
 
Monocytes are circulating macrophage precursors that are the target cell of M. 
tuberculosis when resident in the lungs. Higher monocytes in contacts with a positive 
QFN-GIT at baseline may arise from monocyte proliferation following infection or 
monocyte depletion in the peripheral blood of the baseline negative group due to 
recruitment to granulomata or apoptosis. Either could be protective responses to 
infection, or evidence of immune manipulation by M. tuberculosis to recruit more 
target cells for infection.  
 
Experimental studies of infection of zebrafish lavae with M. marinum suggest that M. 
tuberculosis evades iNOS expressing microbicide macrophages, by displaying 
phthiocerol dimycocerosate (PDIM) lipids that mask underlying PAMPs [281]. M. 
tuberculosis preferentially recruits permissive macrophages (monocytes) without 
iNOS to the site of infection, providing a new source of susceptible target cells within 
which it can replicate. This is also achieved through phenolic glycolipids, that induces 
host production of CCL2 via STING. Support for the relevance of this finding in 
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humans comes from the association of a gain of function MCP-1 (CCL2) mutation 
and increased susceptibility to M. tuberculosis [282].  
 
Possible reasons the effect of a cell type associated with infection at baseline would 
be modified by a measure of M. tuberculosis exposure include: a) increased infectious 
dose of bacilli in the high exposure stratum leading to a stronger response; b) greater 
probability that the positive QFN-GIT followed recent infection, therefore increasing 
probability of detecting a transient increase at baseline.  
 
Haematology parameters associated with infection at either time point  
The hybrid measure that calculated a prevalence of a positive QFN-GIT at either 
baseline or 14 weeks included many of the same participants as the cross-sectional 
comparison, but 76 converters classified as uninfected at baseline were included in the 
infected group along with 544 BPs. An increased lymphocyte count was associated 
with this outcome.  
 
Other host factors 
Age was positively associated with infection in the two comparisons that included 
BPs. The BPs include some people with prevalent infection that could have been 
acquired in the distant past, as well as during the index case’s current illness. Thus the 
positive association between age and infection in these analyses may reflect increased 
time during which infection could have been acquired rather than increased 
susceptibility in older contacts. The primary analysis of incident infection did not find 
evidence of an inverse relationship between age and risk of conversion. However the 
confidence intervals around estimates for relative risk of conversion by age were 
wide, meaning a potentially important relationship can not be excluded. An analysis 
of Ugandan case contacts followed for two years combined incident and prevalent 
infection and may have erroneously concluded age is a more important susceptibility 
factor than is really the case [266]. 
 
BCG vaccination had a protective effect in all three models but the effect was much 
stronger for the primary prospective comparison (RR=0.51) than a comparison of 
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baseline QFN-GIT (RR=0.87) or any positive QFN-GIT (PR=0.85). The estimates for 
the secondary analyses are consistent with those included in a published meta 
analysis, which estimated the overall effect at 0.81 (95% CI 0.71 - 0.92) [163]. The 
stronger effect for the primary comparison may reflect bias arising from the exclusion 
of previously infected susceptible BCG vaccinated contacts, although true differences 
in BCG’s effectiveness against incident versus prevalent infection (the latter being 
lower due to multiple past exposures) or waning BCG effectiveness over time 
especially in the older BP group are possible alternative explanations. 
 
We found a linear relationship between BMI and risk of conversion in the primary 
analysis but not the cross-sectional analysis. A modest univariate relationship between 
BMI and a positive QFN-GIT at baseline or follow up was detected but this was not 
retained in the model. Diabetes was assessed in this study but other potential 
confounding variables such as vitamins, micronutrients or socioeconomic factors were 
not measured. To our knowledge BMI has not been studied as a risk for M. 
tuberculosis conversion. A meta-analysis of 6 cohort studies with median follow up 
between 4 and 11 years shows a consistent log-linear (i.e. negative) relationship with 
BMI and TB disease [253]. More detailed analysis of these potential confounders in 
the INFECT cohort is required before a conclusion is made with respect to obesity as 
a susceptibility factor in M. tuberculosis infection.  
 
Strengths and limitations 
The study detected differences between the phenotypic groups in the cell types 
studied and gives a clear indication of priority cell types for further study. The cohort 
is large and specifically designed to study immunological correlates of EC, and was 
able to adjust for relevant confounders.  
 
Nonetheless the limited number of participants included in the primary analysis meant 
some categories contained small numbers of participants. Specifically, few contacts 
were exposed to a 2+ index case and chance effects within this category this may have 
led to a spurious finding of effect modification according to smear grade with respect 
to BCG and neutrophils. We had postulated measures of effect for correlates of EC 
would be highest in the most heavily exposed stratum (see Chapter 5: Considerations 
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in study design). This was seen to some extent for neutrophils, but not for BCG, and 
because the direction of effects was reversed in the intermediate exposure category 
overall trends were hard to interpret.  
 
The study was designed to identify biological correlates of EC and the prospective 
comparison of PN and converters did identify differences in cell populations at this 
early stage of infection. However, the primary analysis excluded previously infected 
susceptible contacts and this may have biased the estimates of other host factors such 
as BCG vaccination status. This underscores the importance of presenting the 
secondary cross-sectional analyses, to aid in interpretation of the primary analysis.  
 
The secondary analyses were cross-sectional studies meaning markers associated with 
a positive QFN-GIT at baseline may be caused by M. tuberculosis infection, rather 
than predispose an individual to infection. Specifically the higher lymphocyte count in 
contacts with a positive QFN-GIT at baseline is likely to reflect T lymphocyte 
proliferation following infection.  
 
Unmeasured confounding may have influenced the present analysis. It is not possible 
to measure M. tuberculosis exposure directly, and proxy measures must be used. We 
only analysed contact smoking in this analysis, and not exposure to secondhand 
tobacco smoke [283] or other aspects of the home or external environment.  
 
Conclusion 
We have detected differences in the peripheral blood count of case contacts according 
to phenotype. Differences in the immature granulocyte and neutrophil counts of the 
PN group suggest these cell types are important in early clearance. The data also 
suggests a U-shaped relationship between neutrophil count and conversion risk that is 
an interesting focus for further study. We found increased monocytes in the baseline 
positive group, supporting the hypothesis that inducing monocyte recruitment is a 
pathogen virulence factor. The late timing of this event however suggests 




Studies on stored cells should define granulocyte phenotype, and the kinetics of 
monocytes and define which lymphocyte subsets proliferate in converters. Studies on 
other archived specimens should identify genetic and other regulators of the 
neutrophil response to M. tuberculosis . 
 
A PN QFN-GIT was also associated with BCG vaccination, non-smoking and lower 
BMI in the primary analysis.  
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Chapter 9: 25-OH Vitamin D and Early Clearance  
 
Introduction 
Vitamin D modulates the innate response to infection and may have a role in 
prevention of infection. 25-OH vitamin D was measured on case contacts who were 





To test if serum vitamin D is associated with EC. 
 
Hypothesis 
Contacts with a PN IGRA have higher 25-OH vitamin D levels at baseline than those 
who convert their IGRA during follow up. 
 
Variables 
Total 25-OH vitamin D (hereafter, 25-OH vitamin D) was measured in serum at 
baseline, representing the sum of 25-OH vitamin D3 and 25-OH vitamin D2. Although 
1,25-(OH)2 vitamin D is the active form, 25-OH vitamin D is considered the best 
biomarker of vitamin D exposure [284]. Vitamin D cut points were based on expert 
consensus from the literature, which, are defined with reference to risks of non-
infective conditions.  
 
Vitamin D deficiency was defined as a 25-OH vitamin D level of less than 50 nmol 
per liter (20 ng per mL) [285-287] and vitamin D insufficiency as serum 25-OH 
vitamin D levels 50-75 nmol per litre (30 ng per mL) [288]. 
Index case and contact age, sex, contact BCG vaccination, smoking, BMI and 
diabetes were studied as confounders. Measures of M. tuberculosis exposure 
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including index case smear grade, x-ray lung cavities, extent of disease on x-ray, sleep 
proximity, and hours spent with the case on a representative day were also considered 
potential confounders.  
 
Outcome 




25-OH vitamin D levels were measured on all participants with a serum sample 




Serum 25-OH vitamin D2 and 25-OH vitamin D3 concentration were determined by 
isotope-dilution liquid chromatography tandem mass spectroscopy (LC-MS/MS) 
[289]. In brief 25-OH vitamin D3-D6 and 25-OH vitamin D2-D6 internal standards 
were reconstituted to working concentrations using spectrophotometry. Serum 
samples were thawed, denatured with methanol-propanol containing internal standard, 
vortex-mixed, extracted into hexane, and dried under nitrogen. The reconstituted 
extract was chromatographed on a Base Deactivated Silica C8 High-performance 
liquid chromatography column, and the metabolites and internal standards were 
detected by electrospray ionization MS/MS in multiple-reaction monitoring mode on 
a Waters™  instrument. To assess accuracy and inter-assay variability, each batch 
contained four UTAK™ controls containing known concentrations of 25-OH vitamin 
D2 and 25-OH vitamin D3 in pooled serum sample (SRM 972, USNIST).  
 
Statistical methods 
Vitamin D levels were initially compared between the study groups using the 
student’s t-test. The association between Vitamin D and binary QFN-GIT result was 
modelled by a generalised estimating equation that accounted for clustering within 
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households using an independence working correlation and robust standard errors. A 
log link was used to estimate relative risks. Vitamin D was studied as a continuous 
variable, as a fractional polynomial, and categorical variable using clinical cut points. 
The form with the lowest p-value when modelled as a risk for QFN-GIT conversion 
was included in the model, as determined in the preceding chapter (Chapter 8: Results 
of multivariable modelling of clinical and haematological parameters). The variable 
of interest (25-OH vitamin D) and key confounders (index and contact age and sex) 
were retained in the model, other terms were removed in a stepwise fashion until 
remaining terms had a p-value <0.2. The sample size calculation with respect to 
vitamin D was presented previously (Chapter 6: Methods). 
 
Results 
Quality of 25-OH vitamin D measurement 
Serum samples were analysed in 15 batches. Two batches were discarded and analysis 
repeated because the UTAK ™ controls fell outside the predetermined range. For the 
batches that contributed to the final result the coefficients of variation for UTAK™ 
controls were 4% for 25-OH vitamin D3 medium, 8% for 25-OH vitamin D3 low, 5% 
for 25-OH vitamin D2 medium and 11% for 25-OH vitamin D2 low (Figure 19). 25-





Figure 19. Value of medium and low 25-OH vitamin D2 (D2) and 25-OH vitamin D3 
UTAK™ serum controls by batch. 
 
 
Figure 20. Measured vitamin D levels in contacts according to month of collection  
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Distribution of 25-OH vitamin D in study participants  
The distribution of 25-OH vitamin D levels is summarised in Table 34. Total 25-OH 
vitamin D levels largely corresponded to 25-OH vitamin D3, as 25-OH vitamin D2 
levels were, as expected, frequently below the validated threshold of detection of the 
assay (5 nmol/L). Of the 297 participants with 25-OH vitamin D levels, 135 (45.5%) 
had 25-OH-vitamin D less than 50 nmol/L, levels considered deficient. A further 106 
(35.7%) had 25-OH-vitamin D between 50 and 75 nmol/L considered insufficient. 
Only 56 (18.9%) were vitamin D replete.  
 








Mean (sd) 4.4 (3.2) 49.7 (21.3) 54.1 (21.5) 
Median (IQR) 3.9 (2.0 - 6.1) 47.6 (33.7 - 64.7) 51.9 (38.4 - 68.6) 
Median (range) 3.9 (0.0 - 18.5) 47.6 (10.1 - 130.3) 51.9 (11.8 - 132.6) 
 
Correlation 25-OH vitamin D with other variables 
The mean 25-OH vitamin D concentration was 63.3 nmol/L (95% CI 43.2 - 48.9) for 
males and 46.1 nmol/L (95% CI 59.7 - 66.9) in females (difference -17.2 nmol/L; 
95% CI -27.7 -12.7; P<0.0001). It was highest in the youngest children and decreased 
through adolescence in both sexes, with a very slight increase in older age groups 
(Figure 21). Vitamin D was lower in diabetics than non-diabetics and higher in the 
very severely underweight (Table 35). The observed mean vitamin D was similar in 
smokers and non-smokers (P=0.13). 
 
Table 35 continued next page 
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Figure 21. 25-OH vitamin D relationship with age and sex of 299 case contacts who 
were QFN-GIT negative at baseline. 
Note: lines of best fit by fractional polynomial 
 
Table 35. Distribution of 25-OH vitamin D according to contact characteristics  




Female 46.1 43.3 - 48.9 
<0.0001 




Sunda 53.9 51.4 - 56.4 
0.6 
Other 56.2 46.7 - 65.7 
Sleep proximity to index case 
  
 
Different Room 52.4 49.6 - 55.2 
0.008 
Same Room 60.6 55.7 - 65.4 
Hours with the case the day before enrolment 
  
 
<6 53.4 50.3 - 56.5 
0.4* 
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No 53.3 47.8 - 58.9 
0.8 




Non-smoker 53.0 50.1 - 55.8 
0.13 




RCBG<100 mg/dL 53.8 50.8 - 56.9 
0.6* 
HbA1c <5.7% 55.9 50.8 - 61.1 
HbA1c 5.7-6.4% 57.0 49.1 - 64.8 




Very severely underweight 67.3 60.9 - 73.6 
0.13* 
Severely Underweight 56.6 45.7 - 67.6 
Underweight 53.7 48.9 - 58.5 
Normal 51.3 47.6 - 55.0 
Overweight 54.6 47.8 - 61.4 
Obese 51.1 43.0 - 59.3 
BCG: Bacillus Calmette-Guérin vaccination; BMI: Body mass index; RCGB: Random 
capillary blood glucose; HbA1c: glycosylated haemoglobin P-values obtained by T 
test unless otherwise indicated. *P-value by linear regression.  
 
25-OH vitamin D according to outcome (PN or converter) 
Vitamin D levels were available for 297 participants, i.e. all of the baseline negative 
participants except for one PN and one converter. Vitamin D deficiency and 
insufficiency occurred with similar frequency in the PN and converter group. Mean 
25-OH vitamin D level was 54.2 nmol/L (95% CI 51.3 - 57.0) for PN and 53.9 
nmol/L (95% CI 49.0 - 58.8), corresponding to 0.3 nmol/L (95% CI -5.4 - 5.9; P=0.9) 
less in converters. 
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Normal 44 (19.8) 12 (16.0) 
Insufficient 78 (35.1) 28 (37.3) 
Deficient 100 (45.1) 35 (46.7) 
PN: Persistently Negative; Conv: Converter. 
 
Form of 25-OH vitamin D variable included in multivariable model  
25-OH vitamin D was modelled as a categorical variable using definitions of vitamin 
D deficiency and insufficiency, as this achieved a better fit with the data (P=0.7 for 
categorical compared to P=0.9 for linear). The fractional polynomial for 25-OH 
vitamin D was unstable (and lost accuracy at higher values where there were few data, 
as shown in Figure 22).  
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Table 37 shows factors associated with risk of QFN-GIT conversion at 14 weeks 
among those initially QFN-GIT negative. The relative risk of conversion was 1.23 
(95% CI:0.71 - 2.14; P=0.5) for insufficient contacts relative to normal and 1.21 (95% 
CI 0.70 - 2.09; P=0.5) for deficient contacts. The other univariate associations are as 
discussed in the preceding chapter, namely risk of conversion is decreased by BCG 
vaccination and increased by exposure to a high smear grade case. Smoking and 
increased BMI were not associated in the present analysis.  
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Table 37. Univariate relative risk of infection at 14 weeks for those initially QFN-GIT 





RR 95% CI P 
 
n % N %    
Index case age (mean, sd)  40 15 40 15 0.97 0.84 - 1.13 0.7 
Index sex (M vs F) 112 50% 33 43% 0.82 0.54 - 1.23 0.3 
Cough duration (mean, sd) 59 61 58 52 1.00 1.00 - 1.00 0.9 
Highest smear grade 
       
1+/scanty 90 40% 16 21% 1.00 Ref 
 
2+ 64 29% 19 25% 1.52 0.82 - 2.81 0.2 
3+ 69 31% 41 54% 2.47 1.42 - 4.28 0.001 
Cavities (present vs absent) 96 46% 40 55% 1.31 0.87 - 1.98 0.2 
Extent of x-ray disease  48 29 47 26 1.00 0.99 - 1.01 0.8 
Contact age  
    
0.96 0.86 - 1.07 0.5 
Contact sex (M vs F) 104 47% 36 47% 1.02 0.67 - 1.56 0.9 
Cont eth (Sunda vs Other)  202 91% 71 93% 0.96 0.86 - 1.07 0.5 
Sleep prox (diff vs same) 47 21% 15 20% 0.94 0.57 - 1.54 0.8 
Hours with case (mean, sd) 4 4 5 4 1.02 0.97 - 1.07 0.5 
25-OH vitamin D 
       
Normal 44 20% 12 16% 1.00 Ref - 
Insufficient 78 35% 28 37% 1.23 0.71 - 2.14 0.5 
Deficient 100 45% 35 47% 1.21 0.70 - 2.09 0.5 
BCG (yes vs no) 192 86% 53 70% 0.51 0.34 - 0.75 0.001 
Smoking (current vs non-) 53 24% 25 33% 1.39 0.93 - 2.08 0.1 
BMI (mean, sd) 21 5 22 5 1.03 0.99 - 1.06 0.1 
Diabetes 
       
RCBG<100 149 67% 49 65% 1.00 Ref 
 
HbA1c <5.7 52 23% 21 28% 1.16 0.73 - 1.85 0.5 
HbA1c 5.7-6.4 12 5% 3 4% 0.81 0.27 - 2.38 0.7 
HbA1c>6.4 10 5% 3 4% 0.93 0.34 - 2.59 0.9 
Index case age in years scaled 1=10 years; M: male; F:Female; Cont eth.: contact 
ethnicity; Sleep prox: sleep proximity, different vs same room. BCG: Bacillus 
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Calmette-Guérin vaccination; BMI: Body mass index; RCBG: Random Capillary 
Blood Glucose; HbA1c: glycosylated haemoglobin 
 
Adjusted rate of vitamin D deficiency and insufficiency and risk of QFN-GIT 
conversion  
The modelling process is summarised in the Appendix (Table 64) the results are 
presented in Table 38. Relative to vitamin D replete participants the risk of QFN-GIT 
conversion was slightly higher in contacts with vitamin D deficiency (RR=1.12; 95% 
CI 0.65 - 1.85; P=0.7) and vitamin D insufficiency (RR=1.10; 95% CI 0.65 - 1.85; 
P=0.7), but this was not significant.  
 
A strong negative relationship between BCG and conversion was observed (RR 0.54; 
95% CI 0.36 - 0.80; P=0.002) as in the preceding chapter. Risk of QFN-GIT 
conversion was increased with increasing body mass index (RR=1.05 95% CI 1.01 - 
1.09; P=0.02). Other factors influencing risk of conversion in the model included 
contact age: there was a 12% decrease in risk of conversion for every 10-year increase 
in age (95% CI 0.76 - 1.01; P=0.07). The relationship between smoking and risk of 
conversion was of borderline significance in this model (RR=1.59; 95% CI 0.98 - 
2.58; P=0.06). Exposure to an index case with 3+ grade sputum positivity was 
significantly associated with risk of conversion in the multivariate analysis (RR 2.67; 
95% CI 1.58 - 4.54; P<0.0001). This was the only measure of M. tuberculosis 




Table 38. Adjusted relative risk of QFN-GIT conversion at 14 weeks according to 
baseline 25-OH vitamin D concentration.  
RR 95%CI P 
Index case age (scale: 1=10 years) 1.00 0.98 - 1.01 0.7 
Index case sex (M vs F) 0.80 0.54 - 1.19 0.3 
Highest smear grade 1.00 Ref 
 
2+ vs 1+/scanty 1.38 0.76 - 2.50 0.3 
3+ vs 1+/scanty 2.50 1.46 - 4.26 0.001 
Contact age (scale: 1=10 years) 0.88 0.76 - 1.01 0.07 
Contact sex (M vs F) 0.98 0.58 - 1.63 0.9 
BCG vaccination 0.54 0.36 - 0.80 0.002 
Smoking (current vs non-smoker) 1.59 0.98 - 2.58 0.06 
Body mass index 1.05 1.01 - 1.09 0.02 
25-OH vitamin D 
   
Normal 1.00 Ref 
 
Insufficient 1.10 0.65 - 1.85 0.7 
Deficient 1.12 0.64 - 1.98 0.7 
Note: adjusted for age, sex and smear grade of the index case, age and sex of the 
contact, hours spent with the case, Bacillus Calmette-Guérin vaccination, smoking 
and Body mass index. RR= Adjusted relative risk; 95% CI = 95% confidence interval 
 
The effect of 25-OH vitamin D on risk of QFN-GIT conversion was modified by the 
smear grade of the index case (P for interaction =0.043). The adjusted stratum-
specific estimates in Table 39 showed a non-significant trend towards increased risk 
of QFN-GIT conversion in vitamin D deficient contacts exposed to a 1+ or scanty 
case (RR=1.91; 95% CI 0.65 - 5.58; P=0.2), and vitamin D deficient and insufficient 
contacts exposed to a 3+ case (RR=1.74; 95% CI 0.63 - 5.58; P=0.3 and 2.24; 95% CI 
0.83 - 6.26; P=0.1). However, risk of QFN-GIT conversion was reduced in contacts 
exposed to a 2+ grade case (RR=0.55; 95% CI 0.22 - 1.37; p=0.2). There was no clear 
evidence of a dose response. The stratified analysis was based on small numbers, 






Table 39. Stratum-specific post-estimates for relative risk of QFN-GIT conversion by 
vitamin D status and index case smear grade.  






RR 95% CI P 
Scanty/1+ Normal  22 3 0.12 1.00 Ref 
 
Insufficient 32 4 0.11 0.96 0.24 - 3.80 0.954 
Deficient 36 9 0.20 1.91 0.65 - 5.58 0.239 
2+ Normal  9 6 0.40 1.00 Ref 
 
Insufficient 22 4 0.15 0.41 0.17 - 0.96 0.041 
Deficient 33 9 0.21 0.55 0.22 - 1.37 0.203 
3+  Normal  13 3 0.19 1.00 Ref 
 
Insufficient 24 20 0.45 2.27 0.83 - 6.26 0.112 
Deficient 31 17 0.35 1.74 0.63 - 4.80 0.287 
Note: modelled by generalised estimating equation and adjusted for index and contact 
age and sex, Bacillus Calmette-Guérin  vaccination, smoking and body mass index. 
PN: Persistently negative; Conv: Converters; . RR: Post-estimated relative risk 
 
Discussion  
Summary of main findings 
In this study 45.5% of case contacts were vitamin D deficient and a further 35.7% 
were vitamin D insufficient. Only 56 (18.9%) were vitamin D replete. 25-OH vitamin 
D levels were lowest in females and in late adolescence. Vitamin D deficiency and 
insufficiency were not associated with risk of QFN-GIT conversion (RR=1.12; 95% 
CI 0.64 - 1.98; P=0.7 and 1.10; 95% CI 0.65 - 1.85; P=0.7 respectively). However the 
confidence intervals for the estimates were wide, and included potentially clinically 
significant effects. The effect modification with respect to smear grade may have been 
due to random variation given the small numbers in the 2+ stratum. The RR of 
conversion associated with vitamin D deficiency was increased in the highest 
exposure strata compared to the overall model but still not significantly so. There was 
possibly a small effect present, which would require a much larger dataset to verify, 




Strengths of the study included the endemic country setting, and measurement of 25-
OH vitamin D using the reference method LCMS/MS. The study compared 
prospectively defined groups, as reverse causality is a limitation of many 
observational studies of vitamin D deficiency and TB disease [290]. A limitation is 
that the study may be underpowered  as assumptions (outlined in Chapter 6: Methods) 
about the proportion of contacts that would be IGRA positive at baseline and rate of 
vitamin D deficiency were incorrect. We estimated recruiting 900 contacts would lead 
to approximately 400 who were QFN-GIT negative at baseline and approximately 
half would be vitamin D replete, leading to a study with 80% power to detect double 
the risk of QFN-GIT conversion among contacts who were vitamin D deficient or 
insufficient. Instead, only 56 participants were QFN-GIT negative and vitamin D 
replete. Secondly, the analyses of vitamin D levels were restricted to participants with 
a negative QFN-GIT at recruitment, meaning a number of susceptible individuals 
(BP) were not included. The impact of potential selection bias can not be gauged 
without also analysing the BP group as a secondary analysis.  
 
Consistency with other studies 
A study of 198 Spanish TB case contacts reported an inverse dose response between 
serum 25-OH vitamin D levels and risk of TST conversion [162]. Relative to contacts 
with 0 - 22.4 nmol/L of 25-OH vitamin D, the relative risk of TST conversion was 
0.52 (95% CI 0.14 - 1.99; 0.342) for 22.5 - 47.4 nmol/L, 0.15 (0.03 - 0.77;P=0.02) for 
47.5 - 72.4  nmol/L and 0.15 (95% CI 0.03 - 0.17) for ≥72.4 nmol/L*. Potentially the 
Spanish study may have benefited from the broader range of vitamin D levels in its 
study population than that of the present study; 37% of the participants in the Spanish 
study were vitamin D replete.  
 
A feasibility trial of vitamin D supplementation in child case contacts in Mongolia 
included children with 25-OH vitamin D concentrations of <50 nmol/L*. Of 120 
contacts, 34 were TST positive at baseline and 86 remained at risk of conversion. 
Over 6 months, TSTs converted to positive in 5 (11%) children receiving 800 IU 
                                               
*Results have been converted from ng/mL, used in the original report, to nmol/L, to 
enable comparison with the present study. 
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cholecalciferol daily and 11 (27%) receiving placebo (RR: 0.41; 95% CI 0.16, 1.09; 
P=0.06). There was evidence of a dose response, with one TST conversion occurring 
among those whose serum 25-OH vitamin D concentration increased to >50 nmol/L, 
whereas 8 TST conversions occurred in those whose final 25-OH vitamin D 
concentration remained <25 nmol/L (P=0.05). While there was an increased 
possibility of chance findings in a small study, the Mongolian trial included a 
relatively homogenous population in terms of age, smoking and vaccination, and 
randomisation eliminated the likelihood of confounding.  
 
Extensive clinical studies have been performed on vitamin D as an adjunct to TB 
therapy. These have either shown no effect [159, 291] or a modest effect in terms of 
sputum clearance [292-294] or radiological resolution [295]. Some explained these 
negative results as evidence of the difficulty of detecting an effect from 25-OH 
vitamin D in the context of the standard antimycobacterial treatment, leading to 
interest in an alternative potential application in preventing infection [157]. An 
association between vitamin D deficiency and or insufficiency and risk of IGRA 
conversion was not demonstrated in the present study.  
 
Prevalence of vitamin D deficiency and insufficiency 
A surprisingly small proportion of participants were vitamin D replete (18.9%). 
Furthermore, measured concentrations of the UTAK™ serum controls were higher in 
our laboratory than the manufacturers reference value, suggesting our assay may 
slightly overestimate 25-OH vitamin D concentration, and therefore underestimate the 
prevalence of vitamin D deficiency and insufficiency. However, use of the standards 
did show our measurements to be consistent, and this possible systematic 
measurement error will not impact the relative differences between the groups 
studied.  
 
A body of recent evidence reveals high levels of vitamin D deficiency in tropical 
countries, even where there is sufficient ultraviolet B radiation for year-round vitamin 
D synthesis [296]. In such settings the effect of UVB radiation might be blocked by 
air pollution [297], or by covered clothing in women, as has been demonstrated in 
Turkey, Morocco and Lebanon [298-300]. Population based studies in Indonesia are 
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lacking, but a study of healthy volunteer women in Jakarta found 63% (95% CI 55% - 
72%) were deficient [245].  
 
The associations between age, sex, BMI and vitamin D observed in the present study 
have been reported by others. In a study of Thai school children aged 6 - 14 years, 25-
OH vitamin D levels were 19% higher in boys than girls, and for girls 25-OH vitamin 
D was negatively associated with age. Vitamin D deficiency was associated with 
female sex in a study of adolescents in Northern India [301]. The negative association 
with vitamin D and body mass index is well described, and thought to be related to 
vitamin D sequestration in adipose tissue [254, 255].  
 
Conclusion 
We did not observe a relationship with vitamin D levels and risk of QFN-GIT 
conversion. However, the confidence intervals for the effect of vitamin D deficiency 
were wide, meaning the present study does not exclude the possibility that risk of 
conversion is almost doubled in vitamin D deficiency. Further analysis of samples 
from the remainder of the INFECT cohort may improve the precision of our estimate, 
and studies in other settings and populations will also be of value. 
 
As described previously (Chapter 2: Possible mechanisms of early clearance), 
experimental studies show 25-OH vitamin D modulates the innate response to 
infection, including the production of antimicrobial peptides, and cytokine production 
including IL-1. Polymorphisms in vitamin D receptors have been linked to 
susceptibility to TB disease in many populations. Several case-control studies have 
linked vitamin D deficiency to active disease, although their interpretation is 
complicated by potential reverse causality [290]. Despite this, clinical studies have 




Chapter 10: Whole Blood Stimulation Assay  
 
Introduction 
Cytokine signals between immune cells co-ordinate the immune response to infection. 
To provide insight into the mechanism of EC, we sought evidence of different 
cytokine responses in early clearers using a whole blood stimulation assay (WBSA). 
A WBSA is an ex-vivo model of the immune response to infection in which the 
immune cells and serum in peripheral blood are co-cultured with microbial stimuli. 
Selected participants had the resulting cytokines measured by ELISA. This chapter 





To characterise the innate cytokine responses of early clearers. 
 
Hypotheses 
We proposed two hypotheses with respect to the cytokine responses of early clearers. 
Firstly, as pro-inflammatory innate cytokines are correlated with control of infection 
(see Chapter 2: Possible mechanisms of early clearance) in experimental animals and 
models, we hypothesised early clearers would produce higher innate cytokine 
responses to stimulation with mycobacteria:  
Contacts with a PN IGRA have a stronger inflammatory cytokine response 
after whole blood stimulation by mycobacterial stimuli than is seen in those 
who convert their IGRA during follow up. 
Secondly to assess whether these responses are driven by innate immunity, where 
pathogen recognition is by PRRs and not the highly specific adaptive immune system, 
we tested whether this cytokine profile is also elicited by non-mycobacterial stimuli:   
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A PN IGRA is associated with a stronger inflammatory cytokine response to 
whole blood stimulation by mycobacterial and non-mycobacterial stimuli than 
is seen in those who convert their IGRA during follow up. 
 
Measurements 
Blood from each donor was cultured under five different conditions (4 stimulated and 
an unstimulated condition) and six cytokines were measured on each. Two 
mycobacterial stimuli were chosen: M. tuberculosis lysate which includes antigens of 
virulent M. tuberculosis but had to be heat-killed for safety reasons, and BCG as a 
less virulent but live mycobacterium. Streptococcus pneumoniae was used as a 
complex gram-positive stimulus recognised by, among other receptors, TLR2. E. coli 
was used as an example of lipopolysaccharide containing stimulus gram-negative 
bacillus with actions through TLR4. The literature review (Chapter 2: Possible 
mechanisms of early clearance) identified TNF-, IL-1, IL-6 and IL-8 as 
inflammatory cytokines with innate functions implicated in anti-mycobacterial 
immunity. IL-1RA and IL-10 were included as innate cytokines with inhibitory or 
regulatory functions with respect to M. tuberculosis, although no specific hypothesis 
pertained to these cytokines.  
 
Sample selection 
Three batches of samples were selected. The first comprised all WBSA samples 
collected from the time the assay was included in the cohort (June 2014) to December 
2014. The second comprised all contacts known to be PN or converters and randomly 
selected baseline positive samples between December 14 and August 2015. The third 
comprised 23 randomly selected PN and converters recruited between September 
2015 to January 2016. 
 
Laboratory methods 
Compared to PBMC assays, WBSA use a small blood volume, and minimize the 
handling of cells, thereby reducing opportunities for contamination. The procedure is 
simple and can be deployed within a large study with basic laboratory facilities. 
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WBSAs include the patient’s plasma and neutrophils, that are absent in PBMC assays.  
The WBSA was performed immediately upon specimen arrival of blood collected at 
baseline at the laboratory. Whole blood collected in a lithium heparin containing tube 
was diluted five fold in RPMI medium and pipetted into five wells on a 24 well plate. 
In a total volume of 1 mL, cells were either left unstimulated as a negative control, or 
stimulated with the following stimuli at named final concentrations: Mycobacterium 
bovis BCG (Bacillus Calmette-Guérin) Danish strain 1331 reconstituted prior to use 
to an estimated 1 x 105 colony forming units, M. tuberculosis lysate 0.5 µg/mL, S. 
pneumoniae 1 x 105 colony forming units (cfu)/mL, Escherichia coli 1 x 105 cfu/mL. 
The assay was incubated at 37°C in 5% CO2 for 24 hours as previously described 
[302]. After incubation the plates were centrifuged and the supernatant was stored at -
80°C for batched ELISA. Three batches of frozen supernatants were transported 
frozen to the Netherlands where ELISAs were performed at Radboud University. 
Analysis by ELISA for TNF-a, and IL-1b, IL-1RA, IL-10 (RND, Minneapolis, USA) 
and IL-6, IL-8 (Sanquin, Amsterdam, Netherlands). 
 
Data management 
Individual cytokine responses were coded as missing if: 
• participants had no detectable TNF-α, IL-1β, IL-1RA, IL-6, IL-8, IL-10 
response to a particular stimulus, suggesting the sample was not stimulated;  
• there was insufficient sample to perform the ELISA for that cytokine; 
• for a single cytokine, adjacent stimulated samples on an ELISA plate were 
beneath the threshold of detection, suggesting pipetting error; or 
• if a cytokine was not analysed in an entire batch.  
 
Otherwise, when a cytokine response was less than the threshold of detection it was 
coded as the threshold of detection (39 pg/mL for TNF-a; 19.5 pg/mL for IL-1b, 195 
pg/mL for IL-1RA, 312 pg/mL for IL-6 and IL-8 and 4.68 pg/mL for IL-10. 
Contamination was defined as the presence of IL-6 in the (unstimulated) nil well, as 





Cytokine measurement was performed batch wise as recruitment progressed. Once the 
complete dataset was obtained, differences in characteristics of the participant groups 
were compared by chi-squared or Student’s t-tests. Cytokine responses were 
presented as medians and inter quartile range (IQR). Each of the 24 cytokine 
measurements were log-transformed and modelled for their relationship with the 
outcome by generalised estimating equation that accounted for correlation within 
households. Batch was included in each model as a factor variable. The relative risk 
of conversion associated with the cytokine response was obtained from the antilog of 
the modelled coefficient. This statistic represents the ratio of the geometric means of 
the uninfected and infected groups. 
 
The primary analysis compared cytokine responses of PN and converters. To test the 
hypotheses that the PN group had a stronger inflammatory cytokine response to 
mycobacterial stimuli alone, and in combination with other bacterial stimuli we 
compared the TNF-, IL-1, IL-6, and IL-8 responses of the PN group to that of the 
converter group. A higher response to both M. tuberculosis lysate and one of the non-
mycobacterial stimuli was required to satisfy the hypothesis. M. tuberculosis lysate 
was selected as the mycobacterial stimulus as it was easier to standardise dose than 
for live BCG. 
 
Two secondary analyses were performed. In the first, the PN and converter groups are 
restricted to those who are BCG vaccinated. In the second the PN group is restricted 
to those who are highly exposed, defined as exposed to a 3+ case or sleeping in the 
same room as the case (see Chapter 7: Characteristics of the cohort including 
phenotype classification  ). Additionally, an analysis of cytokine levels according to a 
baseline IGRA result is also presented. This analysis compares an IGRA positive 
group with adaptive immune recognition of M. tuberculosis to an IGRA negative 
group without. This analysis does not identify protective or susceptibility factors, but 





Derivation of the sample 
In batch 1: 137 participants (54%) had detectable (>312 pg/µL) IL-6 in the 
unstimulated well, indicating contamination. Their results were excluded. 
Subsequently only one further contaminated sample was detected. The derivation of 
the WBSA data set is described in Figure 23. 
 
Figure 23. Derivation of the WBSA dataset.  
Note: the WBSA was performed on every participant recruited after the first 112 
participants had been recruited. Two hundred and fifty-three consecutive samples 
were selected for batch 1. Batch 2 selected all available samples from contacts who 
were persistently negative or converters, and randomly selected within the baseline 
positive group. Batch 3 only included samples from the primary comparison group 
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and did not include any baseline positive participants. Other outcomes include 
indeterminate IGRA, TB disease and loss to follow up. 
 
IL-6 was detected in 138 nil wells, corresponding to 31% of the analysed samples 
being contaminated. The characteristics of contaminated samples are described in 
Table 40. Almost all contaminated samples were analysed in the first batch, with only 
one contaminated sample being detected thereafter. Nine out of 47 converter samples 
were contaminated whereas 32 out of 129 PN samples were (18% vs 25%; P=0.3). In 
other respects, the characteristics of contaminated and non-contaminated samples 















Persistently Negative 97 (33) 32 (26) 
0.3 
Converter 41 (14) 9 (7) 
Baseline positive 145 (50) 80 (64)  




1 116 (37) 137 (99) 
<0.0005 2 174 (56) 1 (1) 
3 23 (7) 0 (0) 
Index smear grade 
  
 
Scanty1+ 106 (34) 47 (34) 
0.7 2+ 92 (29) 45 (33) 




None 142 (45) 76 (55) 
0.07 




Different room 232 (74) 98 (71) 
0.5 




Female 189 (60) 70 (51) 
0.056 




Never or Quit>6 months ago 228 (73) 106 (77) 
0.4 
Current  85 (27) 32 (23) 
Bacillus Calmette-Guérin vaccination 
 
 
Not vaccinated 68 (22) 29 (21) 
0.8 





As shown in Table 41, 172 of 6,792 of the data points from included participants were 
missing (2.5%). Most missing data (96 data points) arose from IL-8 not being 
measured on batch 3. A further 30 data points were coded missing because E. coli 
responses to all cytokines were beneath the threshold of detection for six participants 
four of whom were converters. As there were only 6 converters in batch 3 it was 
decided to model responses to E. coli on data from batches 1 and 2 only.  
 
Quality of the whole blood stimulation assay  
As shown in Figure 24 cytokine responses to stimuli varied by batch. To gauge the 
effectiveness of the stimulation experiments we plotted the distribution of cytokine 
responses to each stimulus and compared to the nil condition (Figure 25). The median 
response to stimuli was more than one order of magnitude greater than the 95th centile 




Table 41. Missing values in cytokine data by phenotype, from 283 participants.  
 PN Conv BP Total 
TNF-     
Bacillus Calmette-Guérin 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
M. tuberculosis lysate 0 (0.0) 0 (0.0) 1 (0.7) 1 (0.4) 
S. pneumoniae 0 (0.0) 0 (0.0) 1 (0.7) 1 (0.4) 
E. coli 2 (2.1) 4 (9.8) 0 (0.0) 6 (2.1) 
IL-1 
    
Bacillus Calmette-Guérin 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
M. tuberculosis lysate 0 (0.0) 0 (0.0) 1 (0.7) 1 (0.4) 
S. pneumoniae 0 (0.0) 0 (0.0) 1 (0.7) 1 (0.4) 
E. coli 2 (2.1) 4 (9.8) 0 (0.0) 6 (2.1) 
IL-1RA 
    
Bacillus Calmette-Guérin 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
M. tuberculosis lysate 0 (0.0) 0 (0.0) 1 (0.7) 1 (0.4) 
S. pneumoniae 0 (0.0) 0 (0.0) 1 (0.7) 1 (0.4) 
E. coli 2 (2.1) 4 (9.8) 0 (0.0) 6 (2.1) 
IL-6 
    
Bacillus Calmette-Guérin 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
M. tuberculosis lysate 0 (0.0) 1 (2.4) 5 (3.4) 6 (2.1) 
S. pneumoniae 0 (0.0) 0 (0.0) 1 (0.7) 1 (0.4) 
E. coli 2 (2.1) 5 (12.2) 1 (0.7) 8 (2.8) 
IL-8 
    
Bacillus Calmette-Guérin 15 (15.5) 6 (14.6) 1 (0.7) 22 (7.8) 
M. tuberculosis lysate 15 (15.5) 7 (17.1) 5 (3.4) 27 (9.5) 
S. pneumoniae 15 (15.5) 6 (14.6) 2 (1.4) 23 (8.1) 
E. coli 15 (15.5) 7 (17.1) 1 (0.7) 23 (8.1) 
IL-10 
    
Bacillus Calmette-Guérin 5 (5.2) 0 (0.0) 3 (2.1) 8 (2.8) 
M. tuberculosis lysate 5 (5.2) 0 (0.0) 4 (2.8) 9 (3.2) 
S. pneumoniae 5 (5.2) 0 (0.0) 3 (2.1) 8 (2.8) 


















Figure 25. Distribution of cytokine responses by stimulus, pooled for all three batches 
Note: red line represents the cytokine value that corresponds to the 95th centile for 
the Nil condition. Blue: BCG; Red: M. tuberculosis lysate; Green: Strep. 
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Baseline characteristics 
The characteristics of the phenotype groups in the WBSA sub-study are described in 
Table 42. As expected from the analysis of data from the whole cohort (Chapter 7) 
converters were more likely to be current smokers than the PN group (42% vs 23%; 
P=0.03). Otherwise the groups did not differ significantly, however the PN group had 
slightly lower rates of exposure to high smear grade cases (31% vs 44%; P=0.11) and 
higher rates of BCG vaccination (84% vs 73%; P=0.16).  
 




Converter Baseline Positive p-
value∫ 
 
Phenotype 97 (34) 41 (14) 145 (51)  
Age index 
   
 
 




39.5 (18.3 - 77.4) 36.5 (18.3 - 65.3) 35.8 (18.5 - 87.7)  
Cavities 47 (49.0) 22 (55.0) 83 (57.6) 0.5 
Highest smear grade of index case  
 
Scanty/1+ 39 (40.2) 9 (22.0) 50 (34.5) 0.11 
 
2+ 28 (28.9) 14 (34.1) 40 (27.6) 
 
3+ 30 (30.9) 18 (43.9) 55 (37.9)  
Age contact 
   
 
 




29.8 (5.2 - 80.9) 24.6 (8.7 - 80.0) 35.4 (6.7 - 77.5)  
Sex 
   
 
 
Female, n (%) 58 (59.8) 24 (58.5) 91 (62.8) 0.9 
 
Male, n (%) 39 (40.2) 17 (41.5) 54 (37.2)  
Sleep proximity to 
index 
   
 
 
Different Room 74 (76.3) 36 (87.8) 101 (69.7) 0.1 
 




   
 
 
Non-smoker  75 (77.3) 24 (58.5) 105 (72.4) 0.03 
 
Current  22 (22.7) 17 (41.5) 40.0 (27.6) 
BCG vaccination 
   
 
 
No 16 (16.5) 11 (26.8) 35 (24.1) 0.16 
 
Yes 81 (83.5) 30 (73.2) 110 (75.9) 
Elisa Batch 
   
 
 
First 27 (27.8) 7 (17.1) 67 (46.2)  
 
Second 55 (56.7) 28 (68.3) 78 (53.8)  
 




 Mean (SD) 21.6 (5.3) 22.3 (5.5) 23.0 (5.5) 0.5 
Data presented are number (%) of participants unless otherwise stated in the first 
column. BCG: Bacillus Calmette-Guérin; BMI: Body Mass Index. 
Note: ∫ P-value is calculated by chi-squared or t-test according of values for PN vs 
conv. SD: standard deviation; *  
Primary comparison 
Table 43 shows the cytokine response to stimuli for 97 PN contacts versus 41 
converters. IL-6 responses to M. tuberculosis were higher in the PN group than 
converters, although this was of borderline statistical significance (RR=1.30; 95% CI 
0.98 - 1.73; P=0.07). The other inflammatory cytokines TNF-α, IL-1β and IL-8 
responses tended to be higher in the PN group than converters although this was not 
significant (RR=1.16; 95% CI 0.82 - 1.64; P=0.4, RR=1.13; 95% CI 0.81 - 1.58; 
P=0.5, RR=1.20; 95% CI 0.81 - 1.79; P=0.4, respectively).  
 
Responses to non-mycobacterial stimuli were higher for IL-6. The PN group had 
higher IL-6 response to Streptococcus than converters (RR=1.41; 95% CI 1.09 - 1.84; 
P=0.01) and IL-6 responses to E. coli were also higher in the PN group, but of 
borderline statistical significance (RR=1.21; 95% CI 0.97 - 1.50; P=0.09). The PN 
group had higher IL-8 responses to E. coli (RR=1.38; 95% CI 1.04 - 1.84; P=0.03) 
and S. pneumoniae (RR=1.27; 95% CI 0.93 - 1.74; P=0.14) but neither were 
statistically significantly. TNF-α responses to S. pneumoniae and E. coli and IL-1β 




There was no difference in the IL-1RA or IL-10 responses in PN compared to 
converters for mycobacterial or other stimuli.  
 
In summary pro-inflammatory cytokine responses to mycobacterial stimuli in the PN 
group were higher, compared to converters, although this was not significant for any 
of the cytokines studied. For IL-6 and IL-8 PNs had higher responses to non-
mycobacterial stimuli (and S. pneumoniae and E. coli respectively). The modelled 
association of pro-inflammatory cytokines with outcome in this and the secondary 
analyses are summarised in Error! Reference source not found. 
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RR 95% CI P 
TNF-α          
BCG 394 221 - 561 351 172 - 702 402 383 1.07 0.78 - 1.47 0.664 
Mtb 335 146 - 591 225 93 - 447 306 255 1.16 0.82 - 1.64 0.396 
Strep 426 256 - 760 375 189 - 599 459 419 1.13 0.81 - 1.57 0.483 
E. coli 861 472 - 1341 755 430 - 1201 824 664 1.26 0.94 - 1.69 0.127 
IL-1β 
         
BCG 340 175 - 589 331 167 - 507 316 285 1.09 0.74 - 1.62 0.656 
Mtb 188 106 - 441 167 72 - 348 221 172 1.13 0.81 - 1.58 0.466 
Strep 571 380 - 889 632 371 - 1065 585 599 1.00 0.75 - 1.32 0.975 
E. coli 1088 676 - 1801 1099 466 - 1665 1073 909 1.20 0.91 - 1.57 0.195 
IL-1RA 
         
BCG 2184 1500 - 3034 2058 1432 - 3324 2033 2208 0.98 0.80 - 1.19 0.83 
Mtb 1978 1441 - 2781 2026 1426 - 2606 1821 1900 1.01 0.83 - 1.23 0.912 
Strep 1801 950 - 2615 1547 970 - 3542 1579 1673 1.01 0.78 - 1.30 0.947 





         
BCG 4552 2638 - 7780 3341 1941 - 5773 4254 3397 1.14 0.87 - 1.49 0.331 
Mtb 2968 1387 - 9003 1994 968 - 5069 3469 2257 1.30 0.98 - 1.73 0.07 
Strep 2833 1631 - 5045 1677 1095 - 3545 2728 1774 1.41 1.09 - 1.84 0.01 
E. coli 7678 4721 - 9742 6163 3664 - 7890 7055 5348 1.21 0.97 - 1.50 0.089 
IL-8 
         
BCG 11739 7669 - 18263 9904 5854 - 16055 10860 8464 1.28 0.87 - 1.87 0.207 
Mtb 10771 3596 - 26662 7334 3792 - 20561 9593 7208 1.20 0.81 - 1.79 0.362 
Strep 13673 7717 - 19375 11322 4933 - 18281 12493 9888 1.27 0.93 - 1.74 0.135 
E. coli 2863 1736 - 5530 2251 1441 - 3641 3352 2280 1.38 1.04 - 1.84 0.027 
IL-10 
         
BCG 40 23 - 59 32 24 - 53 35 34 0.99 0.74 - 1.33 0.951 
Mtb 19 12 - 49 18 7 - 38 24 21 1.04 0.75 - 1.45 0.8 
Strep 20 12 - 35 15 10 - 30 20 20 0.98 0.73 - 1.31 0.894 
E. coli 94 68 - 136 71 47 - 143 92 73 1.21 0.90 - 1.63 0.207 
PN: Persistently QFN-GIT negative; Conv: QFN-GIT converter; Geo mean: Geometric mean; RR: Relative Risk; CI: Confidence 
Interval; IQR: Interquartile range; BCG: Bacillus Calmette-Guérin; Mtb: M. tuberculosis lysate; Strep: S. pneumoniae.  





Figure 26. Summary of ratio of geometric means (Risk ratios) of pro-inflammatory 
cytokines between the study groups.  
Note: the dotted line at RR=1.0 corresponds to no association between the cytokine 
and the phenotype group. BCG: Bacillus Calmette-Guérin; Mtb: M. tuberculosis 
lysate; Strep: S. pneumoniae 
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Secondary analysis – restricted to BCG vaccinated participants 
The analysis of BCG vaccinated contacts included 81 PN and 30 converters. For the 
analysis of BCG vaccinated participants, the PN group had higher pro-inflammatory 
cytokine responses to mycobacterial stimuli than converters (Table 44). A higher IL-1
 response to M. tuberculosis was seen in the BCG vaccinated PN group than BCG 
vaccinated converters (RR=1.43; 95% CI 1.00 - 2.03; P=0.047). IL-6 response to M. 
tuberculosis was also higher in BCG vaccinated PN group compared to BCG 
vaccinated converters (RR=1.40; 95% CI 1.04 - 1.88; P=0.027). TNF- and IL-8 
response to M. tuberculosis was higher in BCG vaccinated PN than converters but this 
was not-significant (RR=1.27; 95% CI 0.92 - 1.75; P=0.1 and RR=1.38; 95% CI 0.88 
- 2.16; P=0.2 respectively). 
 
With respect to non-mycobacterial stimuli, higher IL-6 was seen in the PN group in 
response to S. pneumoniae RR=1.52; 95% CI 1.52 1.14 - 2.03; P= 0.005) and E. coli 
(RR: 1.26; 95% CI 1.00 - 1.59; P=0.054) although the latter was of borderline 
significance. The IL-1 response to E. coli was also higher in the BCG vaccinated PN 
group though this was of borderline significance (RR=1.35; 95% CI 0.98 - 1.87; 
P=0.069). The TNF- response to E. coli was higher in the BCG vaccinated PN group 
than BCG vaccinated converters (RR=1.48; 95% CI 1.05 - 2.10; P=0.025). The IL-8 
response to E. coli stimulation was higher in the PN group than converters (RR=1.48; 
95% CI 1.06 - 2.04; P=0.02). Both the TNF- and IL-8 resposes to S. pneumoniae 
were higher in EC than converters but this was not significant.  
 
There was no difference in IL-1RA or IL-10 responses to any of the stimuli.  
 
In summary the inflammatory cytokines tended to be higher overall in the BCG 
vaccinated PN than BCG vaccinated converters. Effect sizes were greater than those 
calculated for the primary comparison. IL-1β and IL-6 were higher in response to 
stimulation with M. tuberculosis and IL-6 was higher in response to M. tuberculosis 
and non-mycobacterial stimuli.  
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Table 44. Cytokine responses to stimuli (pg/mL) of PN compared to converters, restricted to 111 BCG vaccinated participants, adjusted 













RR 95% CI P 
TNF-α          
BCG 394 235 - 561 402 172 - 669 407 343 1.18 0.87 - 1.61 0.294 
Mtb 372 152 - 600 185 91 - 352 316 226 1.27 0.92 - 1.75 0.142 
Strep 426 266 - 762 318 189 - 494 472 377 1.27 0.93 - 1.74 0.132 
E. coli 910 526 - 1342 606 340 - 1002 836 566 1.48 1.05 - 2.10 0.025 
IL-1β 
         
BCG 346 210 - 589 348 177 - 590 328 302 1.05 0.75 - 1.48 0.763 
Mtb 216 110 - 512 129 61 - 248 230 142 1.43 1.00 - 2.03 0.047 
Strep 578 380 - 889 571 371 - 943 595 573 1.06 0.82 - 1.37 0.668 
E. coli 1083 715 - 1791 837 390 - 1665 1078 806 1.35 0.98 - 1.87 0.069 
IL-1RA 
         
BCG 2184 1603 - 2944 2194 1453 - 3631 1988 2386 0.87 0.69 - 1.10 0.247 
Mtb 2020 1441 - 2744 1904 1417 - 2979 1818 1881 1.01 0.80 - 1.27 0.963 
Strep 1798 987 - 2615 1480 970 - 3553 1580 1641 1.02 0.75 - 1.38 0.901 





         
BCG 4798 2785 - 7825 3576 2144 - 5773 4491 3587 1.15 0.90 - 1.46 0.26 
Mtb 3483 1397 - 9355 1994 943 - 5552 3671 2284 1.40 1.04 - 1.88 0.027 
Strep 2997 1839 - 5351 1711 1225 - 3545 2786 1681 1.52 1.14 - 2.03 0.005 
E. coli 7678 5022 - 9742 6168 3406 - 7765 7085 5284 1.26 1.00 - 1.59 0.054 
IL-8 
         
BCG 11247 7836 - 18344 10118 8036 - 14753 11424 10418 1.11 0.83 - 1.48 0.475 
Mtb 12224 3596 - 29230 7724 2304 - 20561 10074 6855 1.38 0.88 - 2.16 0.166 
Strep 13897 8479 - 18945 11322 6222 - 17329 12987 10475 1.26 0.94 - 1.68 0.125 
E. coli 3123 1736 - 5664 2564 1611 - 3616 3495 2263 1.48 1.06 - 2.04 0.02 
IL-10 
         
BCG 41 25 - 58 30 24 - 56 36 36 0.95 0.71 - 1.26 0.715 
Mtb 18 11 - 50 18 7 - 38 24 21 1.01 0.70 - 1.46 0.952 
Strep 20 12 - 35 15 11 - 30 20 20 0.99 0.73 - 1.36 0.97 
E. coli 95 68 - 135 71 47 - 143 90 73 1.20 0.85 - 1.68 0.303 
PN: Persistently QFN-GIT negative; Conv: QFN-GIT converter; Geo mean: Geometric mean; RR: Relative Risk; CI: Confidence 
Interval; IQR: Interquartile range; BCG: Bacillus Calmette-Guérin; Mtb: M. tuberculosis lysate; Strep: S. pneumoniae.  








Secondary analysis – PN group restricted to highly exposed PN  
The secondary analysis of 50 highly exposed PN (HEPN) versus all 41 converters is 
presented in Table 45. Of the pro-inflammatory cytokine responses to M. tuberculosis 
lysate only IL-6 was higher in the HEPN group compared to converters, and this was 
not significant (RR=1.30; 95% CI 0.93 - 1.83; P=0.13).  
 
Inflammatory responses to non-mycobacterial stimuli were increased. IL-6 responses 
to S. pneumoniae and E. coli were higher in the HEPN group than converters 
(RR=1.38; 95% CI : 1.00 - 1.90; P=0.048 and RR=1.34; 95% C: 1.04 - 1.72; P=0.022 
respectively). The TNF- response to E. coli was also higher in the HEPN group than 
converters (RR=1.54; 95% CI 1.10 - 2.14; P=0.011). There was also a higher IL-1 
response to E. coli observed but this was of borderline significance (RR=1.39; 95% 
CI 0.99 - 1.94; P=0.056). There was no difference in anti-inflammatory cytokines 
responses, IL-1RA or IL-10, to any of the stimuli.  
 
In summary, there were no differences in inflammatory innate cytokine responses to 
mycobacterial stimuli between PN and converters when the PN group was restricted 
to the most highly exposed.   
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RR 95% CI P 
TNF-α          
BCG 396 221 - 590 351 172 - 702 380 383 1.04 0.74 - 1.48 0.804 
Mtb 359 197 - 530 225 93 - 447 303 255 1.12 0.76 - 1.65 0.582 
Strep 391 266 - 611 375 189 - 599 431 419 1.14 0.80 - 1.61 0.474 
E. coli 943 640 - 1716 755 430 - 1201 980 664 1.54 1.10 - 2.14 0.011 
IL-1β 
         
BCG 355 172 - 491 331 167 - 507 296 285 0.98 0.65 - 1.48 0.931 
Mtb 259 133 - 439 167 72 - 348 228 172 0.97 0.64 - 1.46 0.88 
Strep 563 392 - 744 632 371 - 1065 570 599 1.00 0.74 - 1.35 0.99 
E. coli 1300 793 - 2016 1099 466 - 1665 1203 909 1.39 0.99 - 1.94 0.056 
IL-1RA 
         
BCG 2078 1495 - 2816 2058 1432 - 3324 1856 2208 0.96 0.76 - 1.22 0.753 
Mtb 2021 1268 - 2893 2026 1426 - 2606 1811 1900 1.10 0.86 - 1.41 0.447 
Strep 1881 950 - 2717 1547 970 - 3542 1655 1673 1.22 0.89 - 1.67 0.219 





         
BCG 4989 2697 - 8433 3341 1941 - 5773 4646 3397 1.13 0.84 - 1.53 0.419 
Mtb 4070 1634 - 9355 1994 968 - 5069 4033 2257 1.30 0.93 - 1.83 0.125 
Strep 3276 1774 - 4784 1677 1095 - 3545 2891 1774 1.38 1.00 - 1.90 0.048 
E. coli 9043 5950 - 11822 6163 3664 - 7890 8571 5348 1.34 1.04 - 1.72 0.022 
IL-8 
         
BCG 11876 7836 - 16382 9904 5854 - 16055 10048 8464 1.15 0.77 - 1.73 0.489 
Mtb 9884 4960 - 23394 7334 3792 - 20561 9471 7208 1.03 0.62 - 1.71 0.918 
Strep 13073 7981 - 18248 11322 4933 - 18281 11908 9888 1.18 0.85 - 1.66 0.325 
E. coli 2837 1736 - 5579 2251 1441 - 3641 3446 2280 1.33 0.92 - 1.92 0.126 
IL-10 
         
BCG 41 23 - 62 32 24 - 53 36 34 0.96 0.69 - 1.33 0.797 
Mtb 22 14 - 53 18 7 - 38 28 21 1.10 0.76 - 1.60 0.621 
Strep 21 12 - 38 15 10 - 30 22 20 1.00 0.71 - 1.42 0.995 
E. coli 105 69 - 145 71 47 - 143 100 73 1.24 0.91 - 1.70 0.176 
HEPN: Highly Exposed Persistently QFN-GIT negative; Conv: QFN-GIT converter; Geo mean: Geometric mean; RR: Relative Risk; CI: 
Confidence Interval; IQR: Interquartile range; BCG: Bacillus Calmette-Guérin; Mtb: M. tuberculosis lysate; Strep: S. pneumoniae.  




Findings in cross sectional analysis based on baseline QFN-GIT 
A comparison of cytokine responses according of the 153 BP participants to 121 BN 
participants is presented in Table 46.  
 
The BP group had higher innate cytokine responses to both mycobacterial stimuli. 
Participants with a positive IGRA at baseline had higher TNF- (RR=1.35; 95% 
CI:1.11 - 1.64; P=0.003), IL-1 (RR=1.39; 95% CI:1.08 - 1.80; P=0.011), IL-6 
(RR=1.38; 95% CI:1.12 - 1.70; P=0.002) and responses to M. tuberculosis stimulation 
than the baseline negative group. IL-8 response to M. tuberculosis was higher but this 
was not significant (RR=1.27; 95% CI:0.98 - 1.64; P=0.068). The BP group also had 
higher TNF- (RR=1.30; 95% CI:1.08 - 1.57; P=0.005), IL-1 (RR=1.32; 95% 
CI:1.07 - 1.64; P=0.011), IL-6 (RR=1.24; 95% CI:1.08 - 1.43; P=0.003) responses to 
BCG stimulation than the BN group. 
 
Inflammatory cytokine responses to non-mycobacterial stimuli were also increased in 
the BP group relative to the BN group. Stimulation with S. pneumoniae also produced 
higher responses to TNF- (RR=1.33; 95% CI:1.08 - 1.65; P=0.009), IL-1 
(RR=1.29; 95% CI:1.07 - 1.55; P=0.006), but not IL-6 or IL-8.  
 
The anti-inflammatory cytokine IL-10 response to M. tuberculosis was higher in the 
BP group than the BN group (RR=1.44; 95% CI:1.16 - 1.78; P=0.001) as was the IL-
10 response to BCG (RR=1.35; 95% CI:1.14 - 1.60; P=0.001). IL-1RA was elevated 
in the BP group relative to the BN group although this was of borderline significance 
(RR=1.17; 95% CI 1.00 - 1.38; P=0.051).  
 
S. pneumoniae stimulation also produced higher IL-10 responses in the BP group than 
the BN group (RR=1.26; 95% CI 1.05 - 1.52; P=0.013). None of the groups differed 
with respect to responses to E. coli on any of the measured cytokines.  
 
In summary the BP group had higher IL-1, TNF- and IL-10 responses to both M. 
tuberculosis lysate and BCG and S. pneumoniae than the BN group. Also, the BP 
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group had higher IL-6 responses to BCG and M. tuberculosis than the converter 
group.  
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RR 95% CI P 
TNF-α           
BCG 588 324 - 989 423 237 - 685 570 454 1.30 1.08 - 1.57 0.005 
Mtb 475 243 - 919 362 168 - 594 502 362 1.35 1.11 - 1.64 0.003 
Strep 539 280 - 977 415 256 - 748 568 460 1.33 1.08 - 1.65 0.009 
E. coli 773 452 - 1392 806 457 - 1292 771 761 1.04 0.83 - 1.31 0.725 
IL-1β 
         
BCG 488 283 - 865 369 208 - 680 468 343 1.32 1.07 - 1.64 0.011 
Mtb 370 171 - 753 197 86 - 542 358 220 1.39 1.08 - 1.80 0.011 
Strep 724 411 - 1252 574 380 - 1032 734 596 1.29 1.07 - 1.55 0.006 
E. coli 1131 691 - 1833 1085 634 - 1791 1027 1013 1.03 0.85 - 1.26 0.735 
IL-1RA 
         
BCG 1983 1345 - 3080 2202 1582 - 3324 2054 2148 1.04 0.89 - 1.22 0.595 
Mtb 2075 1349 - 3185 2083 1426 - 2893 2031 1890 1.17 1.00 - 1.38 0.051 
Strep 1655 868 - 2681 1608 947 - 2804 1643 1600 1.16 0.96 - 1.42 0.126 




         
BCG 6550 4288 - 11000 4552 2638 - 7791 6452 4401 1.24 1.08 - 1.43 0.003 
Mtb 7283 3328 - 12090 3107 1336 - 9496 6044 3571 1.38 1.12 - 1.70 0.002 
Strep 4656 2188 - 7366 2906 1468 - 5045 4007 2766 1.15 0.94 - 1.41 0.171 
E. coli 8805 5469 - 13641 6906 4521 - 9676 8207 6558 1.09 0.96 - 1.24 0.176 
IL-8 
         
BCG 12789 7398 - 20006 10951 7411 - 16503 11246 9980 1.16 0.94 - 1.42 0.158 
Mtb 16763 6210 - 25798 9515 3517 - 23120 11973 8724 1.27 0.98 - 1.64 0.068 
Strep 13256 7241 - 21839 12810 7667 - 18826 12053 11449 1.05 0.87 - 1.26 0.6 
E. coli 2746 1717 - 5339 2798 1706 - 4997 3084 3033 0.93 0.78 - 1.12 0.466 
IL-10 
         
BCG 61 38 - 87 37 23 - 61 55 36 1.35 1.14 - 1.60 0.001 
Mtb 55 20 - 83 20 11 - 54 46 26 1.44 1.16 - 1.78 0.001 
Strep 30 16 - 50 18 9 - 31 29 20 1.26 1.05 - 1.52 0.013 
E. coli 117 70 - 176 92 60 - 137 105 86 1.09 0.94 - 1.26 0.272 
BP: Baseline IGRA positive; BN: Baseline IGRA negative; Geo mean: Geometric mean; RR: Relative Risk; CI: Confidence Interval; 
IQR: Interquartile range; BCG: Bacillus Calmette-Guérin; Mtb: M. tuberculosis lysate; Strep: S. pneumoniae.  




Primary endpoint: Cytokine responses to M. tuberculosis in PN compared to 
converters 
Pro-inflammatory cytokine responses to M. tuberculosis lysate were higher in the 
primary comparison, but this was not significant. The IL-6 response to S. pneumoniae 
and IL-8 response to E. coli were higher in the PN group than converters. This could 
suggest a difference in innate responses between the two groups but does not meet the 
critieria specified for either of the hypotheses. 
 
This negative result is consistent with other smaller studies addressing cytokine 
responses associated the EC phenotype with a prospective study design. Mahan et al 
performed a WBSA with culture filtrate protein, the 19 kDa LpqH protein or LPS 
with and without IFN-g pre-treatment in household contacts in Uganda. In a 
comparison of 19 persistently TST negative contacts and 42 who were TST 
converters, there was no difference in TNF- response to these stimuli [174]. PBMC 
experiments on case contacts in the Gambia found higher cytokines in the converter 
group at baseline than the persistently TST negative group [168]. The cytokines 
correlated with conversion were those implicated with infection and developing 
adaptive responses (MCP–3, IL–13, IL–17, IFN–gamma, IP–10, MIP–1b, IL–2RA, 
GMCSF) and there were no differences in the few innate cytokines included (TNF- 
or IL-1). Neither of the studies addressed confounders such as BCG vaccination in 
the analysis, an approach that was important in the present study.  
 
Secondary analyses 
As described in the literature review (chapter 3) prior studies of cytokine responses in 
early clearers have not addressed confounding. The INFECT cohort was designed to 
permit analysis of confounders and effect modifiers, but a multivariable approach to 
cytokine data was not possible due to the small number of subjects analysed in this 
particular substudy. Instead a restricted analysis according to important confounders 




Restricting the analysis to contacts who had been BCG vaccinated did identify higher 
levels of pro-inflammatory cytokine responses to M. tuberculosis and non-
mycobacterial stimuli in PN relative to converters. This was statistically significant 
for IL-6, of borderline significance for IL-1 and a similar but non-significant trend 
seen for TNF- and IL-8. Noting the limitations of this study (discussed in full 
below), the exploratory nature of the restricted analysis, and the need for validation, 
this suggests innate cytokine responses as potential correlates of BCG induced 
protection, and an innate mechanism of action of BCG in vaccinated contacts. The 
analysis did not directly address whether BCG was the cause of this cytokine 
profile as there were insufficient PN and converterswho were not BCG vaccinated to 
analyse, though different cytokine responses in vaccinated and non-vaccinated 
participants is a possible explanation for the increase in effect sizes seen in the BCG 
restricted analysis compared to the overall analysis. Notably we have detected this 
effect in a study where the mean age is 34 years, and BCG vaccination for many 
participants will have been many decades ago. 
 
The mechanism of BCG-induced protection against TB disease or M. tuberculosis 
infection are unknown. A large study of BCG vaccinated South African adolescents 
has excluded CD4+ T cell responses to M. tuberculosis as a correlate of BCG induced 
protection [48]. As previously discussed (Chapter 2: Possible mechanisms of early 
clearance) trained immunity is a form of innate immune memory that alters innate 
immune responses to mycobacterial and other stimuili via epigenetic reprogramming 
of monocytes after BCG vaccination [164, 304]. However, these effects have not been 
correlated to a protective phenotype in humans. The pattern of cytokine responses 
observed in the BCG vaccinated group are consistent with trained immunity. As 
reviewed in detail in (Chapter 2) the proinflammatory cytokines studied up-regulate 
various mechanisms of M. tuberculosis killing, and have been linked to M. 
tuberculosis susceptibility in human genetic studies and animal models.  
 
Secondary analysis: HEPN versus converters 
An analysis of highly exposed PN (HEPN) contacts compared to converters (conv) 
showed higher inflammatory cytokine production in the HEPN group than converters 
but this was not significant. As in the primary comparison there were some 
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differences in the response to E. coli (TNF- and IL-6) and S. pneumoniae (IL-6). 
This analysis was based on small numbers and type II errors are possible. 
Interestingly the effect sizes were similar or lower than in the primary comparison 
suggesting that in this sub-study the HEPN group did not identify as a group with a 
higher proportion of early clearers than the PN group in the primary comparison.  
 
Cytokine responses to M. tuberculosis in baseline positive and baseline negative 
contacts 
The baseline positive (BP) group had higher TNF-, IL-1, IL-6 and IL-10 responses 
to M. tuberculosis and BCG. Sutherland et al compared whole blood cytokine 
responses of 20 household contacts with a positive TST at baseline to 19 with a 
negative TST [305]. They reported TST positive contacts produced more IFN- g, IL-
13 and IL-17 to purified protein derivative (PPD) and higher IFN-y and IL-13 
responses to ESAT-6/CFP-10 fusion protein, but recorded no difference in TNF-, 
IL-10, IL-12 or IL18. This likely reflects a lack of statistical power in the Gambian 
study. The group with a positive QFN-GIT at baseline also had increased TNF-, IL-
1 and IL-10 responses to S. pneumoniae. 
 
In contrast to the initially uninfected participants, this pattern of non-specific 
responses in recently infected participants relative to the BN group could have 
multiple explanations. The first and most likely innate immune priming may lead to 
transiently increased responses to mycobacteria and other pathogens in this group of 
recently infected contacts [306]. Other possible explanations are cross reactivity 
between M. tuberculosis specific and Strep pneumoniae specific CD4+ T cells, or M. 
tuberculosis infection itself has induced training of innate immune responses.  
 
In any case it is apparent that LTBI infection changes the innate cytokine response to 
whole bacterial stimuli, and the WBSA can not be said to test innate responses 
independent of infection, at least in recently exposed contacts. This underscores the 
importance of prospective study design to identify cytokines associated with EC, as 
cross-sectional comparisons are heavily influenced by the effect of recent infection. 
Cobat et al proposed a role for TNF- in EC based on the close proximity of a locus 
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associated with TNF- response to BCG stimulation of whole blood [165], and a 
locus associated with TST negativity identified in the same study sample [307]. The 
present study supports an alternative explanation: that a locus associated with TST 
status will also be associated with TNF- response to mycobacterial stimuli, as both 
the TST and ex-vivo TNF- responses are caused by delayed type hypersensitivity 
response to M. tuberculosis in latently infected individuals. Future efforts to link 
cytokine responses to mycobacteria to host genotype should collect samples prior to 
the development of adaptive immunity.  
 
Anti-inflammatory cytokine IL-10 was elevated in the baseline positive group, 
whereas neither of the anti-inflammatory cytokines differed between the PN and 
converter group. This has been seen in the smaller study of cytokine responses in 
Gambian case contacts study, though this was not significant [308]. Anti-
inflammatory cytokine responses to M. tuberculosis are believed to be important in 
protection against immunopathology in M. tuberculosis disease. However they could 
also be induced by M. tuberculosis to counter protective pro-inflammatory responses.  
 
Limitations 
This study has a number of limitations that should be acknowledged. Firstly, the 
exclusion of 138 samples due to contamination could be a source of bias, as 
contamination was defined by the presence of an inflammatory cytokine, IL-6, in the 
unstimulated (nil) well. However, contamination was all but eliminated after the first 
batch, consistent with an exogenous cause and not with IL-6 being a feature of one of 
the phenotypes under study. It is likely the contamination arose from use of a 
contaminated batch of blood collection tubes, as has been previously described [309], 
as it had resolved before we were aware of the issue and reviewed laboratory 
processes. Furthermore, removing participants with IL-6 in the nil wells resulted in 
the exclusion of a higher proportion of PN than converters. Thus, in the unlikely event 
that IL-6 in the nils was physiologic, and not contamination, the bias resulting from 
the exclusion will be against finding stronger inflammatory responses in the PN 
group. Secondly, the number of participants with cytokine data available limited the 
ability to account for confounding and effect modification by modelling. Specifically, 
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only a restricted analysis of high exposure and BCG vaccinated groups was possible. 
These secondary analyses should be understood as exploratory. Thirdly, we did not 
correct for multiple testing, as this approach maybe overly strict when multiple 
measures taken are correlated, as is the case with these innate cytokines. Fourthly, 




We did not find evidence of higher pro-inflammatory cytokine responses to 
mycobacterial and non-mycobacterial stimuli in the primary comparison of PN and 
converters. This may reflect the sample size being too small to overcome 
heterogeneity within the PN group, especially with respect to BCG vaccination. 
Increased IL-6 and potentially IL-1 responses to M. tuberculosis and E. coli were 
associated with protection against infection in the BCG vaccinated subset.  
 
Further analysis of cytokine responses in the cohort should be performed in a second 
“test” batch of adequate size to confirm or refute these hypotheses. The effect of BCG 
on cytokine responses should be described either by stratification or including as an 
interaction term, as this may identify innate cytokines as correlates of BCG’s 




Chapter 11: Pilot study of RNA Sequencing 
 
Introduction 
Gene expression in peripheral blood could provide a biomarker for EC. Previous 
studies of gene expression in TB household contacts have been small cross sectional 
studies conducted prior to the availability of more sensitive measures of gene 
expression [172, 233]. In this pilot study we aimed to see if RNA sequencing of 
whole blood could detect differences in gene expression between early clearers and 
converters, ahead of a planned larger future study. To mitigate the risk of false 
discovery with a high through-put technique, this pilot study was restricted to analysis 
of candidate innate genes with evidence of a protective function against M. 




The pilot had two objectives: 
1) To test whether contacts with a PN QFN-GIT, and those who convert their 
QFN-GIT, differentially express 45 candidate genes 
2) To provide data to guide sample size calculations for future studies.  
 
Hypothesis 
That the PN group would have higher expression of candidate transcripts with a 
demonstrated protective function in M. tuberculosis infection, than converters. 
 
Measurements 
We compared 45 transcripts between the phenotypic groups, selected on the basis that 
there is evidence that the gene has a protective function in the innate response to M. 
tuberculosis, as previously described (see Chapter 4: Innate immune genes that 





Participants recruited between 22 October 2014 when PAXGene™ tube collection 
was added to cohort recruitment procedures, and 11 March 2015 were eligible for 
inclusion in the pilot. Thirty-two of 55 eligible PN contacts were selected randomly 
within two strata of high and low exposure to M. tuberculosis, where high exposure 
meant contact with a 3+ smear grade index case or sleeping in the same room as the 
index case. Twelve out of seventeen eligible converters and 12 out of 99 BP samples 
were purposively selected. To maximise the probability that the BP group was 
recently infected, we selected contacts who were highly exposed, whose index case 
reported cough for less than ninety days and whose co-habitants did not report 
previous TB. When selecting between similarly exposed participants, selection was 
random, up to a maximum of three participants per household, to minimise the effect 
of clustering.  
 
Laboratory methods 
RNA quantity and quality was determined using the Nanodrop 1000 spectrometer 
(Thermo Fisher Scientific, Landsmeer, the Netherlands) and the Expirion High-
sensitivity RNA analysis kit (Bio-Rad, Waltham, MA, USA), respectively. RNAseq 
libraries were prepared from 1 µg RNA of each cell population using the TruSeq 
RNA sample preparation kit v2 (Illumina) according to the manufacturer’s 
instructions, and these libraries were subsequently sequenced on a HiSeq 2000 
sequencer (Illumina) using single-end sequencing of 50 bp, upon pooling of 10 
samples per lane. Transcripts were quantified as Reads Per Kilobase of transcript per 
Million mapped reads (RPKM), which represents the number of transcripts 
normalised for their length.  
 
Statistical analysis 
Differences in characteristics of the participant groups were compared by the chi-
squared test. Transcripts were measured and responses were presented as medians and 
inter quartile range (IQR). For each of the 45 transcripts the difference between the 
means of the comparator groups was modelled by a generalised estimating equation 
that accounted for clustering within households using an independence working 
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correlation and robust standard errors. A linear model was specified and errors were 
assumed to be normally distributed. A p-value less than 0.05 was considered 
statistically significant in this pilot study, because there was a priori evidence for their 
role in innate immunity from experimental studies.  
 
The primary analysis compared transcript expression in PN and converters. Two 
secondary analyses were performed. In the first included a highly exposed PN group 
(HEPN) defined as exposed to a 3+ case or sleeping in the same room as the case 
(Chapter 7: Characteristics of the cohort including phenotype classification  ). 
Secondly, a comparison according to baseline IGRA result is also presented. This 
analysis compared an IGRA-positive group with adaptive immune recognition of M. 
tuberculosis to an IGRA-negative group without, enabling the findings from the 
primary comparison in which neither protected nor susceptible group were initially 
IGRA positive to be contextualised.  
 
Sample sizes for the future study were estimated based on findings for the upper 
quartile of transcripts differentially expressed in the primary comparison group, as 
measured by their p-values. The difference and standard deviation of the transcripts 
were divided by the mean, to produce a range of standardised differences and standard 
deviations for sample size calculations. Sample sizes were calculated using the 




Of 32 PN contacts, 13 met the definition of high exposure, nine because they were 
exposed to a case with a 3+ smear grade and a further four because they shared a 
bedroom with the case. Compared to the uninfected groups, converters had a lower 
mean age (P=0.04). Eighty-six percent of the participants were BCG vaccinated. The 
















N.  13 19 12 12  
Age index, mean 
(sd) 
46 (11) 43 (15) 40 (12) 40 (13) 0.4 
Age index, median 
(range) 
50 (33 - 63) 39 (20 - 63) 39 (20 - 62) 39 (20 - 60)  
Index case cavities 8 (62) 7 (37) 4 (33) 5 (42) 0.4 
Highest smear grade of index case 
  
 
Scanty1+ 2 (15) 10 (53) 2 (17) 0 (0) 0.12 
2+ 2 (15) 9 (47) 4 (33) 4 (33)  
3+ 9 (69) 0 (0) 6 (50) 8 (67)  
Age contact, mean 
(sd) 
27 (14) 28 (16) 17 (9) 32 (17) 0.04 
Age contact, 
median (range) 
28 (8 - 50) 23 (8 - 61) 12 (7 - 32) 39 (9 - 55)  
Sex contact 
    
 
Female 6 (46) 8 (42) 6 (50) 7 (58) 0.7 
Male 7 (54) 11 (58) 6 (50) 5 (42)  
Sleep proximity to index 
   
 
Different Room,  7 (54) 19 (100) 8 (67) 7 (58) 0.3 
Same room,  6 (46) 0 (0) 4 (33) 5 (42)  
Smoking 
    
 
Never smoked,  8 (62) 14 (74) 9 (75) 10 (83) 0.7 
Current smoker,  5 (38) 5 (26) 3 (25) 2 (17)  
BCG vaccination 
    
 
No 2 (15) 2 (11) 3 (25) 1 (8) 0.3 
Yes 11 (85) 17 (89) 9 (75) 11 (92)  
BMI (mean, sd) 22.3 (4.1) 20.2 (3.7) 19.1 (3.6) 21.7 (5.1) 0.15 
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sd: standard deviation; BCG: Bacillus Calmette-Guérin, BMI :Body Mass Index 
kg/m2. 
Note: * p-value for comparison of persistently negative (i.e. high and low exposure) 

























































































































































































































































































































































































































































































































































The results of comparing 32 PN to 12 converters are shown in Table 48. A total of 
nine of the 45 transcripts differed between the two groups (p-value less than 0.05). 
However, only one transcript was higher in the PN group than converters, as 
hypothesised genes involved in EC would be. Expression of CTSD was 12.4 RPKM 
(95% CI 3.6 to 21.2) higher in PN than converters (P=0.006). CTSD expression is 
graphed in Figure 28. A further ten genes had higher expression in the PN group than 
converters, although differences were not significant at the P<0.05 threshold. 
  
Figure 28. Expression of CTSD in PN and converter groups overall  
Note: individual results (blue) and median (red).  
 
Thirty-three genes had lower levels of mean expression in the PN group than 
converters. Eight of these were significant at the 0.05 threshold. Expression of the 
transcription factor NFKB1 was lower in PN than converters (difference=-1.4 RPKM; 
95% CI:-2.4 to -0.4; P=0.004) The cytosolic DNA pattern recognition receptor AIM2 
had lower expression in PN than converters (difference=-2.0 RPKM; 95% CI:-3.4 to -
0.6; P=0.006). CASP7 and CASP3 expression were also lower in PN than converters 
(difference=-1.2 RPKM; 95% CI:-2.1 to -0.3; P=0.012 and -2.6RPKM 95% CI:-5.1 to 
0.0; P=0.048 respectively). 
 
Table 48 continued next page 
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Expression of the pattern recognition receptor NOD2 was lower in PN than converters 
(difference -5.3RPKM; 95% CI:-9.9 to -0.7; P=0.025) as was expression of cytokine 
IL12B (-18.8RPKM; 95% CI:-35.4 to -2.2; P=0.026). The regulators of autophagy 
BECN1 and ATG5 were higher converters than PN (difference=-0.8RPKM; 95% CI:-
1.5 to 0.0; P=0.042 and RR=-0.9RPKM; 95% CI:-1.8 to 0.0; P=0.043 respectively). 
 
Table 48. Expression of 45 candidate genes modelled by generalised estimating in 














TLR1 27.8 22.3 - 33.5 29.3 25.1 - 38.7 -3.8 -9.1, 1.6 0.168 
TLR2 58.6 49.8 - 63.8 60.7 52.1 - 72.5 -5.3 -17.5, 6.8 0.391 
TLR4 36.2 29.6 - 51.3 42.7 35.9 - 53.1 -6.8 -15.4, 1.7 0.118 
NOD2 18.8 13.7 - 23.3 24.3 17.1 - 28.6 -5.3 -9.9, -0.7 0.025 
CD209 0.14 0.09 - 0.21 0.18 0.10 - 0.21 0.0 -0.1, 0.0 0.759 
AIM2 4.7 4.0 - 7.1 7.8 5.9 - 8.9 -2.0 -3.4, -0.6 0.006 
CLEC4D 3.6 3.0 - 5.3 5.5 3.6 - 6.0 -0.7 -2.0, 0.5 0.245 
TOLLIP 8.9 8.1 - 9.5 8.6 7.9 - 9.3 0.3 -0.2, 0.8 0.219 
NFKB1 14.7 12.8 - 16.5 16.2 15.2 - 16.8 -1.4 -2.4, -0.4 0.004 
MYD88 72.4 65.5 - 81.0 74.1 70.1 - 82.9 -7.2 -18.9, 4.6 0.231 
CARD9 2.5 2.0 - 2.9 2.5 1.9 - 2.7 0.2 -0.2, 0.5 0.286 
IL-1β 18.8 16.6 - 21.9 20.2 18.0 - 23.4 -1.1 -5.4, 3.1 0.593 
TNF-α 4.9 3.9 - 5.3 4.9 4.5 - 5.4 -0.4 -1.0, 0.3 0.245 
IL17A* 0.0 0.0 - 0.0 0.0 0.0 - 15.5 -2.9 -29.3, 23.5 0.829 
IL18 1.7 1.5 - 2.2 1.9 1.7 - 2.2 -0.1 -0.4, 0.2 0.558 
IL6 25.7 0.0 - 59.7 56.0 28.8 - 84.2 0.0 0.0, 0.0 0.079 
IL12A 0.2 0.2 - 0.3 0.3 0.2 - 0.4 0.0 -0.2, 0.1 0.354 
IL12B* 0.0 0.0 - 11.9 23.8 0.0 - 43.8 -18.8 -35.4, -2.2 0.026 
IL32 56.4 48.5 - 61.8 47.2 39.9 - 62.7 10.9 -1.6, 23.3 0.087 
IL-8 2.0 1.5 - 3.2 2.0 1.2 - 4.0 -0.7 -2.5, 1.2 0.468 
CXCL1 4.8 3.3 - 5.9 4.0 3.3 - 5.5 0.6 -0.7, 1.8 0.357 
CXCL2* 52.5 38.9 - 92.2 49.4 39.9 - 145.9 -30.2 -88.3, 27.8 0.307 
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CXCL5 1.4 1.0 - 2.2 1.6 1.1 - 2.4 0.2 -0.5, 0.9 0.652 
PPBP 43.0 27.2 - 59.1 35.9 27.3 - 67.0 0.7 -13.0, 14.4 0.92 
CAMP 10.4 6.6 - 21.4 7.7 6.8 - 12.4 9.4 -1.5, 20.2 0.09 
NOS2* 16.0 0.0 - 35.1 30.7 0.0 - 56.7 -9.34 -25.7, 7.1 0.265 
CYBB 87.1 62.1 - 97.6 106.1 85.5 - 116.2 -16.0 -33.1, 1.1 0.067 
LCN2 4.3 2.4 - 12.2 3.8 1.4 - 6.3 6.4 -2.9, 15.7 0.178 
ATP6V1B1* 0.0 0.0 - 11.0 0.0 0.0 - 23.2 -2.5 -15.2, 10.2 0.703 
CTSD 51.6 45.9 - 62.8 45.4 43.1 - 53.4 12.4 3.6, 21.2 0.006 
ATG5 3.6 3.0 - 5.0 4.6 3.9 - 5.2 -0.9 -1.8, 0.0 0.043 
ATG7 3.6 3.3 - 3.9 3.5 3.1 - 4.3 -0.1 -0.5, 0.3 0.667 
BECN1 10.1 9.3 - 10.9 10.8 10.0 - 11.1 -0.8 -1.5, 0.0 0.042 
IRGM 0.1 0.1 - 0.2 0.2 0.2 - 0.2 0.0 -0.1, 0.0 0.21 
CASP1 47.1 40.1 - 58.5 51.0 43.7 - 60.6 -3.0 -12.1, 6.2 0.526 
CASP3 9.8 7.7 - 12.9 12.8 11.2 - 16.5 -2.6 -5.1, 0.0 0.048 
CASP7 4.5 3.8 - 4.9 5.9 4.4 - 6.5 -1.2 -2.1, -0.3 0.012 
CASP8 30.4 27.9 - 36.9 33.8 29.3 - 38.0 -2.3 -6.6, 2.1 0.305 
CFLAR 21.8 18.2 - 26.7 22.5 20.0 - 27.8 -1.5 -4.3, 1.3 0.303 
TNFRSF1A 76.1 66.1 - 86.5 71.7 63.8 - 89.6 1.2 -9.4, 11.8 0.824 
TNFRSF1B 200 175 - 216 169 156 - 197 18.2 -3.1, 39.5 0.093 
LTA4H 23.7 17.8 - 27 27.2 22 - 30.8 -2.1 -7.0, 2.7 0.387 
VDR 3.8 3.3 - 4.5 4.1 3.6 - 4.4 -0.3 -1.0, 0.4 0.358 
CYP27B1 0.1 0.0 - 0.1 0.1 0.0 - 0.1 0.0 0.0, 0.0 0.824 
FOXP3 2.3 1.7 - 2.8 2.4 2.2 - 2.7 -0.1 -0.5, 0.2 0.409 
PN: Persistently negative; Conv: converter; IQR: interquartile range.  
Note: d: difference mean PN and mean converter CI = 95% confidence interval for d; 
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Sample size  
For the eleven transcripts with the greatest difference between the groups, the 
estimated sample size for a stud with 80% power to detect that effect with genome 
wide significance (=3.6x 10-6) ranged from 353 to 865 (Table 49). In this subset of 
transcripts the mean difference between the groups ranged from 36% to 57% of the 
mean, and the standard deviation ranged from 19% to 130% of the mean.  
 
Table 49. Estimated total sample size required to achieve genome wide significance.  
Transcript Mean 
(PN) 





NFKB1 1.438 0.506 2.21 35% 154% 664 
AIM2 1.958 0.715 0.84 37% 43% 712 
CTSD -12.36 4.486 9.06 36% 73% 353 
CASP7 1.169 0.467 0.67 40% 58% 426 
NOD2 5.286 2.362 2.78 45% 53% 531 
IL12B 0.019 0.008 0.001 45% 5% 528 
BECN1 0.787 0.388 1.48 49% 188% 639 
ATG5 0.903 0.445 0.58 49% 65% 649 
CASP3 2.559 1.293 1.61 51% 63% 678 
CYBB 15.97 8.733 12.79 55% 80% 793 
IL6 0.0191 0.0109 0.01 57% 30% 865 
PN: Persistently negative; d: difference mean PN and mean converter; d/mean: 
difference between means divided by mean; SD/mean: standard deviation divided by 
mean.  
Secondary analysis: Highly exposed persistently negative and converters 
The comparison of 13 highly exposed persistently negative (HEPN) contacts to 12 
converters are presented in Table 50. Expression of ten genes was higher in the 
converters than the HEPN. Eleven genes were higher in the HEPN group but none 
were significantly different at the 0.05 threshold. 
 
Of the 34 genes with higher transcripts in converters than HEPN two differed after 
correction for multiple testing (P< 0.0011), and a further eight were significant at the 
0.05 level. Expression of AIM2, the pattern recognition receptor for cytoplasmic 
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DNA, was greater in converters than HEPN (difference=-2.9 RPKM; 95% CI:-4.2 to -
1.7; P<0.001). Transcripts of the CASP3, the phagocyte membrane bound oxidase, 
were also significantly higher in converters than HEPN (difference=-4.5 RPKM; 95% 
CI:-6.9 to -2.1; P<0.001). 
 
Table 50 continued next page 
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Compared to converters, the HEPN group also expressed lower levels of CYBB 
(difference=-26.2 RPKM; 95% CI:-44.2 to -8.3; P=0.004), the transcript for 
nicotinamide adenine dinucleotide phosphate that generates reactive oxygen species. 
ATG5 expression was lower in the HEPN group than converters (difference=-1.3 
RPKM; 95% CI:-2.2 to -0.4; P=0.004). Also lower in PN than converters was LTA4H 
(difference=-5.1 RPKM; 95% CI:-9.3 to -0.9; P=0.018), the pattern recognition 
receptors NOD2 (difference=-6.2 RPKM; 95% CI:-11.3 to -1.0; P=0.019) and 
CLEC4D (difference=-1.6 RPKM; 95% CI:-2.9 to -0.3; P=0.019) expression. CASP7 
(difference=-1.5 RPKM; 95% CI:-2.5 to -0.4; P=0.007) and CASP1 (difference=-9.3 
RPKM; 95% CI:-18.6 to -0.1; P=0.046) were lower in PN than converters.  
 
Table 50. Expression of 45 candidate transcripts modelled by generalised estimating 
equation for the secondary comparison of HEPN and converters.  
HEPN 
Median 
HEPN IQR Conv 
Media
n 
Conv IQR d 95% CI P 
TLR1 28.1 22.6 - 33.0 29.3 25.1 - 38.7 -4.1 -10.5, 2.3 0.213 
TLR2 59.0 49.1 - 63.8 60.7 52.1 - 72.5 -7.7 -20.5, 5.1 0.238 
TLR4 34.8 29.6 - 49.9 42.7 35.9 - 53.1 -7.7 -17.5, 2.1 0.121 
NOD2 19.1 14.7 - 19.6 24.3 17.1 - 28.6 -6.2 -11.3, -1.0 0.019 
CD209 0.10 0.06 - 0.15 0.18 0.10 - 0.21 0.0 -0.1, 0.0 0.105 
AIM2 4.2 3.9 - 4.7 7.8 5.9 - 8.9 -2.9 -4.2, -1.7 <0.001 
CLEC4D 3.4 1.9 - 3.8 5.5 3.6 - 6.0 -1.6 -2.9, -0.3 0.019 
TOLLIP 8.7 8.3 - 9.2 8.6 7.9 - 9.3 0.2 -0.4, 0.8 0.534 
NFKB1 15.2 13.7 - 15.9 16.2 15.2 - 16.8 -1.3 -2.8, 0.2 0.086 
MYD88 72.8 65.5 - 77.2 74.1 70.1 - 82.9 -9.2 -22.5, 4.1 0.175 
CARD9 2.0 1.8 - 2.6 2.5 1.9 - 2.7 -0.1 -0.6, 0.4 0.812 
IL-1β 18.3 15.7 - 22.5 20.2 18.0 - 23.4 -1.3 -6.2, 3.7 0.62 
TNF-α 4.8 3.9 - 4.9 4.9 4.5 - 5.4 -0.6 -1.2, 0.1 0.08 
IL17A* 0.0 0.0 - 0.0 0.0 0.0 - 15.5 -9.5 -35.4, 16.5 0.474 
IL18 1.6 1.4 - 2.2 1.9 1.7 - 2.2 -0.2 -0.6, 0.2 0.333 
IL6 23.6 0.0 - 48.3 56.0 28.8 - 84.2 0.0 0.0, 0.0 0.147 
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IL12A 0.2 0.1 - 0.3 0.3 0.2 - 0.4 -0.1 -0.2, 0.0 0.095 
IL12B* 0.0 0.0 - 0.0 23.8 0.0 - 43.8 -19.7 -36.9, -2.5 0.025 
IL32 55.0 45.4 - 61.8 47.2 39.9 - 62.7 9.3 -9.5, 28.0 0.333 
IL-8 2.2 1.4 - 3.2 2.0 1.2 - 4.0 -0.7 -2.6, 1.3 0.501 
CXCL1 4.7 3.2 - 5.9 4.0 3.3 - 5.5 0.3 -1.2, 1.9 0.674 
CXCL2* 53.7 42.6 - 90.3 49.4 39.9 - 145.9 -29.1 -90.0, 31.7 0.348 
CXCL5 1.8 1.1 - 2.3 1.6 1.1 - 2.4 0.3 -0.6, 1.3 0.509 
PPBP 41.1 19.0 - 43.7 35.9 27.3 - 67.0 -6.0 -22.2, 10.1 0.462 
CAMP 9.2 7.4 - 21.7 7.7 6.8 - 12.4 4.7 -2.5, 11.8 0.2 
NOS2* 0.0 0.0 - 31.4 30.7 0.0 - 56.7 -13.9 -33.0, 5.1 0.152 
CYBB 76.4 59.9 - 92.3 106.1 85.5 - 116.2 -26.2 -44.2, -8.3 0.004 
LCN2 5.3 2.4 - 11.6 3.8 1.4 - 6.3 2.8 -3.3, 8.9 0.37 
ATP6V1B1* 0.0 0.0 - 22.0 0.0 0.0 - 23.2 0.4 -15.5, 16.3 0.961 
CTSD 48.5 47.7 - 55.1 45.4 43.1 - 53.4 10.7 -5.8, 27.1 0.204 
ATG5 3.4 2.8 - 3.9 4.6 3.9 - 5.2 -1.3 -2.2, -0.4 0.004 
ATG7 3.7 3.3 - 3.9 3.5 3.1 - 4.3 -0.1 -0.5, 0.4 0.732 
BECN1 9.6 9.3 - 11.0 10.8 10.0 - 11.1 -1.0 -2.4, 0.3 0.139 
IRGM 0.2 0.1 - 0.2 0.2 0.2 - 0.2 -0.1 -0.1, 0.0 0.214 
CASP1 41.5 36.3 - 47.0 51.0 43.7 - 60.6 -9.3 -18.6, -0.1 0.046 
CASP3 8.7 7.3 - 9.6 12.8 11.2 - 16.5 -4.5 -6.9, -2.1 <0.001 
CASP7 4.4 3.4 - 4.6 5.9 4.4 - 6.5 -1.5 -2.5, -0.4 0.007 
CASP8 29.4 28.2 - 33.3 33.8 29.3 - 38.0 -3.3 -9.6, 3.0 0.3 
CFLAR 19.9 17.8 - 23.2 22.5 20.0 - 27.8 -2.8 -6.3, 0.8 0.13 
TNFRSF1A 74 72 - 83 72 63.8 - 90 1.6 -10.3, 13.6 0.787 
TNFRSF1B 185.3 176.9 - 205 168.8 156 - 197.1 14.4 -8.3, 37.0 0.215 
LTA4H 19.8 17.5 - 26.2 27.2 21.8 - 30.8 -5.1 -9.3, -0.9 0.018 
VDR 3.5 3.2 - 4.5 4.1 3.6 - 4.4 -0.4 -1.2, 0.4 0.327 
CYP27B1 0.1 0.0 - 0.1 0.1 0.0 - 0.1 0.0 0.0, 0.0 0.521 
FOXP3 2.4 1.9 - 2.9 2.4 2.2 - 2.7 0.0 -0.5, 0.5 0.936 
HEPN: highly exposed persistently negative; Conv: converter; IQR: interquartile 
range; d: difference mean PN and mean converter RPKM; 95% CI 95% confidence 
interval. Note: * scaled by factor of 1000; transcripts measured in RPKM. 
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Secondary analysis: Cross sectional comparison of baseline IGRA 
The cross-sectional comparison of 44 BN contacts to 12 BP participants is presented 
in Table 51. Expression of transcripts of the cytokine IL17A were higher in the 
baseline negative group than the baseline positive group BP (difference -13.3; 95% CI 
-26.5 to -0.1; P=0.048). As shown in Figure 29 IL17 expression was heavily skewed, 
and most contacts had no transcripts detected.  
 
Figure 29. Expression of IL17A according to baseline IGRA, individual results (blue) 




Table 59 continued next page 
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Table 51. Expression of 45 candidate genes modelled by generalised estimating 









d 95% CI P 
TLR1 26.5 23.2 - 31.3 28.1 24.0 - 36.2 -0.7 -5.8, 4.4 0.781 
TLR2 61.0 52.0 - 74.4 59.0 51.3 - 68.0 3.6 -8.9, 16.2 0.57 
TLR4 37.7 32.7 - 47.6 40.6 30.0 - 52.6 -2.5 -10.4, 5.5 0.543 
NOD2 19.4 15.1 - 24.9 19.6 14.7 - 24.8 0.7 -5.4, 6.7 0.823 
CD209 0.17 0.09 - 0.23 0.14 0.10 - 0.20 0.0 -0.1, 0.1 0.587 
AIM2 6.2 5.7 - 6.7 5.8 4.3 - 7.7 1.2 -1.1, 3.4 0.301 
CLEC4D 3.9 3.0 - 5.8 3.8 3.1 - 5.9 0.9 -2.0, 3.7 0.559 
TOLLIP 8.7 7.8 - 9.0 8.8 7.9 - 9.4 -0.5 -1.6, 0.6 0.387 
NFKB1 15.5 13.5 - 16.7 15.2 13.6 - 16.6 -0.2 -2.8, 2.4 0.856 
MYD88 76.1 69.2 - 86.3 72.8 67.9 - 81.4 2.4 -7.3, 12.1 0.632 
CARD9 2.0 1.7 - 2.7 2.5 2.0 - 2.8 -0.3 -0.7, 0.2 0.2 
IL-1β 22.2 17.3 - 24.7 19.4 17.0 - 22.5 4.4 -1.6, 10.3 0.152 
TNF-α 5.3 4.5 - 5.8 4.9 3.9 - 5.3 0.5 0.0, 1.0 0.07 
IL17A* 0.0 0.0 - 0.0 0.0 0.0 - 0.0 -13.3 -26.5, -0.1 0.048 
IL18 2.0 1.7 - 2.3 1.9 1.5 - 2.2 0.1 -0.2, 0.4 0.436 
IL6 24.1 0.0 - 38.5 30.9 0.0 - 69.3 0.0 0.0, 0.0 0.577 
IL12A 0.3 0.2 - 0.3 0.3 0.2 - 0.4 0.0 -0.1, 0.1 0.957 
IL12B* 22.7 0.0 - 58.2 0.0 0.0 - 24.5 15.7 -1.8, 33.1 0.079 
IL32 50.2 47.6 - 61.9 53.3 41.1 - 61.8 -4.4 -14.0, 5.1 0.365 
IL-8 2.6 1.4 - 4.5 2.1 1.4 - 3.2 0.7 -0.9, 2.2 0.393 
CXCL1 4.6 3.8 - 5.4 4.7 3.4 - 5.8 -0.2 -1.2, 0.8 0.696 
CXCL2* 86.5 50.3 - 149.1 51.3 39.0 - 99.9 21.0 -18.7, 60.8 0.3 
CXCL5 1.9 1.4 - 3.2 1.4 1.1 - 2.2 0.7 -0.1, 1.5 0.11 
PPBP 48.5 33.3 - 65.0 42.7 27.5 - 58.6 6.0 -9.4, 21.4 0.447 
CAMP 11.5 6.4 - 14.2 10.4 7.0 - 20.8 -4.3 -12.6, 4.0 0.308 
NOS2* 0.0 0.0 - 35.0 16.9 0.0 - 45.1 -7.5 -25.1, 10.2 0.407 
CYBB 79.9 70.7 - 112.1 93.8 69.4 - 109.9 0.4 -19.1, 19.8 0.971 
LCN2 5.7 2.8 - 9.2 4.2 2.3 - 9.3 -2.9 -10.1, 4.3 0.428 
 




B1* 0.0 0.0 - 22.0 0.0 0.0 - 21.8 -1.3 -9.8, 7.2 0.767 
CTSD 48.6 39.9 - 58.4 48.7 44.2 - 58.5 -6.8 -15.7, 2.0 0.131 
ATG5 3.7 3.4 - 4.8 3.9 3.4 - 5.1 -0.2 -0.7, 0.4 0.533 
ATG7 3.6 3.2 - 4.2 3.6 3.3 - 3.9 0.0 -0.7, 0.6 0.879 
BECN1 9.8 9.1 - 11.8 10.3 9.6 - 11.0 -0.2 -1.6, 1.3 0.816 
IRGM 0.1 0.1 - 0.2 0.2 0.1 - 0.3 0.0 -0.1, 0.0 0.252 
CASP1 51.4 45.3 - 55.7 48.3 41.3 - 58.7 0.5 -6.7, 7.7 0.895 
CASP3 10.9 8.9 - 12.4 10.9 8.1 - 13.9 0.1 -2.4, 2.5 0.963 
CASP7 4.2 3.7 - 5.1 4.6 3.9 - 5.4 -0.5 -1.3, 0.4 0.287 
CASP8 30.1 26.4 - 36.0 32.9 28.8 - 38.0 -1.5 -5.4, 2.5 0.459 
CFLAR 22.7 18.6 - 25.0 21.9 19.1 - 27.4 -0.4 -4.3, 3.5 0.835 
TNFRSF
1A 70 57.8 - 91 75 67 - 86 -3.2 -16.0, 9.6 0.628 
TNFRSF
1B 182.1 153 - 214.9 185.3 168.4 - 213 -12.0 -43.5, 19.5 0.454 
LTA4H 21.0 17.6 - 22.9 25.0 19.1 - 29.1 -2.1 -9.3, 5.0 0.56 
VDR 4.1 3.2 - 4.5 3.8 3.3 - 4.4 -0.2 -0.9, 0.5 0.623 
CYP27B1 0.1 0.0 - 0.1 0.1 0.0 - 0.1 0.0 0.0, 0.0 0.986 
FOXP3 2.2 2.0 - 2.9 2.3 1.8 - 2.7 0.1 -0.4, 0.6 0.632 
BP: baseline positive; BN: baseline negative; IQR: interquartile range; d: difference 
mean Baseline positive - baseline negative; 95% CI 95% confidence interval. 
Note: * scaled by factor of 1000.  
Discussion 
RNA sequencing of unstimulated peripheral blood in IGRA negative contacts during 
M. tuberculosis exposure revealed differences in gene expression that correspond to 
the follow up (14 week) IGRA result. In the primary comparison of PN and 
converters, nine transcripts were different at the 0.05 threshold which was more than 
would be expected by chance alone (1 in 20). A group of ten transcripts, six also 
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CTSD transcripts were more highly expressed in PN than in converters, at a level that 
approached the threshold for multiple testing correction. Cathepsin D is a lysosomal 
acid hydrolase, and its inhibition makes human macrophages permissive to M. 
tuberculosis growth in culture [109]. It is possible that Cathespin D is up-regulated in 
early clearers to promote phagolysosomal killing, or down regulated by M. 
tuberculosis in conversion.   
 
Transcripts for genes involved in M. tuberculosis recognition (NOD2, AIM2), signal 
transduction (NFKB1), induction of apoptosis (CASP3, CASP7), autophagy (BECN1, 
ATG5) and induction of the TH1 response (IL12B) were more highly expressed in 
converters than PN in the primary analysis. The secondary analysis in which early 
clearers were restricted to a highly exposed uninfected group found transcripts 
involved in M. tuberculosis recognition (NOD2, CLEC4D, AIM2), production of 
reactive oxygen species (CYBB), induction of the TH1 response (IL12B), autophagy 
(ATG5), apoptosis (CASP1, CASP7), and metabolism of eicosanoids (LTA4H) were 
differentially expressed. AIM2 and CASP3 were significant at a threshold that 
accounts for multiple testing.  
 
There are no published studies reporting on a transcription signature associated with 
subsequent QFN-GIT conversion or EC as in the present study. RNA sequencing has 
been used to identify expression signatures correlated with progression of latent 
infection to disease [34]. In contrast the comparison based on baseline IGRA detected 
few differences between the comparison groups. Mihret and others identified higher 
FOXP3, CCL19, and TGF1 by dual colour Multiplex Ligation-dependent Probe 
Amplification in QFN-GIT positive versus negative household contacts [172]. The 
transcripts were significant at the 0.05 threshold and among a total of 45 genes 
studied. Of the three, only FOXP3 was included in the present study, and no 
differences were found between the groups. Rakotosamimanana et al found higher 
expression of the apoptosis regulator CFLAR in TST and ELISPOT positive 
household case contacts in Madagascar. This study was focused on four genes 
involved in apoptosis, however the finding was not replicated in the present study 
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[170]. This may arise from differences in phenotype definition, or the heterogeneity of 
the baseline negative group. 
 
The 45 candidate genes analysed in this pilot were selected on the basis of 
experimental evidence for a protective function against M. tuberculosis infection and 
yet most were more strongly expressed in the susceptible group, converters, relative to 
the protected group PN. There are three possible explanations for this finding. Firstly, 
it is possible that individual candidates studied are not protective, for example IL12B 
could better be described as an innate cytokine that initiates the development of 
adaptive immunity that occurs in conversion, however this does not apply to the 
remaining candidates. Secondly, misclassification of contacts insufficiently exposed 
to be infected in the uninfected group could result in lower mean responses in the 
uninfected group. However restricting the analysis to highly exposed uninfected 
versus converters did not substantially alter the finding that transcripts tended to be 
greater in converters than early clearers. Thirdly, an intriguing possibility is that 
transcripts with a protective function in early clearers are expressed at higher levels in 
converters than early clearers, because responses in converters are stimulated by more 
M. tuberculosis as it persists and replicates within the host, amplifying the immune 
response.  Unlike confounding by M. tuberculosis exposure discussed in previous 
chapters, this is a type of bias against the discovery of transcripts associated with EC 
that could not be eliminated even with perfect measurement of the infecting dose of 
bacilli. This effect was not seen in the WBSA experiments in chapter 10. This does 
not prevent identifying a transcription biosignature of EC, but it does make discovery 





Results from a small pilot study should be interpreted with caution, as modelled 
estimates have limited accuracy, particularly for skewed data. Also, differences in 
participant characteristics such as age could be a source of confounding, which could 
be addressed by matching or statistical adjustment in a larger study. Since baseline 
positive individuals were older than the other groups, it is likely that they are enriched 
for past M. tuberculosis exposure as well as recent exposure. Their comparison with 
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the BN group that includes early clearers and converters may not be appropriate. A 
relatively low exposure persistently negative group was found. However it may be 
useful to recruit community controls as expression of transcripts associated with EC 
will be lower in this group. We have shown that neighbourhood controls may be 
appropriate in this regard, although it is difficult to identify an unexposed group in a 




The size of effects detected between candidate genes require sample sizes ranging 
from 353 - 865 participants to detect genome wide-significance. Such sample sizes 
are prohibitively large both with respect to identifying sufficient converters as 
controls and sequencing costs. Alternative approaches include a second validation 
analysis performed on stored samples from the cohort, another cohort, or an 
experimental infection model, or minimising multiple testing by pathway analysis or 
by eliminating correlated transcripts from the analysis. The HEPN group may be the 
most statistically efficient group to focus on in future studies, as the differences from 
converters were apparent despite a smaller number of participants analysed. 
Alternative uses of transcription data, for example in expression quantitative trait loci 
for planned genetic studies can also be explored.   
Conclusion 
RNA sequencing of blood collected from TB case contacts during their exposure 
shows promise for detecting differences that correspond to their 14-week IGRA 
result. A larger scale study is warranted to further define a transcription profile for EC 
and conversion on a genome-wide basis. A validated transcription profile could 
enable early identification of early clearers and converters, raising the efficiency of 
management of case contacts in both research and clinical settings. Caution should be 
exercised in drawing mechanistic conclusions from genes differentially expressed in 
EC and converters, as there is a possibility of confounding by dose as described 
above. Future studies should consider including an unexposed group as a potential 
alternative comparator group as expression of transcripts associated with EC will be 
lower in this group.   
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Chapter 12: Effect of M. tuberculosis lineage on M. 
tuberculosis infection  
 
Introduction 
As outlined previously (Chapter 5 Considerations in study design) risk of M. 
tuberculosis transmission could be influenced by both host or pathogen factors. 
Understanding these pathogen factors is integral to understanding EC, as it identifies 
vulnerabilities in innate defence exploited by the M. tuberculosis. Pathogen factors 
can be conceptualised as those that affect the index case (by inducing a disease 
phenotype that favours transmission) or the contact (by evading mechanisms of EC). 
Therefore, we sought to determine the effect of M. tuberculosis lineage on risk of 
transmission to contacts. Lineage for a subset of index cases was assigned from whole 
genome sequencing. The primary analysis defined risk of transmission as risk of a 




To determine whether the lineage of M. tuberculosis a contact is exposed to 
influences their risk of infection. 
 
Hypothesis  
Contacts with a positive QFN-GIT at baseline or follow up are more likely to have 




M. tuberculosis lineage was a binary variable lineage two (“Beijing”) versus others. 
Other variables were defined as previously described (Chapter 8: Results of 
multivariable modelling of clinical and haematological parameters). 
 




The TANDEM study paid for whole genome sequencing (WGS) of 99 isolates in the 
first instance, enabling this sub-study. The isolates were selected for WGS up to April 
2015, which was the main limitation of inclusion in this sub-study. It is anticipated 
that all TANDEM isolates will be sequenced eventually enabling a more in-depth 
analysis with increased sample size.  
 
Laboratory methods 
M. tuberculosis isolates were suspended in liquid media and stored at -80°C until they 
were thawed and re-cultured for DNA extraction and sequenced at the Beijing 
Genomics Institute in Hong Kong on an Illumina HiSeqTM2000 instrument using 
reads of 100 base-pairs in length in the paired-end modus. After sequencing, the raw 
reads were filtered. Data filtering included removing adapter sequences, 
contamination, and low-quality reads from raw reads. Sequence reads are mapped to 
H37Rv reference genome by Breseq, a tool developed specifically for M. tuberculosis 
genomics [310]. Isolate lineage was inferred using an online platform that assigns 
lineage based the on the SNP barcoding approach described by McNerney et al [311].  
 
Statistical analysis 
The effect of M. tuberculosis lineage on risk of infection was modelled by using a 
generalised estimating equation that accounts for the clustered nature of household 
data. Multivariable models included lineage, as the variable of interest. Other features 
of the index case disease phenotype, namely smear grade and x-ray features, were 
included as potential mediating factors. Age, sex and cough duration of the index 
case, as well as contact age, sex, hours spent with the case, sleep proximity, BCG 
vaccination, smoking, BMI and diabetes were also included. With the exception of 
lineage and index case and contact age and sex, terms were removed in a stepwise 
fashion until remaining terms had a p-value <0.2.  
 
Due to the limited number of sequenced isolates, the comparison of PN against BP 
and converters was selected as the primary outcome. This comparison used data from 
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all three groups and had a maximum sample size. Because some of the baseline 
positive group may not have been infected by the index case isolate, this comparison 
risks bias. Therefore, a secondary analysis of the prospectively defined groups (PN 
and Conv) was conducted to aid interpretation of the primary outcome. A secondary 
analysis according to baseline QFN-GIT was also performed to aid comparison with 
other studies.  
 
Results 
Characteristics of the sequenced isolates  
In total 99 index cases included in INFECT had sequence data available. This 
represents 58% of the 171 index cases recruited up to April 2015. Table 52 
demonstrates that there was no difference in the characteristics of contacts whose 
index case was sequenced and those whose index case was not.  
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Table 52. Characteristics of culture positive index cases selected for whole genome 
sequencing, compared to those that were not.  






Age index, years, mean (sd) 40.8 (14.5) 39.2 (13.7) 39.8 (14.1) 
Sex index 
   
Female 97 (48) 47 (47) 144 (48) 
Male 105 (52) 52 (53) 157 (52) 
Ethnicity 
   
Sunda 182 (90) 84 (85) 266 (88) 
Other 20 (10) 15 (15) 41 (13) 
Cough duration, days, mean (sd) 59.3 (51.7) 52.6 (56.0) 57.1 (53.1) 
Dominant x-ray abnormality 
   
Cavity 107 (56) 49 (51) 156 (54) 
Other abnormality 84 (44) 48 (49) 132 (46) 
Extent of x-ray disease  50.8 (28.4) 47.9 (28.3) 45.0 (28.3) 
Highest smear grade 
   
Scanty or 1+ 64 (32) 28 (28) 92 (31) 
2+ 59 (29) 29 (29) 88 (29) 
3+ 79 (39) 42 (42) 121 (40) 
Values are numbers and percentages unless stated otherwise. SD: standard deviation. 
 
Description of lineages 
Of the 99 sequenced isolates, 32 (32%) were from lineage two. Of the remaining 
isolates, 62 (63%) were from lineage four, and 5 (5%) from the ancestral Indo-
Oceanic lineage. All the lineage two isolates were from the Beijing family. Of the 
lineage four isolates, 14 were from the Latin American Mediterranean sub-lineage, 17 
(17%) X type sub lineage and 11 (11%) from the “mainly T” sub-lineage. In 
summary, the comparison of lineage two versus other lineages comprised 32 lineage 
two isolates and 67 other isolates, predominantly lineage four.  
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Figure 30. Phylogenetic tree from whole genome sequencing of 99 index case 
isolates. 
 
Association of lineage with various characteristics 
 
As discussed variation in strain transmissibility could be mediated by differences in 
disease phenotype, so characteristics of index cases are tabulated according to their 
isolate in Table 53. Index cases from whom a lineage two isolate was cultured were 
younger (mean age 38.5 vs 42.0 years), had a lower smear grade (34% versus 46% 
smear grade 3) and fewer lung cavities (41% vs 55%), but none of these differences 
were statistically significant.  
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Table 53. Characteristics of 99 index cases according to M. tuberculosis lineage.  
Lineage 2  
N (%)  
Other 
N (%)  
p-value 




Female,  16 (50) 31 (46) 
0.7 




Sunda,  29 (91) 55 (82) 
0.3 
Other,  3 (9) 12 (18) 




Cavities* present,  13 (41) 36 (55) 
0.2 
Other abnormalities,  19 (59) 29 (45) 




Scanty1+,  11 (34) 17 (25) 
0.2** 2+,  10 (31) 19 (28) 
3+,  11 (34) 31 (46) 
* Cavities as defined in the methods (chapter 6); ‡ estimated percentage of visible 
lung that was abnormal; ** wilcoxon rank sum test. 
 
Of the 291 contacts, 159 (54.6%) were baseline QFN-GIT positive, 23 (7.9%) 
converted from negative to positive QFN-GIT and 81 (27.8%) were PN. Three (1%) 
had indeterminate QFN-GITs that were not resolved, eight (2.8%) had unevaluated 
symptoms and 11 (3.8%) were lost to follow up. Six had TB disease (2.1%), three 
definite, one probable and two possible. Two of the co-prevalent cases (aged 41 and 
48 years) were exposed to lineage two isolates and four (aged 5, 5, 32 and 75 years) to 
lineage four isolates.  
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Primary comparison  
The primary comparison of contacts with a PN QFN-GIT versus those whose QFN-
GIT was positive at baseline or converted during follow up included data from 271 
contacts. Nineteen (23%) out of 81 PN contacts were exposed to a lineage two isolate, 
compared to 73 (38%) of the 190 contacts with a positive QFN-GIT at baseline (Table 
54). A positive QFN-GIT at baseline or follow up was 21% more likely in contacts of 
an index case with a lineage two isolate compared to contacts of an index case with 
another isolate (95% CI 0 - 47%; P=0.047). Consistent with the results from the wider 
cohort (Chapter 8: Results of multivariable modelling of clinical and haematological 
parameters), there was also an increased prevalence of a positive QFN-GIT with 
exposure to an index case with a 3+ smear grade (PR=1.40; 95% CI 1.08 - 1.82; 
P=0.01), sleep proximity to the case and increasing BMI (PR=1.02; 95% CI 1.00 - 
1.03; P=0.045). BCG vaccination was associated with a lower prevalence of infection 
(PR=0.79; 95% CI 0.69 - 0.91; P=0.001).  
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Table 54. Univariate prevalence ratio of infection at baseline or 14 weeks modelled 





PR 95% CI P 
Lineage: (2 vs Other) 19 23 73 38 1.21 1.00 - 1.47 0.047 
Index age (mean sd) 0.1 1.4 4 1.5 0.98 0.92 - 1.05 0.66 
Index sex (M vs F) 39 48 101 53 1.06 0.87 - 1.29 0.55 
Cough (days; mean, sd) 59 77 56 60 1.00 1.00 - 1.00 0.90 
Highest smear grade 
       
1+/scanty 36 44 46 24 1.00 ref 
 
2+ 21 26 55 29 1.29 0.96 - 1.74 0.09 
3+ 24 30 89 47 1.40 1.08 - 1.82 0.01 
Cavities (present vs absent) 35 43 92 48 1.03 0.85 - 1.25 0.74 
Extent of disease (mean, sd) 46 29 50 29 1.00 1.00 - 1.00 0.44 
Age contacts  (mean, sd) 3 2 3.1 1.8 1.02 0.98 - 1.06 0.39 
Contact sex (M vs F) 43 53 78 41 0.86 0.72 - 1.03 0.11 
Contact eth (Sunda vs other) 9 11 14 7 0.98 0.93 - 1.03 0.41 
Sleep prox (same vs diff) 15 19 59 31 1.20 1.03 - 1.39 0.02 
Hours with case (mean sd) 4.1 3.9 4.7 3.9 1.01 0.99 - 1.04 0.28 
BCG vacc (yes vs no) 71 88 139 73 0.79 0.69 - 0.91 0.001 
Smoking (current vs non-) 23 28 55 29 1.01 0.86 - 1.19 0.92 
BMI (mean, sd) 21 5 22 5 1.02 1.00 - 1.03 0.045 
Diabetes 
       
RCBG<100 48 59 119 63 1.00 ref 
 
HbA1c <5.7 23 28 57 30 1.00 0.82 - 1.21 1.00 
HbA1c 5.7-6.4 4 5 6 3 0.84 0.51 - 1.38 0.49 
HbA1c>6.4 6 7 8 4 0.80 0.51 - 1.25 0.33 
Note: values are numbers and percentages unless otherwise stated. For binary 
exposures the frequency of the exposure (Lineage 2, male sex, sunda ethnicity, BCG 
vaccination, current smoking) is presented. M: Male; F: Female; Index case age 
scaled by 10 years; Sleep prox: Sleep proximity same room versus different; BCG 
vacc: Bacillus Calmette-Guérin vaccination; BMI: Body mass index; RCGB: Random 
capillary blood glucose; HbA1c: glycosylated haemoglobin. 
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Multivariable modelling  
 
Exposure to a lineage two index case remained a risk factor for infection at baseline 
or follow up in the multivariable model (RR=1.22; 95% CI 1.02 - 1.46; P=0.03) ( 
Table 55). Testing for interaction with the main effect identified BCG vaccination as a 
potential modifier of this effect of lineage on risk of infection, but interaction terms 
were not significant at the <0.05 threshold (P=0.1). 
 
Table 55. Adjusted prevalence ratio for positive QFN-GIT at baseline or 14 weeks 
according to M. tuberculosis lineage.   
PR 95% CI P 
Lineage (2 vs other) 1.22 1.02 - 1.46 0.03 
Index case age (scale: 1=10 years) 0.99 0.92 - 1.07 0.8 
Index case sex (Male vs Female) 1.00 0.85 - 1.18 1 
Highest smear grade 
   
2+ vs 1+/scanty 1.27 0.96 - 1.69 0.1 
3+ vs 1+/scanty 1.43 1.11 - 1.83 0.005 
Contact age (scale: 1=10 years) 1.02 0.98 - 1.06 0.3 
Contact sex (Male vs Female) 0.88 0.74 - 1.04 0.1 
Sleep proximity (same room vs different) 1.18 1.02 - 1.37 0.03 
BCG vaccination (yes vs no) 0.81 0.70 - 0.93 0.004 
BCG: Bacillus Calmette-Guérin vaccination. 
Note: Adjusted for GEE for age, sex and smear grade of the index case, age and sex 
of the contact, sleep proximity to the case and BCG vaccination. Estimated by 
generalised estimating equation. 
 
Secondary analyses: Association of lineage with a positive QFN-GIT 
at follow up, for those initially negative  
Univariate analysis 
The secondary comparison of contacts with a PN QFN-GIT compared to those who 
converted included data from 104 contacts. Nineteen (23%) of 81 PN contacts were 
exposed to a lineage two isolate, whereas 7 (30%) of the 23 converters were exposed 
to a lineage two isolate (
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Table 56). The univariate RR of a positive QFN-GIT in contacts exposed to a lineage 
two isolate compared to other lineages was 1.31, although the finding was not 
significant (95% CI 0.52 - 3.31; P=0.57). Other factors were associated with the 
outcome as in the analysis of the wider cohort (Chapter 8: Results of multivariable 
modelling of clinical and haematological parameters). Smear grade was the only 
characteristic of the index case that was significantly associated with the contact 
converting their QFN-GIT (Univariate RR=3.85; 95% CI 1.12 - 13.16; P=0.03. BCG 
vaccination was strongly associated with a reduced risk of QFN-GIT conversion 
(RR=0.39; 95% CI 0.21 - 0.74; P<0.001) and there was a non-significant positive 
relationship between BMI and risk of conversion was observed (RR=1.05; 95% CI 
0.99 - 1.12; P=0.09).    
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Table 56. Univariate relative risk of infection at follow up for 104 contacts initially 
QFN-GIT negative.  
 PN 
N     % 
Conv 
N     % 
RR 95% CI P 
Lineage (2 vs other) 19 23 7 30 1.31 0.52 - 3.31 0.57 
Index age ( mean sd) 4.1 1.4 3.8 1.2 0.91 0.69 - 1.19 0.49 
Index sex (Male vs 
Female) 
39 48 10 43 0.86 0.38 - 1.95 0.73 
Cough duration (mean, sd) 59 77 66 68 1.00 1.00 - 1.01 0.76 
Highest smear grade 
       
1+/scanty 36 44 4 17 1.00 ref 
 
2+ 21 26 4 17 1.60 0.40 - 6.34 0.50 
3+ 24 30 15 65 3.85 1.12 - 13.16 0.03 
Cavities (present vs 
absent) 
35 43 12 52 1.18 0.54 - 2.59 0.67 
Extent of x-ray disease 
(mean, sd) 
46 29 49 25 1.00 0.99 - 1.01 0.67 
Age contacts (mean, sd) 3 2 2.6 1.6 0.91 0.75 - 1.11 0.37 
Contact sex 43 53 9 39 0.55 0.25 - 1.22 0.14 
Contact ethnicity 9 11 1 4 0.89 0.67 - 1.17 0.39 
Sleep proximity 15 19 5 22 1.17 0.43 - 3.18 0.76 
Hours with case (mean sd) 4.1 3.9 5.3 3.9 1.06 0.97 - 1.16 0.18 
BCG vacc (yes vs no) 71 88 15 65 0.39 0.21 - 0.74 0.00 
Smoking (current vs non-) 23 28 5 22 0.75 0.32 - 1.77 0.52 
BMI continous (mean, sd) 21 5 23 6 1.05 0.99 - 1.12 0.09 
Note: values are numbers and percentages unless otherwise stated. For binary 
exposures the frequency of the exposure (Lineage 2, male sex, sunda ethnicity, BCG 
vaccination, current smoking) is presented. Index case age scaled by 10 years. BCG: 
Bacillus Calmette-Guérin vaccination; BMI: Body mass index; estimates by GEE. 
Contents of PN and Conv columns are numbers and percentages unless otherwise 
stated. 
 
Multivariable modelling  
The adjusted RR of QFN-GIT conversion in contacts exposed to a lineage two isolate 
compared to other lineages was 1.33, but this analysis is based on small numbers, and 
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the finding is not significant (95% CI 0.72 - 2.47; P=0.4). As shown in Table 57 
exposure to a 3+ smear grade case and hours spent with the case the day before 
enrolment were associated with an increased risk of risk of conversion. BCG was 
associated with a reduced risk of infection (RR=0.35; 95% CI 0.17 - 0.71; P<0.001). 
The adjusted estimate for BCG was 12% stronger than the univariate estimate, 
suggesting some confounding. Testing for interaction identified contact sex, BMI and 
BCG vaccination as a potential modifiers of the effect of lineage on risk of infection, 
(p=0.06, p=0.11, p=0.14 respectively).  
 
Table 57. Adjusted relative risk of positive QFN-GIT at 14 weeks according to M. 
tuberculosis lineage, for those initially QFN-GIT negative.   
RR 95% CI P 
Lineage (2 vs other) 1.33 0.72 - 2.47 0.4 
Index case age (scale: 1=10 years) 0.86 0.69 - 1.09 0.2 
Index case sex (Male vs Female) 1.04 0.52 - 2.10 0.9 
Highest smear grade 
   
2+ vs 1+/scanty 1.19 0.32 - 4.39 0.8 
3+ vs 1+/scanty 3.80 1.39 - 10.38 0.009 
Contact age (scale: 1=10 years) 0.82 0.63 - 1.07 0.1 
Contact sex (Male vs Female) 0.88 0.37 - 2.06 0.8 
Hours with case the day before enrolment  1.09 1.00 - 1.19 0.04 
BCG vaccination (yes vs no) 0.35 0.17 - 0.71 0.004 
BMI 1.06 0.99 - 1.12 0.09 
BCG: Bacillus Calmette-Guérin vaccination; BMI: Body mass index. 
Note: Adjusted for age, sex and smear grade of the index case, age and sex of the 
contact, sleep proximity to the case and BCG vaccination. Estimated by generalised 
estimating equation. 
 
Association of lineage with a positive QFN-GIT at baseline  
Univariate analysis 
The comparison of baseline QFN-GIT included data from 282 contacts. Twenty-eight 
(24%) out of 115 BN contacts were exposed to a lineage two isolate, whereas 66 
(40%) of the 167 BP were exposed to a lineage two isolate (Table 58). The univariate 
PR of a positive QFN-GIT at baseline in contacts exposed to a lineage two isolate was 
1.31 (95% CI 1.03 - 1.67; P=0.03). The prevalence ratio of a positive QFN-GIT at 
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baseline was higher in those who slept in the same room as the index (PR 1.30; 95% 
CI 1.07 - 1.58; P=0.011). In contrast to the univariate associations seen on the full 
cohort, an increased PR for infection was not seen in those exposed to a 3+ case 
versus a 1+ or scanty case or those exposed to lung cavities or spending longer with 
the case. BCG vaccination was associated with a decreased risk of infection although 
this was not significant (PR=0.86; 95% CI 0.70 - 1.06; P=0.17).  
 
Table 58. Univariate risk of infection at baseline modelled by generalised estimating 









PR 95% CI P 
Lineage: (2 vs others) 28 24 66 57 1.31 1.03 - 1.67 0.03 
Index age,( mean sd) 4.1 1.4 4 1.5 0.98 0.89 - 1.08 0.68 
Index sex (M vs F) 53 46 91 79 1.15 0.90 - 1.47 0.28 
Cough duration (mean, sd) 58 72 56 59 1.00 1.00 - 1.00 0.82 
Highest smear grade 
       
1+/scanty 41 36 42 37 1.00 ref 
 
2+ 30 26 51 44 1.24 0.88 - 1.77 0.22 
3+ 44 38 74 64 1.24 0.90 - 1.70 0.19 
Cavities (present vs absent) 51 44 80 70 1.04 0.81 - 1.33 0.78 
Extent of x-ray disease (mean, sd) 47 27 50 29 1.00 1.00 - 1.01 0.57 
Age contacts (years) mean sd 2.9 1.9 3.2 1.8 1.04 0.99 - 1.09 0.13 
Contact sex (M vs F) 56 49 70 61 0.89 0.74 - 1.08 0.25 
Contact eth. (Sunda vs Other) 12 10 13 11 0.98 0.92 - 1.04 0.50 
Sleep proximity 22 19 54 47 1.30 1.07 - 1.58 0.01 
Hours with case (mean sd) 4.3 3.9 4.7 3.9 1.01 0.98 - 1.04 0.52 
BCG vacc (yes vs no) 93 81 124 108 0.86 0.70 - 1.06 0.17 
Smoking (current vs non-) 32 28 50 43 1.04 0.85 - 1.28 0.70 
BMI (mean, sd) 22 6 22 5 1.01 0.99 - 1.03 0.45 
Diabetes 
       
RCBG<100 67 58 105 91 1.00 ref 
 
HbA1c <5.7 35 30 49 43 0.96 0.75 - 1.22 0.71 
HbA1c 5.7-6.4 4 3 6 5 0.98 0.61 - 1.59 0.94 
HbA1c>6.4 9 8 7 6 0.72 0.43 - 1.21 0.21 
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Note: values are numbers and percentages unless otherwise stated. For binary 
exposures the frequency of the exposure (male sex, sunda ethnicity, BCG vaccination, 
current smoking) is presented. Index case age is scaled by 10:1. BN: Baseline QFN-
GIT negative, includes persistently negative and converter groups; BP baseline QFN-
GIT positive; M: male; F: Female; Contact eth: Contact ethnicity; BCG vacc: 
Bacillus Calmette-Guérin vaccination; BMI: Body mass index; RCGB: Random 
capillary blood glucose; HbA1c: glycosylated haemoglobin. 
 
Multivariable modelling  
The results of multivariable modelling are presented in Table 59. Exposure to a 
lineage two case remained a risk factor for infection at baseline up in the 
multivariable model (PR=1.29; 95% CI 1.01 - 1.65; P=0.04) relative to other 
lineagess and the estimate was unchanged from the univariate estimate. Aside from 
contact age and sex, no host factors remained in the model. Testing for interaction 
identified index case age and sex as potential modifiers of the effect on risk of 
infection, but interaction terms were not significant at the <0.05 threshold.  
 
Table 59. Adjusted prevalence ratio for positive QFN-GIT at baseline according to M. 
tuberculosis lineage.  
PR 95% CI P 
Lineage (two vs others) 1.29 1.01 - 1.65 0.04 
Index case age (scale: 1=10 years) 0.98 0.88 - 1.08 0.7 
Index case sex (Male vs Female) 1.14 0.89 - 1.45 0.3 
Contact age (scale: 1=10 years) 1.03 0.98 - 1.08 0.2 
Contact sex (Male vs Female) 0.89 0.73 - 1.09 0.3 
Sleep proximity (same room vs different) 1.31 1.08 - 1.59 0.006 
Adjusted for age, sex and smear grade of the index case, age and sex of the contact 
and sleep proximity to the case. Estimated by generalised estimating equation. 
 
Discussion 
Lineage two isolates comprised 32% of isolates in this study, consistent with previous 
reports from Bandung [312]. Exposure to an index case with a lineage two isolate was 
associated with a 22% increased prevalence of a positive QFN-GIT (at baseline or 
follow up) in contacts in this subset of the cohort. The secondary analysis of PN and 
converters revealed a RR of conversion of 1.31 for contacts exposed to a lineage two 
isolate compared to other lineages. As expected this effect was not significant, 
 
228   
  
however the direction of the result is consistent with the increased prevalence of 
infection observed in the primary analysis with lineage two. The slightly higher 
estimate for the comparison of PN and converters may suggest the primary 
comparison is slightly biased towards the null by misclassification. Index cases with a 
lineage two isolate were not more likely to have lung cavities or a higher bacillary 
burden in sputum.  
 
A strength of the present study is the direct measurement of transmission, defined as 
passing infection from index case to contact. In contrast many other studies infer 
transmission from the frequency of clustered isolates in surveillance culture 
collections. Clustering in such studies may arise from more efficient transmission of a 
particular isolate but also from differences in progression of LTBI to active disease. 
These studies inappropriately use the terms “clustering” and “transmission” 
interchangeably. The approach used in the present study also uses data from almost all 
members of the cohort, reducing selection bias. Furthermore, studies of clustered 
isolates can not be certain of the ascertainment of secondary cases, particularly with 
respect to transmission to children, who will often be culture negative [313]. 
   
This study has three important limitations. Firstly it is assumed that a positive QFN-
GIT at baseline is related to the index case in the primary analysis, which will not 
always be the case. This risks misclassification bias, but, as borne out by the 
secondary analyses this likely had a modest effect, and may underestimate the 
increased transmission risk associated with lineage two. Secondly, the analysis of the 
prospectively defined group was underpowered. Thirdly the distribution of lineages 
and size of the study meant only an analysis of lineage two versus all other lineages 
was possible.  
 
Consistency of the main result with other literature 
Our finding of an increased prevalence of M. tuberculosis infection in Indonesian case 
contacts of index cases with lineage two isolates compared to others, mostly lineage 
four, is consistent with the global emergence of lineage two over recent decades [314, 
315]. However, the result differs from the other published studies of M. tuberculosis 
transmission that, like the present study, defined transmission as acquisition of latent 
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infection by household case contacts. In a study of 1,800 household case contacts in 
the Gambia, de Jong et al analysed the effect of spoligotype defined lineage on 
tuberculosis skin test positivity at baseline and follow up three months [316]. No 
difference in the risk of TST positivity was found according to M. tuberculosis 
spoligotype. The cohort was also followed for two years for progression to active 
disease. M. tuberculosis sunsu stricto more often progressed to active disease than the 
ancestral M. africanum, but there was no difference in progression between the 
modern lineages. It should be noted that only 4% of isolates were from the Beijing 
family, meaning the estimate for lineage two lacks precision. A small study (n=219) 
of child case contacts aged under 5 years in South Africa also did not show an 
increased risk of infection determined by TST (odds ratio, 1.5; 95% confidence 
interval, 0.8 to 2.7) [317]. These differences may reflect random variations in the 
estimates or differences in population susceptibility to different lineages [318]. 
  
Noting the limitations of clustered analyses discussed above, these have tended to 
show increased clustering of lineage two isolates. A large study in a district of Malawi 
explored transmission networks by whole genome sequencing of isolates stored from 
pulmonary TB cases over 15 years. They found the odds of transmission were three 
times higher for lineage two compared to lineage four [319]. A study set in 5 sites in 
different Chinese provinces from 2009 - 2012 used VNTR genotyping to conclude 
Beijing isolates were more likely to be associated with clustering than others (1.56; 
95% CI 1.23 - 2.96; P<0.001) [320]. Modern Beijing strains were also more often in a 
cluster (42.9% vs 31.3%) in a study of 909 spoligotyped isolates from pulmonary TB 
patients 2002 and 2007 in Kobe, Japan [321]. A clutering analysis of samples 
genotyped by spoligotyping, VNTR and RFLP in Vietnam found lineage two isolates 
were less transmissible than lineage three, but more transmissible than other lineages 
[322]. In contrast, two studies performed in low prevalence countries did not find 
increased transmission associated with the lineage two. A study of 10,389 isolates 
collected by the Dutch National Institute for Public Health and genotyped by a 
combination of RFLIP and VNTR found no difference in the clustering based on 
lineage [323]. Similarly a population-based study in Alberta Canada did not find 
lineage two isolates to be associated with increased transmission [324].  
 
Higher transmission of lineage two isolates in this study were not associated with 
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higher rates of higher smear grade or lung cavities. This is counter to the 
“inflammatory hypothesis” that posits the induction of an inflammatory disease 
phenotype in the index case by lineage two increases transmission, as is seen in 
mouse infection models [325]. TB disease caused by lineage two in humans has been 
associated with increased rates of disseminated disease [326] and perhaps increased 
fatalities [327] but not more cavitary disease or sputum bacillary burden [328, 329]. 
 
Two alternative explanations for the increased transmissibility of lineage two isolates 
include their attenuated response to treatment, leading to prolonged infectivity of the 
index case, or evasion of EC in the contact. A previous study of pulmonary TB cases 
in Bandung and Jakarta Indonesia found linage two was associated with higher risk of 
smear positivity after six months of treatment, independent of drug resistance [330]. 
Lineage two could evade EC in the contact by evading recognition and reducing the 
pro-inflammatory cytokine production during infection, as seen in ex-vivo studies 
[331, 332]. A Chinese study found BCG vaccination and BMI were risk factors for 
clustering among lineage two isolates, both factors associated with EC in the present 
study [333]. The emergence of lineage two has been hypothesized to be driven by 
widespread BCG vaccination [334]. 
 
Conclusion 
Exposure to M. tuberculosis from lineage two was associated with increased 
prevalence of infection in the subset of the cohort with lineage data available. This 
was despite index cases with lineage two isolates tending to have lower smear grade 
and fewer lung cavities. Thus lineage two transmission may be increased by evading 
host immunity in the contact, rather than inducing a disease phenotype in the index 
case that favours transmission. WGS should be extended across the cohort to enable 
detailed study of the interplay of host pathogen factors in the cohort.  
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Chapter 13: Conclusions and Recommendations 
 
EC is defined as the eradication of M. tuberculosis infection by innate immunity. 
Prior evidence for this phenotype includes the observation that a proportion of TB 
case contacts remain uninfected, even despite heavy exposure (Chapter 1). Other 
investigators have validated the association of certain genetic loci with the phenotype 
(Chapter 3). To advance understanding of EC and its underlying mechanisms we 
sought to characterise the clinical and epidemiological characteristics of early 
clearers, conduct initial studies of their innate immune response to M. tuberculosis, 
and assess whether vitamin D deficiency is negatively associated with EC.  
 
Describing differences in immune function in early clearers  
The studies in this thesis demonstrate that early clearers are a distinct immunological 
phenotype and are not merely insufficiently exposed to be infected. At the time of M. 
tuberculosis exposure early clearers have raised immature granulocytes relative to 
converters; this is a “left shift” and is typical of the early response to bacterial 
infection. Early clearers mount a stronger innate inflammatory response to M. 
tuberculosis than IGRA converters; ECs were less likely to have low neutrophils 
(Chapter 8), they had higher innate cytokine responses (Chapter 10), and higher 
expression of CTSD (Chapter 11), the gene for the lysosomal peptidase Cathespin D.  
Future studies are planned to characterise these responses in more detail, using 
samples stored from the INFECT cohort. An innate cell phenotyping sub-study 
recruited participants with a negative baseline QFN-GIT who consented to additional 
blood draws at two and 14 weeks. Blood cells collected at these time points have been 
fixed both with and without stimulation for detailed analysis by flow assisted cell 
sorting and intracellular cytokine staining. Monocyte subpopulations will be a focus 
on this analysis, given the monocyte cytokines (IL-6, IL-1b) associated with EC and 
their speculated role in trained innate immunity [304]. An additional batch of whole 
blood stimulation assay supernatants will also be analysed to validate the findings 
reported in this thesis.   
 
 
232   
  
BCG vaccination, early clearance and trained immunity 
This study was not intended to focus on the mechanism of BCG mediated protection. 
However, the surprisingly strong association of BCG vaccination with EC in the 
epidemiological analysis (Chapter 8) prompted its consideration as an important 
mediating variable in the studies of biomarkers that followed. This indeed was the 
case for the analysis of cytokine responses (Chapter 10), where higher responses were 
only observed in the BCG restricted analysis.  
 
The association of BCG induced protection with innate cytokine responses is a key 
finding of this thesis and could have important impact both as correlate of protection 
for M. tuberculosis vaccine studies, and as an insight that advances understanding of 
the mechanism of EC.  
 
Firstly, innate cytokine responses could be biomarkers of BCG induced protection. 
Biomarkers of vaccine induced protection, known as correlates of protection, enable 
rapid evaluation of candidate vaccines in small clinical studies in which induction of 
the correlate is an intermediate endpoint. Currently, lack of correlates of protection 
mean M. tuberculosis vaccines are evaluated in large, lengthy and expensive field 
studies. A valid correlate of protection would also enable studies to address long 
standing questions about variation in BCG’s effect across individuals and geographic 
areas. Validating this association is a priority question for future research.  
 
Secondly, the BCG vaccinated ECs had higher IL-6 & IL-1b responses to M. 
tuberculosis as well as other stimuli, indicating EC is independent of highly specific T 
cell receptor recognition. It is consistent with EC being mediated by the innate 
immune system, in which pathogens are recognised by PAMPs common across 
different species of bacteria by PRRs on innate immune cells.  
 
This finding is at odds with the conventional view of vaccine function, where 
immunological memory can only be induced by adaptive immune mechanisms. BCG 
has been presumed to act through the induction of specific CD4+ T cells that 
recognise M. tuberculosis and initiate a protective response [45]. However, evidence 
that CD4+ T cells correlate with vaccine induced protection has always been limited 
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and a number of recent observations have challenged the assumption. A clinical trial 
of BCG vaccine in neonates found no relationship between BCG specific CD4+T 
cells and protection against TB disease [48]. The MVA85A vaccine successfully 
induced M. tuberculosis specific CD4+ T cells in recipients but did not confer any 
protection in field studies [46,47]. Advances in molecular characterisation of M. 
tuberculosis infection also revealed that reinfection after treatment is common, 
meaning the CD4+ T cell responses that arise during infection are not associated with 
sterilising immunity [141]. 
 
The association of innate cytokines with BCG mediated protection reported in this 
thesis contributes to the emerging understanding of innate immunity as central to 
BCG mediated protection from M. tuberculosis. The recent description of trained 
innate immunity provides a key to understanding how BCG can induce 
immunological memory independent of adaptive immune recognition of M. 
tuberculosis. Trained innate immunity has been proposed as a form of vaccine 
induced memory that is induced by epigenetic reprogramming of monocytes [164]. It 
is thought to be the basis of the non-specific effects of BCG vaccination that includes 
a reduction in all-cause mortality. In small clinical trials BCG vaccination trained 
enhanced cytokine responses in healthy volunteers [164]. Our results suggest that 
such cytokine responses are associated with BCG induced M. tuberculosis protection 
and support the premise that trained innate immunity is the basis BCG induced 
protection in humans.  
 
Validating the cytokine profile associated with BCG mediated protection in other 
cohorts is a priority for future research. A vaccinated birth cohort in a high 
transmission setting is an attractive design for a validation study. Such a study would 
have the advantage of recording vaccination status at the time of vaccination, and 
biomarkers measured at pre-specified intervals after neonatal vaccination would not 
be confounded by age. The trained innate immunity hypothesis posits that epigenetic 
reprogramming trains innate immune memory following BCG vaccination, so 
identifying epigenetic markers associated with protection is also important. To date, 
studies of epigenetic changes following BCG vaccination have focused on histone 
modifications [346]. The INFECT bioarchive includes DNA that could be studied for 
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different patterns of methylation, but new recruitment would be required to obtain 
peripheral blood mononuclear cells required for studies of histone modification. 
 
Further research on trained innate immunity is required to translate this knowledge 
into interventions that improve protection against M. tuberculosis above that currently 
conferred by BCG. Whereas vaccines can be rationally design to induce antibodies to 
particular epitopes, it is not currently known whether BCG could be manipulated 
genetically to strengthen, broaden or prolong innate responses. Alternatively, 
evidence for innate immune training by BCG might be considered “proof of concept” 
for host directed therapies to promote early clearance. A review by Hawn et al 
identified a number of small molecules that modulate the innate response to 
mycobacteria [66]. Clinical studies in healthy volunteers are required to better 
quantify the impact of host directed therapies, potentially using innate cytokine 
production as an endpoint.  
 
Lineage two and evasion of Early Clearance 
BCG vaccination was partially protective against M. tuberculosis infection in this and 
other studies. This highlights the need for better understanding of the circumstances in 
which BCG vaccination fails to induce protection as another important question. In 
this study, exposure to a lineage two isolate was associated with a higher prevalence 
of infection in contacts, suggesting it more successfully evades EC than lineage four 
(Chapter 12). Lineage two has emerged in East Asia and beyond in recent decades 
[314, 315], concurrent with the widespread use of BCG vaccination [334]. 
 
Extending the analysis of lineage across the whole cohort would enable the hypothesis 
that BCG interacts with M. tuberculosis lineage to be tested. Demonstrating 
interaction would support the idea that lineage two has evolved to evade BCG 
induced protection, and could influence settings in which the vaccine is used. Whole 
genome sequencing of index case isolates would also enable identification of 
individual genes associated with evasion of early clearance.  
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25-OH Vitamin D and early clearance 
This study did not show an association between 25-OH vitamin D deficiency and 
early clearance, however the surprisingly high prevalence of deficiency meant the 
study lacked the power to exclude some potentially clinically significant effects. This 
finding differs from another smaller observational study performed in Spain where 
participants had higher 25-OH vitamin D levels [162]. A randomised control trial to 
assess the effect of vitamin D supplementation on risk of conversion in QFN-GIT 
negative case contacts could definitively assess the role of 25-OH vitamin D in early 
clearance. The present study demonstrates that TB case contacts in Bandung would be 
a good population for such a trial, due to their high rate of Vitamin D deficiency and 
our ability to organise recruitment of cases and their contacts quickly after index case 
diagnosis.  
 
Advancing knowledge of early clearance and methodology  
We anticipated misclassification as early clearers those insufficiently exposed to be 
infected would present a methodological challenge (Chapter 5). We measured M. 
tuberculosis exposure in a variety of ways, and pragmatically defined a group of 
highly exposed persistently uninfected contacts. Restricting the EC group according 
to exposure did not substantially alter findings from an unrestricted analysis (Chapters 
8, 10, 11). This could reflect poor correlation between the measurements and true M. 
tuberculosis exposure, poor definition of high exposure or merely that most contacts 
in the cohort were highly exposed. Further work is required to optimise the definition 
of high exposure in the INFECT cohort, because resource intensive studies planned 
on stored specimens should be performed on samples with the highest probability of 
EC. Using a multifactor risk score for infection is a potential alternative approach. 
 
These studies have shown that analysing peripheral blood can identify differences in 
cell populations and cytokine responses in asymptomatic case contacts. However, 
other biomarkers, like gene expression in unstimulated blood (Chapter 11) showed, if 
anything, that expression of innate immune candidate genes were lower in early 
clearers than converters. This suggests RNA sequencing may have limited value as a 
discovery platform for identifying genes associated with EC, at least when performed 
on whole blood. Single cell RNA sequencing or sequencing of bronchioalveolar 
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lavage samples are alternative approaches that could be considered for future studies. 
However studies on samples from this cohort could define a “transcription signature” 
for EC; a combination of genes that are collectively sensitive and specific for 
conversion. A signature could have predictive clinical value, and enable identification 




The studies in this thesis have identified a pro-inflammatory phenotype of early 
clearance; and represents the first comprehensive study of innate immune function in 
EC. The association of ECwith BCG suggests trained innate immunity as a priority 
mechanism for future study. Innate cytokine responses maybe correlates of protection 
for the BCG vaccine. The association of enhanced innate immune responses with 
protection from M. tuberculosis infection suggests host directed therapies that 
modulate the innate response a potential avenue for interventions to prevent M. 
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Appendix 
Table 60. Form of variables used in model, according to comparison. 
Model: QFN-GIT at 





at baseline or 
follow up 
Index age linear linear linear 
Index sex (M vs F) binary binary binary 
cough duration  binary  binary linear 
Highest smear categorical (3) categorical (3) categorical (3) 
Cavities (present vs 
absent) 
binary binary binary 
Extent of x-ray 
disease 
linear linear linear 





Contact sex binary binary binary 
Contact ethnicity binary binary binary 
Sleep proximity binary binary binary 
Hours with case  linear linear linear 
BCG vaccination  binary binary binary 
Smoking ?quit binary binary binary 
BMI  continuous continuous continuous 
Diabetes categorical (4) categorical (4) categorical (4) 
Hemoglobin g/dl linear linear linear 
Haematocrit (%) linear linear linear 
Mean Cell Volume 
(fL) 
linear linear linear 
Reticulocyte linear linear linear 
Absolute 
Reticulocytes  
linear linear linear 
Reticulocyte 
hemoglobin (pg) 
linear linear linear 
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Platelets (/1000) linear linear linear 
Neutrophils (1000/uL) linear linear categorical (4) 
Lymphocytes 
(1000/uL) 
linear linear linear 
Monocytes (1000/uL) linear linear linear 
Immature Granulocyte 
(1000/uL) 
linear linear linear 
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Table 61. p-values for variables included in each successive version of model of final QFN-GIT, for those negative at baseline.  
Iteration: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 
Index Age 0.9 0.9 1 1 1 1 1 1 0.9 0.9 0.8 0.8 0.6 0.8 0.8 0.7 
Index Sex 0.3 0.3 0.3 0.3 0.3 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.5 0.4 0.4 0.3 
Ethnicity contact 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.5 0.5 0.4 
      
Cough duration  0.7 0.7 0.9 0.8 0.9 
           
Extent x-ray disease 0.7 0.7 0.6 0.6 0.6 0.7 
          
Cavities 0.7 0.7 0.5 0.5 0.5 0.4 0.4 0.4 0.4 0.4 0.5 0.5 0.4 
   
Contact age (/10) 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.4 0.4 0.4 0.3 0.3 0.2 0.2 0.2 0.2 
Contacts sex 0.6 0.6 0.6 0.6 0.6 0.8 0.8 0.9 0.9 0.8 0.8 0.8 0.7 0.7 0.8 0.9 
Hours with case 0.08 0.08 0.06 0.07 0.07 0.07 0.08 0.05 0.05 0.06 0.06 0.09 0.1 0.1 0.1 0.08 
Sleep proximity 0.8 0.8 0.9 
             
BCG 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 <.00001 <.00001 0.001 0.002 0.002 0.001 
Smoking  0.01 0.01 0.03 0.03 0.03 0.03 0.03 0.05 0.06 0.06 0.05 0.02 0.01 0.03 0.03 0.04 
BMI  0.1 0.1 0.06 0.06 0.06 0.06 0.06 0.08 0.1 0.08 0.08 0.02 0.02 0.006 0.008 0.01 
Hemoglobin 0.4 0.4 0.7 0.7 0.1 0.2 0.2 0.2 0.2 0.3 0.3 
     
Hematocrit 0.8 0.7 0.8 0.8 
            
MCV 1 
               
Reticulocyte 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.5 0.4 0.4 0.4 0.5 
    
Abs reticulocytes 0.4 0.4 0.5 0.5 0.5 0.5 0.5 0.6 
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Ret hemologlobin 0.9 0.8 
              
Platelets (1000) 0.6 0.6 0.6 0.6 0.6 0.5 0.6 0.5 0.5 
       
Immat grans 0.007 0.007 0.01 0.01 0.009 0.007 0.006 0.004 0.004 0.005 0.005 0.003 0.003 0.002 0.003 0.002 
Monocytes 0.1 0.08 0.2 0.2 0.2 0.3 0.3 0.3 0.3 0.3 0.3 0.4 0.4 0.2 0.2 
 
Lymphocytes 0.5 0.5 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.3 0.4 0.4 0.4 0.5 
  
Diabetes 0.6 0.6 0.5 0.5 0.5 0.6 0.06 
         
Highest smear 0.01 0.01 0.02 0.02 0.02 0.01 0.01 0.007 0.008 0.007 0.005 0.004 0.002 0.0003 0.0002 0.0003 




268     
 
Table 62. p-values for each variable in each iteration of model of QFN-GIT at baseline. 
Iteration 1 2 3 4 5 6 7 8 9 10 11 12 
Index Age 0.3 0.3 0.3 0.3 0.4 0.4 0.3 0.3 0.3 0.3 0.3 0.3 
Index Sex 0.1 0.1 0.1 0.1 0.2 0.2 0.1 0.1 0.1 0.1 0.1 0.1 
Smear grade 0.4 0.4 0.4 0.4 0.3 0.3 0.3 0.3 0.2 0.2 
  
Cough duration 
(15) 0.3 0.3 0.3 0.3 0.4 0.4 0.4 0.4 
    
Extent x-ray 
disease 0.9 
           
Cavities 0.05 0.05 0.04 0.04 0.04 0.04 0.03 0.03 0.03 0.03 0.008 0.009 
Contact age 0.004 0.004 0.004 0.007 0.006 0.005 0.004 0.004 0.004 0.002 0.002 0.002 
Contact sex 0.2 0.2 0.2 0.2 0.2 0.1 0.2 0.2 0.2 0.3 0.3 0.2 
Contact ethnicity 0.1 0.1 0.1 0.2 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 
Hours with case 0.05 0.05 0.05 0.05 0.04 0.04 0.04 0.04 0.04 0.03 0.04 0.05 
Sleep proximity 0.03 0.03 0.03 0.03 0.01 0.01 0.008 0.008 0.008 0.007 0.008 0.009 
BCG 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.008 0.007 
Smoking 0.3 0.3 0.3 0.2 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.09 
BMI 0.3 0.3 0.3 0.3 0.4 0.4 0.4 
     
Diabetes 0.8 0.8 0.9 
         
Hemoglobin 0.07 0.07 0.07 0.05 0.07 0.07 0.07 0.07 0.07 0.09 0.1 0.1 
Hematocrit 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 
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MCV 0.6 0.6 0.6 0.6 0.9 
       
Reticulocyte 0.3 0.3 0.3 0.4 0.4 0.4 
      
Abs reticulocytes 0.9 0.9 
          
Ret hemologlobin 0.6 0.6 0.6 0.6 
        
Platelets (1000) 0.2 0.2 0.2 0.2 0.3 0.2 0.2 0.2 0.2 
   
Neutrophils 
(quart) 0.4 0.4 0.4 0.4 0.2 0.2 0.2 0.1 0.1 0.09 0.1 0.1 
Immat grans 0.3 0.3 0.3 0.3 0.2 0.2 0.2 0.2 0.2 0.09 0.09 0.1 
Lymphocytes 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.05 0.03 0.04 
Monocytes 0.01 0.009 0.008 0.008 0.004 0.004 0.006 0.007 0.007 0.01 0.009 0.008 
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Table 63. p-values for each variable included in each iteration of model of positive QFN-GIT at baseline or follow up. 
Iteration 1 2 3 4 5 6 7 8 9 10 11 12 13 
Age index 0.5 0.5 0.5 0.5 0.5 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 
Sex index 0.6 0.6 0.6 0.7 0.7 0.5 0.6 0.5 0.5 0.6 0.6 0.5 0.5 
Cough >15 
days 0.2 0.2 0.2 0.3 0.3 0.4 0.4 0.4 0.4 
    
Extent x-ray 
disease 0.6 0.6 0.6 0.6 0.6 0.7 
       
Cavities 0.1 0.1 0.1 0.1 0.1 0.08 0.09 0.09 0.09 0.08 0.09 0.08 0.09 
Highest 
smear 0.01 0.01 0.01 0.01 0.009 0.005 0.006 0.006 0.006 0.005 0.005 0.005 0.005 
Age contacts 0.2 0.2 0.2 0.3 0.3 0.2 0.2 0.07 0.07 0.06 0.04 0.05 0.03 
Sex Contacts 0.2 0.2 0.1 0.1 0.1 0.2 0.2 0.1 0.1 0.2 0.2 0.08 0.1 
Ethnicity 
contacts 0.1 0.1 0.1 0.1 0.1 0.09 0.09 0.09 0.09 0.09 0.1 0.09 0.09 
Hours with 
case 0.01 0.01 0.01 0.004 0.004 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 
Sleep 
proximity 0.3 0.3 0.3 0.2 0.2 0.09 0.08 0.08 0.08 0.09 0.09 0.08 0.08 
BCG <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 
Smoking 0.02 0.02 0.02 0.008 0.006 0.009 0.01 0.01 0.01 0.01 0.008 0.01 0.01 
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BMI 0.7 0.7 0.7 0.6 0.6 0.6 0.6 
      
Diabetes 0.8 0.8 0.8 0.9 
         
Hemoglobin 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.5 
  
Hematocrit 0.6 0.6 0.6 0.4 0.4 0.4 0.4 0.4 0.4 0.4 
   
MCV 0.8 0.8 
           
Reticulocyte 0.6 0.6 0.6 0.7 0.7 
        
Abs retics 1 
            
Ret. Hb 0.9 0.9 1 
          
Platelet 0.2 0.2 0.2 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.4 
 
Neutrophils 0.3 0.3 0.3 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.1 
Immat grans  0.6 0.6 0.6 0.5 0.5 0.6 0.5 0.5 
     
Lymphs 0.02 0.02 0.02 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.02 
Monocytes 0.08 0.08 0.07 0.05 0.05 0.07 0.07 0.06 0.06 0.06 0.06 0.06 0.07 
Abs retics: absolute reticulocyte count; Ret Hb: reticulocyte haemoglobin; Immat grans: Immature granulocytes; Lymphs: Lymphocytes 
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Table 64. P-values for each variable in each iteration of model of vitamin D and QFN-GIT at follow up.  
Iteration: 1 2 3 4 5 6 7 8 
Index Age 0.4 0.4 0.4 0.4 0.4 0.4 0.7 0.7 
Index Sex 0.3 0.3 0.3 0.4 0.3 0.3 0.3 0.3 
Ethnicity contact 0.9 
       
Cough duration (days) 0.8 0.8 0.8 
     
Extent x-ray disease 0.5 0.5 0.5 0.5 
    
Cavities 0.5 0.5 0.5 0.4 0.4 0.5 
  
Highest smear 0.004 0.003 0.004 0.003 0.002 0.002 0.0005 0.0006 
Contact age (/10) 0.07 0.07 0.07 0.07 0.07 0.08 0.07 0.07 
Contact sex 0.8 0.8 0.8 0.9 0.9 1 1 0.9 
Hours with case 0.3 0.3 0.3 0.3 0.3 0.2 0.3 
 
Sleep proximity 0.9 0.9 
      
BCG <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 0.001 0.002 0.002 
Smoking  0.009 0.009 0.009 0.01 0.01 0.02 0.05 0.06 
BMI continuous 0.03 0.03 0.03 0.03 0.03 0.03 0.02 0.02 
Diabetes 0.5 0.4 0.5 0.5 0.5 
   
Vitamin D is not shown as it is the variable of interest and would not be removed based on p-value. 
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